Genetic variation in PNPLA3 confers susceptibility to n

Nature Genetics

40, 1461-1465

DOI: 10.1038/ng.257

Citation Report

#	Article	IF	Citations
1	Nonsynonymous variants and fatty liver disease. Nature Genetics, 2008, 40, 1394-1395.	9.4	3
3	Variation in PNPLA3 is associated with outcomes in alcoholic liver disease. Nature Precedings, 2009, , .	0.1	0
4	Variation in PNPLA3 is associated with outcomes in alcoholic liver disease. Nature Precedings, 2009, , .	0.1	0
5	Mammalian patatin domain containing proteins: a family with diverse lipolytic activities involved in multiple biological functions. Journal of Lipid Research, 2009, 50, S63-S68.	2.0	275
6	Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins. Human Molecular Genetics, 2009, 18, 4669-4676.	1.4	49
7	Dissociation Between Fatty Liver and Insulin Resistance in Humans Carrying a Variant of the Patatin-Like Phospholipase 3 Gene. Diabetes, 2009, 58, 2616-2623.	0.3	291
8	Adipocyte metabolism and obesity. Journal of Lipid Research, 2009, 50, S395-S399.	2.0	178
9	Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. European Journal of Endocrinology, 2009, 160, 593-602.	1.9	76
10	Nonalcoholic fatty liver disease. Journal of Lipid Research, 2009, 50, S412-S416.	2.0	177
11	Role of ectopic fat in the pathogenesis of insulin resistance. Clinical Lipidology, 2009, 4, 457-464.	0.4	5
12	Systematic haplotype analysis resolves a complex plasma plant sterol locus on the Micronesian Island of Kosrae. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13886-13891.	3.3	23
13	A Mouse Model for the Metabolic Effects of the Human Fat Mass and Obesity Associated FTO Gene. PLoS Genetics, 2009, 5, e1000599.	1.5	282
14	Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. European Journal of Endocrinology, 2009, 161, 705-713.	1.9	77
15	Burning hepatic fat: Therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease. Hepatology, 2009, 49, 348-351.	3.6	24
16	The genes that underlie fatty liver disease: The harvest has begun. Hepatology, 2009, 49, 692-694.	3.6	11
17	Advances in pediatric nonalcoholic fatty liver disease. Hepatology, 2009, 50, 1282-1293.	3.6	235
18	Fetal obesity syndrome: Maternal nutrition as a cause of nonalcoholic steatohepatitis. Hepatology, 2009, 50, 1696-1698.	3.6	3
19	Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease. Journal of Gastroenterology, 2009, 44, 976-982.	2.3	57

#	Article	IF	Citations
20	Genetic determinants of cardiovascular disease in Hispanics. Current Cardiovascular Risk Reports, 2009, 3, 175-180.	0.8	1
21	A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia, 2009, 52, 1056-1060.	2.9	256
22	Inherited susceptibility to non-alcoholic fatty liver disease. Diabetologia, 2009, 52, 1000-1002.	2.9	6
23	Nonâ€alcoholic fatty liver disease from pathogenesis to management: an update. Obesity Reviews, 2010, 11, 430-445.	3.1	161
24	The liver and the waistline: Fifty years of growth. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, S105-18.	1.4	45
25	Alanine aminotransferase, Î³â€glutamyltransferase (GGT) and allâ€cause mortality: results from a populationâ€based Danish twins study alanine aminotransferase, GGT and mortality in elderly twins. Liver International, 2009, 29, 1494-1499.	1.9	24
26	The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver International, 2010, 30, 795-808.	1.9	56
27	A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. Journal of Lipid Research, 2009, 50, 2111-2116.	2.0	334
28	Tri-iodothyronine upregulates adiponutrin mRNA expression in rat and human adipocytes. Molecular and Cellular Endocrinology, 2009, 311, 39-46.	1.6	14
29	Genome-wide association studies reach hepatology. Journal of Hepatology, 2009, 50, 1278-1280.	1.8	2
30	Non-alcoholic fatty liver disease pathogenesis: The present and the future. Digestive and Liver Disease, 2009, 41, 615-625.	0.4	222
31	Drug-induced liver injury: insights from genetic studies. Pharmacogenomics, 2009, 10, 1467-1487.	0.6	90
32	Genetics of Common Obesity and Nonalcoholic Fatty Liver Disease. Gastroenterology, 2009, 136, 1492-1495.	0.6	16
33	Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors. Gastroenterology, 2009, 137, 865-872.	0.6	646
34	Nonalcoholic Fatty Liver Disease Liver Fat Score and Fat Equation to Predict and Quantitate Hepatic Steatosis: Promising But Not Prime Time!. Gastroenterology, 2009, 137, 772-775.	0.6	15
35	Histopathology of Non-Alcoholic Fatty Liver Disease. Clinics in Liver Disease, 2009, 13, 533-544.	1.0	116
36	Rationale and targets for antifibrotic therapies. Gastroenterologie Clinique Et Biologique, 2009, 33, 949-957.	0.9	19
37	Epidemiology and Natural History of Non-Alcoholic Steatohepatitis. Clinics in Liver Disease, 2009, 13, 511-531.	1.0	347

#	Article	IF	Citations
38	Thiazolidinediones and the liver in humans. Current Opinion in Lipidology, 2009, 20, 477-483.	1.2	49
40	2. Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalchoholic Steatohepatitis (NASH). The Journal of the Japanese Society of Internal Medicine, 2009, 98, 2101-2111.	0.0	0
41	Recent advances in nonalcoholic fatty liver disease. Current Opinion in Gastroenterology, 2010, 26, 202-208.	1.0	126
42	Interrelationships between Hepatic Fat and Insulin Resistance in Non- Alcoholic Fatty Liver Disease. Current Diabetes Reviews, 2010, 6, 341-347.	0.6	27
43	Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proceedings of the Nutrition Society, 2010, 69, 211-220.	0.4	178
44	Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Current Opinion in Lipidology, 2010, 21, 247-252.	1.2	73
45	Nutrition and metabolism: nutritional therapy for disordered triglyceride metabolism and nonalcoholic fatty liver disease. Current Opinion in Lipidology, 2010, 21, 545-547.	1.2	6
46	The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenetics and Genomics, 2010, 20, 1-8.	0.7	79
47	Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation. Current Opinion in Clinical Nutrition and Metabolic Care, 2010, 13, 391-396.	1.3	27
49	Antagonizing MicroRNA-122 and treatment of hepatitis C virus infection. Hepatology, 2010, 51, 1461-1463.	3.6	2
50	A Weighted False Discovery Rate Control Procedure Reveals Alleles at FOXA2 that Influence Fasting Glucose Levels. American Journal of Human Genetics, 2010, 86, 440-446.	2.6	28
51	The latest idea in NAFLD/NASH pathogenesis. Clinical Journal of Gastroenterology, 2010, 3, 263-270.	0.4	16
52	Fatty liver disease in children: eat now pay later. Hepatology International, 2010, 4, 375-385.	1.9	33
53	Nontriglyceride Hepatic Lipotoxicity: The New Paradigm for the Pathogenesis of NASH. Current Gastroenterology Reports, 2010, 12, 49-56.	1.1	56
54	Hepatic Gene Networks in Morbidly Obese Patients With Nonalcoholic Fatty Liver Disease. Obesity Surgery, 2010, 20, 1698-1709.	1.1	32
55	Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regulatory Toxicology and Pharmacology, 2010, 56, 237-246.	1.3	66
56	Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology, 2010, 51, 679-689.	3.6	1,579
57	Kupffer cells promote hepatic steatosis via interleukin-1Î²-dependent suppression of peroxisome proliferator-activated receptor Î± activity. Hepatology, 2010, 51, 511-522.	3.6	381

#	Article	IF	Citations
58	The utility of genome-wide association studies in hepatology. Hepatology, 2010, 51, 1833-1842.	3.6	41
59	Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology, 2010, 51, 1593-1602.	3.6	378
60	Patatin-like phospholipase domain containing 3: A case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease. Hepatology, 2010, 51, 1463-1465.	3.6	26
61	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 2010, 51, 1209-1217.	3.6	563
62	The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology, 2010, 52, 894-903.	3.6	403
63	PNPLA3variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology, 2010, 52, 904-912.	3.6	317
64	Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology, 2010, 52, 1134-1142.	3.6	195
65	I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology, 2010, 52, 1274-1280.	3.6	252
66	A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology, 2010, 52, 1281-1290.	3.6	195
67	PNPLeAse get the fats right: Does lipogenesis or lipolysis cause NASH?1. Hepatology, 2010, 52, 818-822.	3.6	16
68	Emerging genes associated with the progression of nonalcoholic fatty liver disease. Hepatology, 2010, 52, 807-811.	3.6	12
69	Patatin-like phospholipase domain-containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease. Hepatology, 2010, 52, 1189-1192.	3.6	32
70	Early transjugular intrahepatic portosystemic shunt in patients with cirrhosis and variceal bleeding. Hepatology, 2010, 52, 1847-1850.	3.6	4
71	Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology, 2010, 52, 1836-1846.	3.6	1,857
72	Defining the quality characteristics of endoscopy for acute variceal hemorrhage in cirrhosis. Hepatology, 2010, 52, 1850-1851.	3.6	0
73	Nonalcoholic fatty liver disease: is it all in the genes?. Hepatology, 2010, 52, 1851-1854.	3.6	0
74	Liver fibrosis: from animal models to mapping of human risk variants. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 635-646.	1.0	18
75	Nonalcoholic fatty liver disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 695-708.	1.0	158

#	Article	IF	Citations
76	Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology, 2010, 10, 102.	0.8	53
77	Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Medical Genetics, 2010, 11, 172.	2.1	140
78	Tissueâ€Specificity and Ethnic Diversity in Obesityâ€Related Risk of Cancer May Be Explained by Variability in Insulin Response and Insulin Signaling Pathways. Obesity, 2010, 18, 1071-1078.	1.5	10
79	Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. International Journal of Obesity, 2010, 34, 190-194.	1.6	161
80	Variant in PNPLA3 is associated with alcoholic liver disease. Nature Genetics, 2010, 42, 21-23.	9.4	388
81	Getting biological about the genetics of diabetes. Nature Medicine, 2010, 16, 388-391.	15.2	35
82	A fresh look at NASH pathogenesis. Part 1: The metabolic movers. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 672-690.	1.4	153
83	Failure of islet Î²â€cell compensation for insulin resistance causes type 2 diabetes: What causes nonâ€alcoholic fatty liver disease and nonâ€alcoholic steatohepatitis?. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1594-1597.	1.4	8
84	Nonalcoholic fatty liver disease in children. Current Opinion in Clinical Nutrition and Metabolic Care, 2010, 14, 1.	1.3	72
87	Specifically PNPLA3-Mediated Accumulation of Liver Fat in Obese Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E430-E436.	1.8	39
88	Effects of PNPLA3 on Liver Fat and Metabolic Profile in Hispanic Children and Adolescents. Diabetes, 2010, 59, 3127-3130.	0.3	100
89	Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. American Journal of Clinical Nutrition, 2010, 92, 1522-1527.	2.2	175
90	A feed-forward loop amplifies nutritional regulation of PNPLA3. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7892-7897.	3.3	319
91	Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut, 2010, 59, 1303-1307.	6.1	149
92	Genome-wide association studies and genetic risk assessment of liver diseases. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 669-681.	8.2	68
93	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut, 2010, 59, 267-273.	6.1	148
94	A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis. Journal of Biological Chemistry, 2010, 285, 6706-6715.	1.6	507
95	A common variant in the adiponutrin gene influences liver enzyme values. Journal of Medical Genetics, 2010, 47, 116-119.	1.5	57

#	Article	IF	Citations
98	On the Use of Variance per Genotype as a Tool to Identify Quantitative Trait Interaction Effects: A Report from the Women's Genome Health Study. PLoS Genetics, 2010, 6, e1000981.	1.5	175
99	Environmental and Genetic Determinants of Fatty Liver in Humans. Digestive Diseases, 2010, 28, 169-178.	0.8	32
100	A new Thematic Series: Genetics of human lipid diseases. Journal of Lipid Research, 2010, 51, 1621-1623.	2.0	0
101	Novel Insights into the Pathophysiology of Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2010, 30, 391-401.	1.8	106
102	Non-Invasive Diagnostic Tests for Non-Alcoholic Fatty Liver Disease. Current Molecular Medicine, 2010, 10, 166-172.	0.6	27
103	Genetics of the Metabolic Complications of Obesity. Progress in Molecular Biology and Translational Science, 2010, 94, 349-372.	0.9	1
104	Fibrosis in the Liver. Progress in Molecular Biology and Translational Science, 2010, 97, 151-200.	0.9	29
105	Apolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver Disease. New England Journal of Medicine, 2010, 363, 193-195.	13.9	5
106	Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Review of Endocrinology and Metabolism, 2010, 5, 403-423.	1.2	22
109	Apolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver Disease. New England Journal of Medicine, 2010, 362, 1082-1089.	13.9	384
110	Liver Fat in the Pathogenesis of Insulin Resistance and Type 2 Diabetes. Digestive Diseases, 2010, 28, 203-209.	0.8	98
111	From the metabolic syndrome to NAFLD or vice versa?. Digestive and Liver Disease, 2010, 42, 320-330.	0.4	406
112	Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2010, 14, 591-604.	1.0	59
113	Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1Î² in Mice. Gastroenterology, 2010, 139, 323-334.e7.	0.6	640
114	Genetic Covariance Between Î³-Glutamyl Transpeptidase and Fatty Liver Risk Factors: Role of Î²2-Adrenergic Receptor Genetic Variation in Twins. Gastroenterology, 2010, 139, 836-845.e1.	0.6	53
115	Genome-Wide Association Study Identifies Variants Associated With Histologic Features of Nonalcoholic Fatty Liver Disease. Gastroenterology, 2010, 139, 1567-1576.e6.	0.6	270
116	The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status. Journal of Hepatology, 2010, 52, 244-251.	1.8	90
117	The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. Journal of Hepatology, 2010, 53, 335-338.	1.8	146

#	Article	IF	Citations
118	Dissecting the evolutionary genetics of iron overload in non-alcoholic fatty liver disease. Journal of Hepatology, 2010, 53, 793-794.	1.8	3
119	Emerging roles of secreted phospholipase A2 enzymes: Lessons from transgenic and knockout mice. Biochimie, 2010, 92, 561-582.	1.3	141
120	Fatty liver and lipotoxicity. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 299-310.	1.2	232
121	Regulation of the promoter region of the human adiponutrin/PNPLA3 gene by glucose and insulin. Biochemical and Biophysical Research Communications, 2010, 402, 767-772.	1.0	35
122	Biosynthesis and bioavailability of long-chain polyunsaturated fatty acids in non-alcoholic fatty liver disease. Progress in Lipid Research, 2010, 49, 407-419.	5.3	42
123	Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review. Advances in Pediatrics, 2010, 57, 85-140.	0.5	40
124	The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 251-264.	8.2	626
125	Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. Atherosclerosis, 2010, 208, 305-316.	0.4	82
126	Lipid-induced insulin resistance: unravelling the mechanism. Lancet, The, 2010, 375, 2267-2277.	6.3	944
127	The Role of Muscle Insulin Resistance in the Pathogenesis of Atherogenic Dyslipidemia and Nonalcoholic Fatty Liver Disease Associated with the Metabolic Syndrome. Annual Review of Nutrition, 2010, 30, 273-290.	4.3	105
128	Genetic and Environmental Susceptibility to Non-Alcoholic Fatty Liver Disease. Digestive Diseases, 2010, 28, 255-260.	0.8	73
129	Pathology of nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 195-203.	8.2	417
130	Hepatitis C and metabolic syndrome. Expert Review of Endocrinology and Metabolism, 2010, 5, 209-215.	1.2	0
131	Secreted phospholipase A2 revisited. Journal of Biochemistry, 2011, 150, 233-255.	0.9	204
133	Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. Expert Opinion on Pharmacotherapy, 2011, 12, 2657-2672.	0.9	20
134	Phospholipase A₂ Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention. Chemical Reviews, 2011, 111, 6130-6185.	23.0	953
135	Chronic Liver Disease in the Hispanic Population of the United States. Clinical Gastroenterology and Hepatology, 2011, 9, 834-841.	2.4	85
136	Advances in Pediatric Nonalcoholic Fatty Liver Disease. Pediatric Clinics of North America, 2011, 58, 1375-1392.	0.9	46

#	Article	IF	Citations
137	Liver fibrogenesis and genetic factors. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, S3-S9.	0.7	7
138	Animal models of nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 35-44.	8.2	399
139	Inflammation in nonalcoholic steatohepatitis. Expert Review of Gastroenterology and Hepatology, 2011, 5, 189-200.	1.4	72
140	Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 97-113.	2.7	253
141	The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease. Chemical Reviews, 2011, 111, 6022-6063.	23.0	321
142	Analysis of Single Nucleotide Polymorphisms in Caseâ€“Control Studies. Methods in Molecular Biology, 2011, 719, 219-234.	0.4	1
143	Human Fatty Liver Disease: Old Questions and New Insights. Science, 2011, 332, 1519-1523.	6.0	1,780
144	Mammalian Triacylglycerol Metabolism: Synthesis, Lipolysis, and Signaling. Chemical Reviews, 2011, 111, 6359-6386.	23.0	218
145	Clan Genomics and the Complex Architecture of Human Disease. Cell, 2011, 147, 32-43.	13.5	330
146	Association of PNPLA3 SNP rs738409 with liver density in African Americans with type 2 diabetes mellitus. Diabetes and Metabolism, 2011, 37, 452-455.	1.4	22
148	Genetic modifiers of non-alcoholic fatty liver disease progression. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1557-1566.	1.8	59
149	Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. Journal of Hepatology, 2011, 55, 145-153.	1.8	116
150	Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: Non-invasive elastography-based study in chronic liver disease. Journal of Hepatology, 2011, 55, 299-306.	1.8	78
151	Viral genotype-specific role of PNPLA3 , PPARG , MTTP, and IL28B in hepatitis C virus-associated steatosis. Journal of Hepatology, 2011, 55, 529-535.	1.8	98
152	Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. Journal of Hepatology, 2011, 55, 732-733.	1.8	32
153	Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. Journal of Hepatology, 2011, 55, 906-912.	1.8	138
154	Focus. Journal of Hepatology, 2011, 55, 1-2.	1.8	4
155	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. Journal of Hepatology, 2011, 55, 1409-1414.	1.8	74

#	Article	IF	Citations
156	Modulation of the effect of PNPLA3 I148M mutation on steatosis and liver damage by alcohol intake in patients with chronic hepatitis C. Journal of Hepatology, 2011, 55, 1470-1471.	1.8	16
157	Focus. Journal of Hepatology, 2011, 55, 503-504.	1.8	1
158	Reply to: â€œModulation of the effect of PNPLA3 I148M mutation on steatosis and liver damage by alcohol intake in patients with chronic hepatitis Câ€. Journal of Hepatology, 2011, 55, 1471-1472.	1.8	5
159	APOC3 polymorphisms and non-alcoholic fatty liver disease: Resolving some doubts and raising others. Journal of Hepatology, 2011, 55, 1184-1186.	1.8	6
160	Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends in Endocrinology and Metabolism, 2011, 22, 353-363.	3.1	293
161	Recent progress in phospholipase A2 research: From cells to animals to humans. Progress in Lipid Research, 2011, 50, 152-192.	5.3	437
162	Hepatology Elsewhere. Journal of Clinical and Experimental Hepatology, 2011, 1, 49-52.	0.4	0
163	Molecular characteristics of nonâ€cancerous liver tissue in nonâ€B nonâ€C hepatocellular carcinoma. Hepatology Research, 2011, 41, 711-721.	1.8	25
164	Clinicopathological features of nonâ€alcoholic fatty liver disease. Hepatology Research, 2011, 41, 911-920.	1.8	25
165	Angiotensinogen gene haplotype is associated with the prevalence of Japanese nonâ€alcoholic steatohepatitis. Hepatology Research, 2011, 41, 1223-1229.	1.8	15
166	Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2011, 5, 253-263.	1.4	53
167	Genetics of non-alcoholic fatty liver disease and associated metabolic disorders. Avances En DiabetologÃa, 2011, 27, 186-197.	0.1	3
168	The role of lipid droplets in metabolic disease in rodents and humans. Journal of Clinical Investigation, 2011, 121, 2102-2110.	3.9	526
170	Mechanisms of Lipotoxicity in NAFLD and Clinical Implications. Journal of Pediatric Gastroenterology and Nutrition, 2011, 53, 131-140.	0.9	157
171	The Importance of Global Studies of the Genetics of Type 2 Diabetes. Diabetes and Metabolism Journal, 2011, 35, 91.	1.8	14
172	Bioinformatics-Driven Identification and Examination of Candidate Genes for Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2011, 6, e16542.	1.1	21
173	Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits. PLoS Genetics, 2011, 7, e1001324.	1.5	796
174	Association of PNPLA3 (rs738409 C>G) with liver damage in liver diseases: one step closer to personalized medicine?. Personalized Medicine, 2011, 8, 595-597.	0.8	5

#	Article	IF	Citations
175	Genetics in liver disease: new concepts. Current Opinion in Gastroenterology, 2011, 27, 231-239.	1.0	19
177	Effects of Hesperidin on the Progression of Hypercholesterolemia and Fatty Liver Induced by High-Cholesterol Diet in Rats. Journal of Pharmacological Sciences, 2011, 117, 129-138.	1.1	87
178	Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism, 2011, 13, 692-702.	2.2	92
179	Pathogenesis of alcoholâ€induced liver disease: Classical concepts and recent advances. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1089-1105.	1.4	138
180	Systematic review: the diagnosis and staging of nonâ€alcoholic fatty liver disease and nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2011, 33, 525-540.	1.9	254
181	Systematic review: the epidemiology and natural history of nonâ€alcoholic fatty liver disease and nonâ€alcoholic steatohepatitis in adults. Alimentary Pharmacology and Therapeutics, 2011, 34, 274-285.	1.9	2,569
182	Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study. Liver International, 2011, 31, 412-416.	1.9	70
183	Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. Liver International, 2011, 31, 461-473.	1.9	41
184	The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver International, 2011, 31, 1326-1331.	1.9	65
185	PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver International, 2011, 31, 1137-1143.	1.9	102
186	PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes. Liver International, 2011, 31, 1332-1336.	1.9	25
187	Understanding the relationship between <scp>PNPLA</scp>3, <scp>NAFLD</scp> and insulin resistance: do ethnic differences bring more questions or more answers?. Liver International, 2011, 31, 1246-1249.	1.9	5
188	Genetics of Liver Injury and Fibrosis. Alcoholism: Clinical and Experimental Research, 2011, 35, 800-803.	1.4	6
189	Expanding the range of ZNF804A variants conferring risk of psychosis. Molecular Psychiatry, 2011, 16, 59-66.	4.1	140
190	A Common Variant in the PNPLA3 Gene is a Risk Factor for Non-Alcoholic Fatty Liver Disease in Obese Taiwanese Children. Journal of Pediatrics, 2011, 158, 740-744.	0.9	86
191	PNPLA3 I148M polymorphism and liver damage in obese children. Journal of Pediatrics, 2011, 159, 876.	0.9	3
192	Misidentification of a transverse occipital suture as a persistent mendosal suture. Journal of Pediatrics, 2011, 159, 876-877.	0.9	4
193	Treatment of Atherogenic Liver Based on the Pathogenesis of Nonalcoholic Fatty Liver Disease: A Novel Approach to Reduce Cardiovascular Risk?. Archives of Medical Research, 2011, 42, 337-353.	1.5	35

#	Article	IF	Citations
195	Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nature Reviews Endocrinology, 2011, 7, 456-465.	4.3	272
196	Cryptogenic Chronic Hepatitis and Its Changing Guise in Adults. Digestive Diseases and Sciences, 2011, 56, 3421-3438.	1.1	46
197	Molecular characterization, expression and chromosomal localization of porcine PNPLA3 and PNPLA4. Biotechnology Letters, 2011, 33, 1327-1337.	1.1	4
198	Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. Molecular Biology Reports, 2011, 38, 1145-1150.	1.0	56
199	Prevalence, gender, ethnic variations, and prognosis of NASH. Journal of Gastroenterology, 2011, 46, 63-69.	2.3	207
201	Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology, 2011, 53, 86-95.	3.6	252
202	Beta-blockers in patients with cirrhosis and refractory ascites. Hepatology, 2011, 53, 1783-1783.	3.6	7
203	Need for a three-focused approach to nonalcoholic fatty liver disease. Hepatology, 2011, 53, 1773-1773.	3.6	9
204	Dissociation betweenAPOC3variants, hepatic triglyceride content and insulin resistance. Hepatology, 2011, 53, 467-474.	3.6	122
205	Pathogen DNA also contributes to interferon regulatory factor 3 activation in hepatic cells: Implications for alcoholic liver diseases. Hepatology, 2011, 53, 1783-1784.	3.6	3
206	Bile acid sequestrants improve glycemic control in type 2 diabetes: A proposed mechanism implicating glucagon-like peptide 1 release. Hepatology, 2011, 53, 1784-1784.	3.6	27
207	Does the donor mannose-binding lectin genotype really predict the risk of bacterial infections after liver transplantation?. Hepatology, 2011, 53, 1786-1787.	3.6	6
208	Insulin resistance links nonalcoholic fatty liver to cardiovascular diseases. Hepatology, 2011, 53, 1785-1786.	3.6	2
209	Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology, 2011, 53, 791-799.	3.6	227
211	Is endotoxemia a therapeutic target in liver injury?. Hepatology, 2011, 53, 1785-1785.	3.6	1
212	Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story. Hepatology, 2011, 53, 1774-1775.	3.6	1
213	The impact of human immunodeficiency virus infection in liver transplantation for hepatocellular carcinoma. Hepatology, 2011, 53, 1777-1778.	3.6	2
214	Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. Hepatology, 2011, 53, 1776-1776.	3.6	49

#	Article	IF	Citations
215	Noninvasive assessment of cystic fibrosis-associated liver disease with acoustic radiation force impulse imaging. Hepatology, 2011, 53, 1779-1780.	3.6	10
218	Patatin-like phospholipase domain-containing protein 3 genotype and hepatocellular carcinoma in chronic hepatitis C. Hepatology, 2011, 53, 1777-1777.	3.6	6
219	Noninvasive assessment of liver fibrosis: The need for better validation. Hepatology, 2011, 53, 1781-1782.	3.6	10
220	Methods and interest of noninvasive assessment of liver fibrosis are still in debate. Hepatology, 2011, 53, 1781-1781.	3.6	7
221	Metaâ€analysis of the influence of I148M variant of patatinâ€like phospholipase domain containing 3 gene () Tj ETQq0 0 0 rgBT /Overlo Hepatology, 2011, 53, 1883-1894.	3.6	766
222	Reply: The utility of noninvasive imaging in cystic fibrosis liver disease. Hepatology, 2011, 53, 1780-1781.	3.6	0
224	Outcome of patients suffering from a spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure and treated with antivirals. Hepatology, 2011, 54, 1108-1109.	3.6	2
225	Lack of an association between an apolipoprotein C3 genetic variant and the liver fat content in patients with type 2 diabetes. Hepatology, 2011, 54, 1109-1110.	3.6	2
226	Vitamin D deficiency may link diabetes and liver neoplasms. Hepatology, 2011, 54, 1111-1111.	3.6	1
227	Carnitine palmitoyltransferase as a potential target for treating diabetes: Is inhibition or activation preferable?. Hepatology, 2011, 54, 1110-1111.	3.6	0
228	Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology, 2011, 54, 60-69.	3.6	166
229	Profound differences of microRNA expression patterns in hepatocytes and hepatoma cell lines commonly used in hepatitis C virus studies. Hepatology, 2011, 54, 1111-1112.	3.6	9
230	Updated management of hepatocellular carcinoma. Hepatology, 2011, 54, 1113-1113.	3.6	10
231	Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis. Hepatology, 2011, 54, 509-521.	3.6	67
232	Stem cells or macrophages: Which contribute to bone marrow cell therapy for liver cirrhosis?. Hepatology, 2011, 54, 1103-1103.	3.6	3
233	Association of the cannabinoid receptor 2 (CB2) Gln63Arg polymorphism with indices of liver damage in obese children: An alternative way to highlight the CB2 hepatoprotective properties. Hepatology, 2011, 54, 1102-1102.	3.6	17
234	Reply:. Hepatology, 2011, 54, 1104-1104.	3.6	0
235	Reply:. Hepatology, 2011, 54, 1102-1103.	3.6	2

#	Article	IF	Citations
236	Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology, 2011, 54, 837-845.	3.6	74
237	Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology, 2011, 54, 1104-1105.	3.6	4
238	Human hepatic stellate cells are liver-resident antigen-presenting cells. Hepatology, 2011, 54, 1107-1107.	3.6	4
239	Reply:. Hepatology, 2011, 54, 1105-1105.	3.6	0
240	Clinical correlation of miR-375 and alpha-fetoprotein in hepatocellular carcinoma: Comparison in mice and humans. Hepatology, 2011, 54, 1105-1106.	3.6	5
242	Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial. Hepatology, 2011, 54, 1631-1639.	3.6	150
243	Prominent regulatory but weak antigen-presenting cell function of hepatic stellate cells. Hepatology, 2011, 54, 1108-1108.	3.6	10
244	Noninvasive assessment of liver fibrosis: The clinical context and question are important. Hepatology, 2011, 54, 2277-2277.	3.6	8
245	I148M variant of PNPLA3 confer increased risk for nonalcoholic fatty liver disease not only in European population, but also in Chinese population. Hepatology, 2011, 54, 2276-2276.	3.6	17
246	Apolipoprotein CIII overexpressing mice are predisposed to dietâ€induced hepatic steatosis and hepatic insulin resistance. Hepatology, 2011, 54, 1650-1660.	3.6	114
247	Targeting the renin-angiotensin system: Potential beneficial effects of the angiotensin II receptor blockers in patients with nonalcoholic steatohepatitis. Hepatology, 2011, 54, 2277-2278.	3.6	4
248	Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?. Hepatology, 2011, 54, 1118-1120.	3.6	19
249	Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. Hepatology, 2011, 54, 2279-2279.	3.6	25
250	Metabolic Syndrome Is Also a Risk Factor for Primary Liver Cancer in Patients Younger than 65 Years of Age?. Hepatology, 2011, 54, 2278-2279.	3.6	6
251	Clusters of differentiation 24 polymorphism and hepatocellular carcinoma. Hepatology, 2011, 54, 2274-2275.	3.6	5
253	Idiopathic noncirrhotic intrahepatic portal hypertension is an ongoing problem in India. Hepatology, 2011, 54, 2275-2276.	3.6	15
255	Genetics and epigenetics in the fibrogenic evolution ofÂchronic liver diseases. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 269-280.	1.0	33
256	Adiposity, Inflammation, and Risk for Death in Black and White Men and Women in the United States: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1805-1814.	1.8	26

#	Article	IF	Citations
257	Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease. Clinical Lipidology, 2011, 6, 305-314.	0.4	30
259	The Impact of Human Gene Polymorphisms on HCV Infection and Disease Outcome. Seminars in Liver Disease, 2011, 31, 375-386.	1.8	19
260	Relevance ofTNF-Î± gene polymorphisms in nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2011, 5, 155-158.	1.4	6
261	Genetics of Alcoholic and Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2011, 31, 128-146.	1.8	101
263	Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opinion on Emerging Drugs, 2011, 16, 121-136.	1.0	18
264	Genetic determinants of hepatic steatosis in man. Journal of Lipid Research, 2011, 52, 593-617.	2.0	115
265	Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. Journal of Lipid Research, 2011, 52, 318-329.	2.0	190
266	Nonalcoholic steatohepatitis. Current Opinion in Lipidology, 2011, 22, 479-488.	1.2	98
267	The Metabolically Benign and Malignant Fatty Liver. Diabetes, 2011, 60, 2011-2017.	0.3	158
268	Lipids in the Wrong Place: Visceral Fat and Nonalcoholic Steatohepatitis. Diabetes Care, 2011, 34, S367-S370.	4.3	37
269	Non-alcoholic fatty liver disease: what's new under the microscope?. Gut, 2011, 60, 1152-1158.	6.1	31
270	Sex-dependent hepatic transcripts and metabolites in the development of glucose intolerance and insulin resistance in Zucker diabetic fatty rats. Journal of Molecular Endocrinology, 2011, 47, 129-143.	1.1	24
271	Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight lossâ€“induced decrease in liver fat in humans. American Journal of Clinical Nutrition, 2011, 94, 104-111.	2.2	131
272	Expert opinion on current therapies for nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy, 2011, 12, 1901-1911.	0.9	13
273	The impact of genetic variability on liver disease in the Hispanic/Latin-American population. Autoimmunity, 2011, 44, 549-554.	1.2	1
274	A Comparison of Approaches to Control for Confounding Factors by Regression Models. Human Heredity, 2011, 72, 194-205.	0.4	8
275	Expression and Characterization of a PNPLA3 Protein Isoform (I148M) Associated with Nonalcoholic Fatty Liver Disease. Journal of Biological Chemistry, 2011, 286, 37085-37093.	1.6	240
276	A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Human Molecular Genetics, 2011, 20, 3884-3892.	1.4	205

#	Article	IF	Citations
277	Genome-Wide Association Analysis of Soluble ICAM-1 Concentration Reveals Novel Associations at the NFKBIK, PNPLA3, RELA, and SH2B3 Loci. PLoS Genetics, 2011, 7, e1001374.	1.5	76
278	Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis?. Expert Review of Gastroenterology and Hepatology, 2011, 5, 265-277.	1.4	2
279	Tsc2, a positional candidate gene underlying a quantitative trait locus for hepatic steatosis. Journal of Lipid Research, 2012, 53, 1493-1501.	2.0	9
280	PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E1063-E1069.	1.8	76
281	Toward a Unifying Hypothesis of Metabolic Syndrome. Pediatrics, 2012, 129, 557-570.	1.0	148
283	Genetic-related and carbohydrate-related factors affecting liver fat accumulation. Current Opinion in Clinical Nutrition and Metabolic Care, 2012, 15, 392-396.	1.3	26
284	From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients. Current Opinion in Infectious Diseases, 2012, 25, 10-16.	1.3	68
285	Quantitative Trait Loci Affecting Liver Fat Content in Mice. G3: Genes, Genomes, Genetics, 2012, 2, 1019-1025.	0.8	5
286	Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Human Molecular Genetics, 2012, 21, 3500-3512.	1.4	198
287	Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. American Journal of Clinical Nutrition, 2012, 95, 892-900.	2.2	109
288	Systemic SIRT1 insufficiency results in disruption of energy homeostasis and steroid hormone metabolism upon highâ€fatâ€diet feeding. FASEB Journal, 2012, 26, 656-667.	0.2	52
289	Adiponectin as an Independent Predictor of the Presence and Degree of Hepatic Steatosis in the Dallas Heart Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E982-E986.	1.8	39
290	Pancreatic Steatosis and Its Relationship to Î²-Cell Dysfunction in Humans. Diabetes Care, 2012, 35, 2377-2383.	4.3	102
292	Cold exposure down-regulates adiponutrin/PNPLA3 mRNA expression and affects its nutritional regulation in adipose tissues of lean and obese Zucker rats. British Journal of Nutrition, 2012, 107, 1283-1295.	1.2	3
293	Visceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content. International Journal of Obesity, 2012, 36, 774-782.	1.6	31
294	The Interaction of rs738409, Obesity, and Alcohol: A Population-Based Autopsy Study. American Journal of Gastroenterology, 2012, 107, 1668-1674.	0.2	23
295	Pediatric Metabolic Syndrome. , 2012, , .		8
296	Dietary Fat Is a Lipid Source in 2,3,7,8-Tetrachlorodibenzo-Ï•Dioxin (TCDD)-Elicited Hepatic Steatosis in C57BL/6 Mice. Toxicological Sciences, 2012, 128, 377-386.	1.4	46

#	Article	IF	Citations
298	Non-Alcoholic Steatohepatitis: New Insights from OMICS Studies. Current Pharmaceutical Biotechnology, 2012, 13, 726-735.	0.9	41
299	Modelling Metabolic Pathways Involved in the Pathogenesis of Non-Alcoholic Fatty Liver Disease. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2012, 45, 912-917.	0.4	0
300	Nonalcoholic fatty liver disease and lipids. Current Opinion in Lipidology, 2012, 23, 345-352.	1.2	49
302	Slow Growth. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 438-438.	0.9	0
303	LPIN1 rs13412852 Polymorphism in Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 588-593.	0.9	59
304	Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options. Current Vascular Pharmacology, 2012, 10, 162-172.	0.8	42
305	Sex and race differences in the prevalence of fatty liver disease as measured by computed tomography liver attenuation in European American and African American participants of the NHLBI family heart study. European Journal of Gastroenterology and Hepatology, 2012, 24, 9-16.	0.8	21
306	2012 Meet-The-Professor: Endocrine Case Management. , 2012, , .		0
307	Science of Nonalcoholic Fatty Liver Disease in Anti-Aging Medicine 2011. Anti-aging Medicine, 2012, 9, 24-33.	0.7	1
308	Uric Acid as a Surrogate for Fructose Intake Is Not Supported. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 439-439.	0.9	0
309	Adiposity in children and adolescents: correlates and clinical consequences of fat stored in specific body depots. Pediatric Obesity, 2012, 7, e42-61.	1.4	63
310	Review article: is nonâ€alcoholic fatty liver disease a spectrum, or are steatosis and nonâ€alcoholic steatohepatitis distinct conditions?. Alimentary Pharmacology and Therapeutics, 2012, 36, 815-823.	1.9	173
311	Cholesteryl ester transfer protein gene polymorphisms increase the risk of fatty liver in females independent of adiposity. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1520-1527.	1.4	33
312	The Genetic Epidemiology of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2012, 16, 467-485.	1.0	43
313	Role of mitochondria in nonalcoholic fatty liver disease-from origin to propagation. Clinical Biochemistry, 2012, 45, 610-618.	0.8	108
314	Does fructose consumption contribute to non-alcoholic fatty liver disease?. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 554-560.	0.7	85
315	Hepatocellular carcinoma in nonâ€alcoholic steatohepatitis: Growing evidence of an epidemic?. Hepatology Research, 2012, 42, 1-14.	1.8	106
316	Understanding the Role of PNPLA3 Genetic Variants in Patients with Chronic Hepatitis C Infection. Digestive Diseases and Sciences, 2012, 57, 1977-1979.	1.1	1

#	Article	IF	Citations
317	It is Patatin-like Phospholipase Domain-containing 3 Gene (PNPLA3)â€"All the Way. Journal of Clinical and Experimental Hepatology, 2012, 2, 94-96.	0.4	0
318	Describing the role of ethnicity in the progression of NAFLD: Easier said than done?. Hepatology, 2012, 56, 2005-2005.	3.6	2
319	Metabolic oxidation controls the hepatic stem cells (HpSCs) fate and the hepatic lineage organization in physiologic and pathologic conditions. Hepatology, 2012, 56, 2006-2007.	3.6	3
320	Reply:. Hepatology, 2012, 56, 2005-2006.	3.6	0
321	Population-based Risk Factors for Elevated Alanine Aminotransferase in a South Texas Mexicanâ€"American Population. Archives of Medical Research, 2012, 43, 482-488.	1.5	13
322	A little+a little equals a lotâ€"Does the combination of modest increases of liver inflammation and plasma cholesterol augment atherosclerosis?. Atherosclerosis, 2012, 220, 321-322.	0.4	0
323	Nonalcoholic Fatty Liver in Children and Adolescents: An Overview. Journal of Adolescent Health, 2012, 51, 305-312.	1.2	37
324	Vertebrate patatin-like phospholipase domain-containing protein 4 (PNPLA4) genes and proteins: a gene with a role in retinol metabolism. 3 Biotech, 2012, 2, 277-286.	1.1	6
325	Is Nonalcoholic Fatty Liver Disease in Children the Same Disease as in Adults?. Clinics in Liver Disease, 2012, 16, 587-598.	1.0	10
326	Nonalcoholic Fatty Liver Disease in Pediatric Patients. Journal of Parenteral and Enteral Nutrition, 2012, 36, 43S-48S.	1.3	9
327	Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: Pathogenetic role of genetic background and intrauterine environment. Annals of Medicine, 2012, 44, 29-40.	1.5	94
328	Fatty liver disease. , 2012, , 293-359.		16
329	Blindly Using Wald's Test Can Miss Rare Diseaseâ€Causal Variants in Caseâ€Control Association Studies. Annals of Human Genetics, 2012, 76, 168-177.	0.3	25
330	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. Journal of Hepatology, 2012, 56, 448-454.	1.8	156
331	Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. Journal of Hepatology, 2012, 56, 663-670.	1.8	87
332	Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. Journal of Hepatology, 2012, 56, 1209-1210.	1.8	18
333	Reply to: â€œInteraction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patientsâ€. Journal of Hepatology, 2012, 56, 1210-1212.	1.8	4
334	Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. Journal of Hepatology, 2012, 57, 663-674.	1.8	140

#	Article	IF	Citations
335	Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). Journal of Hepatology, 2012, 57, 384-391.	1.8	233
336	Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. Journal of Hepatology, 2012, 57, 492-498.	1.8	48
337	Liver triacylglycerol lipases. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 762-769.	1.2	66
338	Genetic predisposition and increasing dietary fructose exposure: The perfect storm for fatty liver disease in Hispanics in the U.S.. Digestive and Liver Disease, 2012, 44, 711-713.	0.4	12
339	Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell, 2012, 148, 852-871.	13.5	1,681
340	FAT SIGNALS - Lipases and Lipolysis in Lipid Metabolism and Signaling. Cell Metabolism, 2012, 15, 279-291.	7.2	852
341	Diacylglycerol Activation of Protein Kinase CÎµ and Hepatic Insulin Resistance. Cell Metabolism, 2012, 15, 574-584.	7.2	247
342	Nuclear Receptors Reverse McGarry's Vicious Cycle to Insulin Resistance. Cell Metabolism, 2012, 15, 615-622.	7.2	33
343	Adiponutrin Functions as a Nutritionally Regulated Lysophosphatidic Acid Acyltransferase. Cell Metabolism, 2012, 15, 691-702.	7.2	258
344	A Role for Period 2 in Cardioprotection. Cell Metabolism, 2012, 16, 2-4.	7.2	3
345	Leptin in the Liver: A Toxic or Beneficial Mix?. Cell Metabolism, 2012, 16, 1-2.	7.2	14
346	Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: A narrative review. GastroenterologÃa Y HepatologÃa, 2012, 35, 32-41.	0.2	45
347	The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterology, 2012, 12, 111.	0.8	62
348	Prevalence and factors associated with nonalcoholic fatty liver disease in shanghai work-units. BMC Gastroenterology, 2012, 12, 123.	0.8	77
349	Genetic variant I148M in PNPLA3 is associated with the ultrasonography-determined steatosis degree in a Chinese population. BMC Medical Genetics, 2012, 13, 113.	2.1	31
350	PNPLA 3I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Medical Genetics, 2012, 13, 82.	2.1	21
351	Nonâ€alcoholic fatty liver disease. Journal of Diabetes, 2012, 4, 266-280.	0.8	46
352	Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2012, 16, 397-419.	1.0	58

#	Article	IF	Citations
353	Non-alcoholic Fatty Liver Disease: East Versus West. Journal of Clinical and Experimental Hepatology, 2012, 2, 122-134.	0.4	37
354	Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. Journal of Clinical and Experimental Hepatology, 2012, 2, 135-144.	0.4	70
355	Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications. Gastroenterology, 2012, 142, 711-725.e6.	0.6	711
356	Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. Gastroenterology, 2012, 143, 1244-1252.e12.	0.6	142
357	PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Digestive and Liver Disease, 2012, 44, 1037-1041.	0.4	100
358	PNPLA3 Ile148Met variant and hepatocellular carcinoma: A matter of fat. Digestive and Liver Disease, 2012, 44, 974-975.	0.4	3
360	Genetic variants of TNFÎ±, IL10, IL1Î², CTLA4 and TGFÎ²1 modulate the indices of alcohol-induced liver injury in East Indian population. Gene, 2012, 509, 178-188.	1.0	25
361	Genomics and HCV infection: Progression of fibrosis and treatment response. Journal of Hepatology, 2012, 57, 1110-1125.	1.8	89
362	Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2012, 10, 837-858.	2.4	229
363	Mechanisms of Simple Hepatic Steatosis. Clinics in Liver Disease, 2012, 16, 505-524.	1.0	23
364	Atypical angiopoietin-like protein that regulates ANGPTL3. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19751-19756.	3.3	375
365	Metabolic Syndrome and Related Liver Diseases. , 2012, , 137-157.		0
366	Non-alcoholic steatohepatitis: an overview including treatments with herbals as alternative therapeutics. Journal of Applied Biomedicine, 2012, 10, 119-136.	0.6	12
367	Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. Journal of Hepatology, 2012, 57, 1276-1282.	1.8	232
368	Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes. Clinical Nutrition, 2012, 31, 520-525.	2.3	36
369	Insulin resistance is associated with elevated serum pigment epitheliumâ€“derived factor (PEDF) levels in morbidly obese patients. Acta Diabetologica, 2012, 49, 161-169.	1.2	27
370	The Nutrigenetics and Nutrigenomics of the Dietary Requirement for Choline. Progress in Molecular Biology and Translational Science, 2012, 108, 159-177.	0.9	16
371	Studying non-alcoholic fatty liver disease with zebrafish: a confluence of optics, genetics, and physiology. Cellular and Molecular Life Sciences, 2012, 69, 3953-3961.	2.4	55

#	Article	IF	Citations
372	Hepatic Fat Accumulation Is Modulated by the Interaction between the rs738409 Variant in the PNPLA3 Gene and the Dietary Omega6/Omega3 PUFA Intake. PLoS ONE, 2012, 7, e37827.	1.1	94
373	Paradoxical Lower Serum Triglyceride Levels and Higher Type 2 Diabetes Mellitus Susceptibility in Obese Individuals with the PNPLA3 148M Variant. PLoS ONE, 2012, 7, e39362.	1.1	78
374	The PNPLA3 rs738409 G-Allele Associates with Reduced Fasting Serum Triglyceride and Serum Cholesterol in Danes with Impaired Glucose Regulation. PLoS ONE, 2012, 7, e40376.	1.1	28
375	Cannabinoid Receptor Type 2 Functional Variant Influences Liver Damage in Children with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e42259.	1.1	44
376	Genetic and metabolic liver disease. , 2012, , 157-259.		8
377	NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut and Liver, 2012, 6, 149-171.	1.4	334
378	Nonalcoholic Fatty Liver Disease: A Pathological View. , 0, , .		5
379	Auxiliary Liver Transplantation for Amanita phalloides Poisoning. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 438-438.	0.9	3
380	The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection. Digestive Diseases and Sciences, 2012, 57, 2213-2221.	1.1	25
381	Lipolytic proteomics. Mass Spectrometry Reviews, 2012, 31, 570-582.	2.8	4
382	Glucokinase links KrÃ¼ppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. Hepatology, 2012, 55, 1083-1093.	3.6	55
383	Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice. Hepatology, 2012, 56, 270-280.	3.6	75
384	I148M PNPLA3 variant and progressive liver disease: A new paradigm in hepatology. Hepatology, 2012, 56, 791-791.	3.6	30
385	Interstrain differences in liver injury and one-carbon metabolism in alcohol-fed mice. Hepatology, 2012, 56, 130-139.	3.6	52
386	PNPLA1 mutations cause autosomal recessive congenital ichthyosis in golden retriever dogs and humans. Nature Genetics, 2012, 44, 140-147.	9.4	208
387	Increased prevalence of diabetic complications in Japanese patients with type 1 diabetes and nonalcoholic fatty liver disease. Diabetology International, 2012, 3, 37-41.	0.7	5
388	Genetic Variation in the Peroxisome Proliferator Activated Receptor-Gamma Gene Is Associated with Histologically Advanced NAFLD. Digestive Diseases and Sciences, 2012, 57, 952-957.	1.1	44
389	A caseâ€“control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease. Molecular Biology Reports, 2012, 39, 7381-7388.	1.0	21

#	Article	IF	Citations
390	A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Human Genetics, 2012, 131, 1145-1152.	1.8	84
391	Inflammation and fibrogenesis in steatohepatitis. Journal of Gastroenterology, 2012, 47, 215-225.	2.3	123
392	Diet-induced obesity affects expression of adiponutrin/PNPLA3 and adipose triglyceride lipase, two members of the same family. International Journal of Obesity, 2012, 36, 225-232.	1.6	23
393	Fish to meat intake ratio and cooking oils are associated with hepatitis C virus carriers with persistently normal alanine aminotransferase levels. Hepatology Research, 2012, 42, 982-989.	1.8	5
394	Implications of <scp>PNPLA</scp>3 polymorphism in chronic hepatitis <scp>C</scp> patients receiving peginterferon plus ribavirin. Alimentary Pharmacology and Therapeutics, 2012, 35, 1434-1442.	1.9	35
395	APOC3 and PNPLA3 in nonâ€alcoholic fatty liver disease: Need to clear the air. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 848-851.	1.4	21
396	Assessment of inflammation and fibrosis in nonâ€alcoholic fatty liver disease by imagingâ€based techniques. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1281-1292.	1.4	30
397	Ethnicity and nonalcoholic fatty liver disease. Hepatology, 2012, 55, 769-780.	3.6	181
398	Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology, 2012, 55, 781-789.	3.6	205
400	Unraveling the genetics of fatty liver in obese children: Additive effect of P446L GCKR and I148M PNPLA3 polymorphisms. Hepatology, 2012, 55, 661-663.	3.6	37
401	Genetic variants in candidate genes influencing NAFLD progression. Journal of Molecular Medicine, 2012, 90, 105-118.	1.7	39
402	Liver and diabetes. A vicious circle. Hepatology Research, 2013, 43, 51-64.	1.8	166
403	Relevance of CYP2E1 to Non-alcoholic Fatty Liver Disease. Sub-Cellular Biochemistry, 2013, 67, 165-175.	1.0	17
404	Nonâ€alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 68-76.	1.4	212
405	A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. Obesity, 2013, 21, 2138-2145.	1.5	57
406	High-carbohydrate diets induce hepatic insulin resistance to protect the liver from substrate overload. Biochemical Pharmacology, 2013, 85, 306-312.	2.0	46
407	Comparative genomics and functional study of lipid metabolic genes in Caenorhabditis elegans. BMC Genomics, 2013, 14, 164.	1.2	84
408	Desmosterol in human nonalcoholic steatohepatitis. Hepatology, 2013, 58, 976-982.	3.6	42

#	Article	IF	Citations
409	Nonalcoholic fatty liver disease following liver transplantation. Hepatology International, 2013, 7, 400-412.	1.9	8
410	Ethnicity predicts metabolic syndrome after liver transplant. Hepatology International, 2013, 7, 741-748.	1.9	8
411	Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. Diabetologia, 2013, 56, 886-892.	2.9	48
412	Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Human Genetics, 2013, 132, 783-792.	1.8	164
413	The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. Journal of Gastroenterology, 2013, 48, 405-412.	2.3	33
414	Molecular Epidemiology of HCV in Asia. Current Hepatitis Reports, 2013, 12, 133-142.	0.3	1
415	Non-alcoholic fatty liver disease and insulin resistance: From bench to bedside. Diabetes and Metabolism, 2013, 39, 16-26.	1.4	93
416	DNA Methylation Analysis in Nonalcoholic Fatty Liver Disease Suggests Distinct Disease-Specific and Remodeling Signatures after Bariatric Surgery. Cell Metabolism, 2013, 18, 296-302.	7.2	424
418	Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C. SpringerPlus, 2013, 2, 251.	1.2	6
419	Association of the I148M/PNPLA3 variant with elevated alanine transaminase levels in normal-weight and overweight/obese Mexican children. Gene, 2013, 520, 185-188.	1.0	34
420	Association Between Variants in or Near PNPLA3, GCKR, and PPP1R3B With Ultrasound-Defined Steatosis Based on Data From the Third National Health and Nutrition Examination Survey. Clinical Gastroenterology and Hepatology, 2013, 11, 1183-1190.e2.	2.4	128
421	Type 2 diabetes mellitus in pediatrics: a new challenge. World Journal of Pediatrics, 2013, 9, 293-299.	0.8	12
422	Liver enzymes and type 2 diabetes: A complex two-way relationship. Journal of Diabetes and Its Complications, 2013, 27, 301-302.	1.2	5
423	Exploration of a symptoms experience in people with obesity-related nonalcoholic fatty liver disease. Nursing Outlook, 2013, 61, 242-251.e2.	1.5	3
425	Mechanisms of liver involvement in systemic disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 471-483.	1.0	29
426	Genetic signatures in choline and 1â€carbon metabolism are associated with the severity of hepatic steatosis. FASEB Journal, 2013, 27, 1674-1689.	0.2	40
427	NAFLD, NASH and liver cancer. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 656-665.	8.2	842
428	Association between the Pro12Ala polymorphism of PPAR-Î³ gene and the non-alcoholic fatty liver disease: A meta-analysis. Gene, 2013, 528, 328-334.	1.0	15

#	Article	IF	Citations
429	The biophysics and cell biology of lipid droplets. Nature Reviews Molecular Cell Biology, 2013, 14, 775-786.	16.1	759
430	A 360-degree overview of paediatric NAFLD: Recent insights. Journal of Hepatology, 2013, 58, 1218-1229.	1.8	154
431	PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. Journal of Hepatology, 2013, 58, 312-318.	1.8	112
432	Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome. Nutrition in Clinical Practice, 2013, 28, 40-51.	1.1	52
433	Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology, 2013, 57, 601-609.	3.6	1,321
434	ChIP-seq in steatohepatitis and normal liver tissue identifies candidate disease mechanisms related to progression to cancer. BMC Medical Genomics, 2013, 6, 50.	0.7	8
435	Markers in Nonalcoholic Steatohepatitis. Advances in Clinical Chemistry, 2013, 61, 67-125.	1.8	16
436	Obesity, insulin resistance, NASH and hepatocellular carcinoma. Seminars in Cancer Biology, 2013, 23, 483-491.	4.3	128
437	Autophagy Deficiency by Hepatic FIP200 Deletion Uncouples Steatosis From Liver Injury in NAFLD. Molecular Endocrinology, 2013, 27, 1643-1654.	3.7	95
438	The global NAFLD epidemic. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 686-690.	8.2	1,426
439	PNPLA3, a genetic marker of progressive liver disease, still hiding its metabolic function?. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 30-35.	0.7	24
440	Association between liver-specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease. Hepatology, 2013, 57, 590-600.	3.6	71
441	Genetic and clinical markers of elevated liver fat content in overweight and obese hispanic children. Obesity, 2013, 21, E790-7.	1.5	12
442	Association of proinsulin and hepatic steatosis in a random, population-based sample. European Journal of Endocrinology, 2013, 168, 195-202.	1.9	3
443	Lipids and HCV. Seminars in Immunopathology, 2013, 35, 87-100.	2.8	89
444	Molecular dynamics simulation of PNPLA3 I148M polymorphism reveals reduced substrate access to the catalytic cavity. Proteins: Structure, Function and Bioinformatics, 2013, 81, 406-414.	1.5	16
445	The ERLIN1-CHUK-CWF19L1 gene cluster influences liver fat deposition and hepatic inflammation in the NHLBI Family Heart Study. Atherosclerosis, 2013, 228, 175-180.	0.4	50
446	PNPLA3 I148M variant and hepatocellular carcinoma: A common genetic variant for a rare disease. Digestive and Liver Disease, 2013, 45, 619-624.	0.4	55

#	Article	IF	Citations
447	Hepatitis C virus co-opts innate immunity component for lipid droplet formation. Journal of Hepatology, 2013, 59, 1118-1120.	1.8	5
448	Hepatic menin recruits SIRT1 to control liver steatosis through histone deacetylation. Journal of Hepatology, 2013, 59, 1299-1306.	1.8	56
449	Genetic Variation in the Patatin-Like Phospholipase Domain-Containing Protein-3 (PNPLA-3) Gene in Asian Indians with Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders, 2013, 11, 329-335.	0.5	40
450	An integrated view of liver injury and disease progression in nonalcoholic steatohepatitis. Hepatology International, 2013, 7, 800-805.	1.9	3
451	The Future Liver of the Asia Pacific: Fatter and Firmer from More Fructose and Fortune?. Journal of Clinical and Experimental Hepatology, 2013, 3, 106-113.	0.4	10
452	Common Genetic Variants and Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2013, 11, 1191-1193.	2.4	10
453	Patatin-Like Phospholipase Domain-Containing Protein 3 rs738409-G in Recipients of Liver Transplants Is a Risk Factor for Graft Steatosis. Clinical Gastroenterology and Hepatology, 2013, 11, 1667-1672.	2.4	81
454	Genetic determinants of cardiometabolic risk: A proposed model for phenotype association and interaction. Journal of Clinical Lipidology, 2013, 7, 65-81.	0.6	33
455	Non-invasive monitoring of cell metabolism and lipid production in 3D engineered human adipose tissues using label-free multiphoton microscopy. Biomaterials, 2013, 34, 8607-8616.	5.7	35
456	ChREBP in NASH â€“ A liver transcription factor comes in from the cold. Journal of Hepatology, 2013, 59, 178-179.	1.8	6
457	The role of hepatokines in metabolism. Nature Reviews Endocrinology, 2013, 9, 144-152.	4.3	411
458	Review article: the diagnosis of nonâ€alcoholic fatty liver disease â€“ availability and accuracy of nonâ€invasive methods. Alimentary Pharmacology and Therapeutics, 2013, 37, 392-400.	1.9	156
459	Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 330-344.	8.2	1,381
460	Cirrhosis. , 2013, , 935-954.		0
461	Hepatic manifestations of metabolic syndrome. Diabetes/Metabolism Research and Reviews, 2013, , .	1.7	24
462	Genomic aspects of NAFLD pathogenesis. Genomics, 2013, 102, 84-95.	1.3	80
464	Type 2 Diabetes. Diabetes Care, 2013, 36, 1047-1055.	4.3	306
465	Gastrointestinal complications of obesity: Non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Practice and Research in Clinical Endocrinology and Metabolism, 2013, 27, 195-208.	2.2	61

#	Article	IF	Citations
466	Hepatitis C virus infection activates an innate pathway involving IKK-Î± in lipogenesis and viral assembly. Nature Medicine, 2013, 19, 722-729.	15.2	167
467	Defining Hepatic Dysfunction Parameters in Two Models of Fatty Liver Disease in Zebrafish Larvae. Zebrafish, 2013, 10, 199-210.	0.5	54
468	Non-alcoholic fatty liver disease: more than just ectopic fat accumulation. Drug Discovery Today Disease Mechanisms, 2013, 10, e47-e54.	0.8	6
469	NAFLD in Asiaâ€"as common and important as in the West. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 307-318.	8.2	377
470	Dissociating fatty liver and diabetes. Trends in Endocrinology and Metabolism, 2013, 24, 4-12.	3.1	130
471	A Candidate Gene Study for the Association of Host Single Nucleotide Polymorphisms with Liver Cirrhosis Risk in Chinese Hepatitis B Patients. Genetic Testing and Molecular Biomarkers, 2013, 17, 681-686.	0.3	9
472	Allostasis in Nonalcoholic Fatty Liver Disease: Implications for Risk Assessment. Digestive Diseases and Sciences, 2013, 58, 302-308.	1.1	3
473	The genetics of NAFLD. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 645-655.	8.2	297
474	Role of patatinâ€like phospholipase domainâ€containing 3 on lipidâ€induced hepatic steatosis and insulin resistance in rats. Hepatology, 2013, 57, 1763-1772.	3.6	72
475	Characterization of european ancestry nonalcoholic fatty liver disease-associated variants in individuals of african and hispanic descent. Hepatology, 2013, 58, 966-975.	3.6	126
476	Genetic Variation at NCAN Locus Is Associated with Inflammation and Fibrosis in Non-Alcoholic Fatty Liver Disease in Morbid Obesity. Human Heredity, 2013, 75, 34-43.	0.4	78
477	Increased Activin Bioavailability Enhances Hepatic Insulin Sensitivity While Inducing Hepatic Steatosis in Male Mice. Endocrinology, 2013, 154, 2025-2033.	1.4	25
478	Functional validation of GWAS gene candidates for abnormal liver function during zebrafish liver development. DMM Disease Models and Mechanisms, 2013, 6, 1271-8.	1.2	30
479	Characterization of genome-wide transcriptional changes in liver and adipose tissues of ZDF (fa/fa) rats fed R-Î±-lipoic acid by next-generation sequencing. Physiological Genomics, 2013, 45, 1136-1143.	1.0	29
480	Hepatic Fatty Acid Trafficking: Multiple Forks in the Road. Advances in Nutrition, 2013, 4, 697-710.	2.9	115
481	Peroxisome Proliferator-Activated Receptor Genetic Polymorphisms and Nonalcoholic Fatty Liver Disease: Any Role in Disease Susceptibility?. PPAR Research, 2013, 2013, 1-8.	1.1	21
482	The Association Between Hepatic Fat Content and Liver Injury in Obese Children and Adolescents. Diabetes Care, 2013, 36, 1353-1360.	4.3	37
483	Lipoprotein Metabolism, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2013, 33, 380-388.	1.8	118

#	Article	IF	Citations
484	Identification of Combined Genetic Determinants of Liver Stiffness within the SREBP1c-PNPLA3 Pathway. International Journal of Molecular Sciences, 2013, 14, 21153-21166.	1.8	13
485	Coordinated Regulation of Hepatic Energy Stores by Leptin and Hypothalamic Agouti-Related Protein. Journal of Neuroscience, 2013, 33, 11972-11985.	1.7	9
486	Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH). International Journal of Molecular Sciences, 2013, 14, 20704-20728.	1.8	325
487	Dietary treatment of nonalcoholic steatohepatitis. Current Opinion in Gastroenterology, 2013, 29, 170-176.	1.0	17
488	Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Current Opinion in Organ Transplantation, 2013, 18, 251-258.	0.8	46
489	Measures of Adiposity and Fat Distribution and Risk of Diabetesâ€"Reply. JAMA - Journal of the American Medical Association, 2013, 309, 339.	3.8	3
490	Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Expert Review of Clinical Immunology, 2013, 9, 727-738.	1.3	7
491	A common variant in the peroxisome proliferatorâ€"activated receptor-Î³ coactivator-1Î± gene is associated with nonalcoholic fatty liver disease in obese children. American Journal of Clinical Nutrition, 2013, 97, 326-331.	2.2	45
492	Pediatric Nonalcoholic Fatty Liver Disease. Topics in Clinical Nutrition, 2013, 28, 335-355.	0.2	1
493	PNPLA3-Associated Steatohepatitis: Toward a Gene-Based Classification of Fatty Liver Disease. Seminars in Liver Disease, 2013, 33, 369-379.	1.8	81
494	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Journal of Clinical Pathology, 2013, 66, 1033-1045.	1.0	70
495	A Critical Appraisal of Advances in Pediatric Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2013, 32, 317-324.	1.8	20
496	An Ounce of Prevention Is Better Than a Pound of Cure: A Patient-Centered Approach to Hepatocellular Carcinoma. Journal of Clinical Oncology, 2013, 31, 1499-1501.	0.8	3
497	Racial/ethnic differences in hepatic steatosis in a populationâ€based cohort of postâ€menopausal women: the Michigan Study of Women's Health Across the Nation. Diabetic Medicine, 2013, 30, 1433-1441.	1.2	11
499	Abdominal fat interacts with <scp>PNPLA</scp>3 I148M, but not with the <scp>APOC</scp>3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. Journal of Viral Hepatitis, 2013, 20, 517-523.	1.0	47
500	Role of thiazolidinediones, insulin sensitizers, in nonâ€alcoholic fatty liver disease. Journal of Diabetes Investigation, 2013, 4, 517-524.	1.1	37
501	Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity. Obesity, 2013, 21, 1935-1941.	1.5	17
502	Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction. Molecular Carcinogenesis, 2013, 52, 139-147.	1.3	68

#	Article	IF	Citations
503	Investigation of PNPLA3 and IL28B Genotypes on Diabetes and Obesity After Liver Transplantation: Insight Into Mechanisms of Disease. American Journal of Transplantation, 2013, 13, 2450-2457.	2.6	46
504	The I148M Variant of PNPLA3 Reduces the Response to Docosahexaenoic Acid in Children with Non-Alcoholic Fatty Liver Disease. Journal of Medicinal Food, 2013, 16, 957-960.	0.8	60
505	<scp>I</scp>mpact of leptin receptor gene variants on risk of nonâ€alcoholic fatty liver disease and its interaction with adiponutrin gene. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 873-879.	1.4	33
506	PNPLA3 gene-by-visceral adipose tissue volume interaction and the pathogenesis of fatty liver disease: The NHLBI Family Heart Study. International Journal of Obesity, 2013, 37, 432-438.	1.6	49
508	Steatosis in the Liver. , 2013, 3, 1493-1532.		33
509	Biochemistry and pathophysiology of intravascular and intracellular lipolysis. Genes and Development, 2013, 27, 459-484.	2.7	277
510	Characteristics and diagnosis of <scp>NAFLD</scp>/<scp>NASH</scp>. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 64-70.	1.4	190
511	Tenth Annual LIPID Metabolites and Pathways Strategy (LIPID MAPS) Meeting. Clinical Lipidology, 2013, 8, 403-405.	0.4	0
512	Alcoholic liver disease/nonalcoholic fatty liver disease index. European Journal of Gastroenterology and Hepatology, 2013, 25, 899-904.	0.8	21
513	Oxidized metabolites of linoleic acid as biomarkers of liver injury in nonalcoholic steatohepatitis. Clinical Lipidology, 2013, 8, 411-418.	0.4	27
514	Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology, 2013, 58, 1245-1252.	3.6	69
515	Solute carrier family 2 member 1is involved in the development of nonalcoholic fatty liver disease. Hepatology, 2013, 57, 505-514.	3.6	25
516	Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment. Current Pharmaceutical Design, 2013, 19, 5219-5238.	0.9	184
517	Pathophysiology of NASH: Perspectives for a Targeted Treatment. Current Pharmaceutical Design, 2013, 19, 5250-5269.	0.9	140
518	A Frequent PNPLA3 Variant Is a Sex Specific Disease Modifier in PSC Patients with Bile Duct Stenosis. PLoS ONE, 2013, 8, e58734.	1.1	28
519	Systems Biology Elucidates Common Pathogenic Mechanisms between Nonalcoholic and Alcoholic-Fatty Liver Disease. PLoS ONE, 2013, 8, e58895.	1.1	47
520	Sexually Dimorphic Genome-Wide Binding of Retinoid X Receptor alpha (RXRÎ±) Determines Male-Female Differences in the Expression of Hepatic Lipid Processing Genes in Mice. PLoS ONE, 2013, 8, e71538.	1.1	21
521	No Correlation between PNPLA3 rs738409 Genotype and Fatty Liver and Hepatic Cirrhosis in Japanese Patients with HCV. PLoS ONE, 2013, 8, e81312.	1.1	30

#	Article	IF	Citations
522	The Etiology, Diagnosis and Prevention of Liver Cirrhosis. Deutsches Ärzteblatt International, 2013, 110, 85-91.	0.6	119
523	Current Concepts and Management Approaches in Nonalcoholic Fatty Liver Disease. Scientific World Journal, The, 2013, 2013, 1-10.	0.8	67
524	Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment. World Journal of Gastroenterology, 2014, 20, 8377.	1.4	76
525	Traditional but Not HIV-Related Factors Are Associated with Nonalcoholic Fatty Liver Disease in Asian Patients with HIV-1 Infection. PLoS ONE, 2014, 9, e87596.	1.1	42
526	Association between the PNPLA3 I148M Polymorphism and Non-Alcoholic Fatty Liver Disease in the Uygur and Han Ethnic Groups of Northwestern China. PLoS ONE, 2014, 9, e108381.	1.1	17
527	Targeting Hepatic Glycerolipid Synthesis and Turnover to Treat Fatty Liver Disease. Advances in Hepatology, 2014, 2014, 1-14.	1.3	7
528	Non-Alcoholic Fatty Liver Disease. Deutsches Ärzteblatt International, 2014, 111, 447-52.	0.6	134
529	Non-Alcoholic Fatty Liver Disease in Children: Focus on Nutritional Interventions. Nutrients, 2014, 6, 4691-4705.	1.7	31
530	Fatty liver in childhood. World Journal of Hepatology, 2014, 6, 33.	0.8	11
531	Gender and racial differences in nonalcoholic fatty liver disease. World Journal of Hepatology, 2014, 6, 274.	0.8	242
532	A Review of Fatty Liver/NASH and Liver Cirrhosis: Genetics, Prevention, Nutritional, Behavioral Modification, Exercise, Pharmaceutical, Biophysics and Biotech Therapy. Journal of Liver, 2014, 3, .	0.3	1
533	Nonalcoholic fatty liver disease and polycystic ovary syndrome. World Journal of Gastroenterology, 2014, 20, 8351.	1.4	128
534	Non-alcoholic fatty liver disease: What the clinician needs to know. World Journal of Gastroenterology, 2014, 20, 12956.	1.4	154
535	Pediatric non-alcoholic fatty liver disease: New insights and future directions. World Journal of Hepatology, 2014, 6, 217.	0.8	46
536	The Metabolic Syndrome and Chronic Liver Disease. Current Pharmaceutical Design, 2014, 20, 5010-5024.	0.9	35
537	Pooled genetic analysis in ultrasound measured non-alcoholic fatty liver disease in Indian subjects: A pilot study. World Journal of Hepatology, 2014, 6, 435.	0.8	28
538	Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 8393.	1.4	118
539	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. Annals of Hepatology, 2014, 13, 356-363.	0.6	18

#	Article	IF	Citations
540	Causal Relationship of Non-alcoholic Fatty Liver Disease with Obesity and Insulin Resistance. Journal of Korean Diabetes, 2014, 15, 76.	0.1	16
542	Role of the PNPLA3 I148M Polymorphism in Nonalcoholic Fatty Liver Disease and Fibrosis in Korea. Digestive Diseases and Sciences, 2014, 59, 2967-2974.	1.1	33
543	Non-Alcoholic Fatty Liver Disease: Diagnosis and Investigation. Digestive Diseases, 2014, 32, 586-596.	0.8	10
544	Cholangiocyte lipoapoptosis: Implications for biliary damage during nonalcoholic fatty liver disease. Hepatology, 2014, 60, 1809-1811.	3.6	6
545	Personalizing care for nonalcoholic fatty liver disease patients: what are the research priorities?. Personalized Medicine, 2014, 11, 735-743.	0.8	8
546	Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH). International Journal of Molecular Sciences, 2014, 15, 7352-7379.	1.8	106
547	Serum TAG Analysis Differentiates Between Genetic and Obesity-Associated NAFLD. Diabetes, 2014, 63, 42-44.	0.3	6
548	SteatoNet: The First Integrated Human Metabolic Model with Multi-layered Regulation to Investigate Liver-Associated Pathologies. PLoS Computational Biology, 2014, 10, e1003993.	1.5	17
549	Fatty Liver, NASH, and Alcoholic Liver Disease. , 2014, , 1817-1824.		1
550	Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterology, 2014, 5, 211-218.	0.9	254
551	Non-alcoholic fatty liver disease in patients with diabetes mellitus. Expert Review of Endocrinology and Metabolism, 2014, 9, 503-514.	1.2	0
552	Debate-a bridge too far: Nonalcoholic fatty liver disease will not exhaust the donor pool. Liver Transplantation, 2014, 20, S38-S41.	1.3	5
553	CDKN1A: A double-edged sword in fatty liver?. Cell Cycle, 2014, 13, 1371-1372.	1.3	8
554	<scp>PNPLA3</scp> in endâ€stage liver disease: Alcohol consumption, hepatocellular carcinoma development, and transplantationâ€free survival. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1477-1484.	1.4	39
555	Hepatic steatosis and <scp>PNPLA</scp>3 I148<scp>M</scp> variant are associated with serum <scp>F</scp>etuinâ€<scp>A</scp> independently of insulin resistance. European Journal of Clinical Investigation, 2014, 44, 627-633.	1.7	24
556	Systematic review with metaâ€analysis: the I148M variant of patatinâ€like phospholipase domainâ€containing 3 gene (PNPLA3) is significantly associated with alcoholic liver cirrhosis. Alimentary Pharmacology and Therapeutics, 2014, 40, 571-581.	1.9	63
557	Commentary: dissecting the PNPLA3 association with liver fat and stiffness, and interaction with diet. Alimentary Pharmacology and Therapeutics, 2014, 39, 894-895.	1.9	2
558	PNPLA3 I148M (rs738409) genetic variant and age at onset of atâ€risk alcohol consumption are independent risk factors for alcoholic cirrhosis. Liver International, 2014, 34, 514-520.	1.9	41

#	Article	IF	Citations
559	Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet, The, 2014, 384, 1953-1997.	6.3	492
560	Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. Journal of Lipid Research, 2014, 55, 2676-2684.	2.0	59
561	Commentary: dissecting the PNPLA3 association with liver fat and stiffness, and interaction with diet â€“ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2014, 39, 895-896.	1.9	0
562	Association between thePNPLA3(rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology, 2014, 59, 2170-2177.	3.6	193
563	Racial differences in nonalcoholic fatty liver disease in the U.S. population. Obesity, 2014, 22, 292-299.	1.5	100
564	Relationship of SREBP-2 rs2228314 G>C Polymorphism with Nonalcoholic Fatty Liver Disease in a Han Chinese Population. Genetic Testing and Molecular Biomarkers, 2014, 18, 653-657.	0.3	10
565	Fibrogenesis in alcoholic liver disease. World Journal of Gastroenterology, 2014, 20, 8048.	1.4	33
566	PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Human Molecular Genetics, 2014, 23, 4077-4085.	1.4	293
567	PNPLA3 mediates hepatocyte triacylglycerol remodeling. Journal of Lipid Research, 2014, 55, 739-746.	2.0	96
568	Clinical Features of Pediatric Nonalcoholic Fatty Liver Disease. Clinical Pediatrics, 2014, 53, 1318-1325.	0.4	11
569	Studies on Periodontal Disease. Oxidative Stress in Applied Basic Research and Clinical Practice, 2014, , .	0.4	0
570	The Interaction between Diabetes, Body Mass Index, Hepatic Steatosis, and Risk of Liver Resection: Insulin Dependent Diabetes Is the Greatest Risk for Major Complications. HPB Surgery, 2014, 2014, 1-10.	2.2	12
571	DNA markers in molecular diagnostics for hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2014, 14, 803-817.	1.5	21
572	The Hepatitis C Virus Core Protein Inhibits Adipose Triglyceride Lipase (ATGL)-mediated Lipid Mobilization and Enhances the ATGL Interaction with Comparative Gene Identification 58 (CGI-58) and Lipid Droplets. Journal of Biological Chemistry, 2014, 289, 35770-35780.	1.6	29
573	The PNPLA3 I148M variant and chronic liver disease: When a genetic mutation meets nutrients. Food Research International, 2014, 63, 239-243.	2.9	6
574	Focus. Journal of Hepatology, 2014, 60, 1-2.	1.8	17
575	The adiponutrin I148M variant is a risk factor for HCV-associated liver cancer in North-African patients. Infection, Genetics and Evolution, 2014, 21, 179-183.	1.0	20
576	Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. Journal of Gastroenterology, 2014, 49, 1056-1064.	2.3	62

#	Article	IF	Citations
577	Dietary supplementation with soy isoflavones or replacement with soy proteins prevents hepatic lipid droplet accumulation and alters expression of genes involved in lipid metabolism in rats. Genes and Nutrition, 2014, 9, 373.	1.2	28
578	The PNPLA3 Ile148Met interacts with overweight and dietary intakes on fasting triglyceride levels. Genes and Nutrition, 2014, 9, 388.	1.2	31
579	Mechanisms of Liver Injury in Non-Alcoholic Steatohepatitis. Current Hepatology Reports, 2014, 13, 119-129.	0.4	37
580	Genetic and Epigenetic Associations with NAFLD: Focus on Clinical Decision Making and Novel Concepts in Disease Pathogenesis. Current Hepatology Reports, 2014, 13, 97-105.	0.4	1
581	Non-alcoholic fatty liver disease in a young multiracial Asian population: a worrying ethnic predilection in Malay and Indian males. Hepatology International, 2014, 8, 121-127.	1.9	23
582	Whole-Exome Sequencing Identifies Rare and Low-Frequency Coding Variants Associated with LDL Cholesterol. American Journal of Human Genetics, 2014, 94, 233-245.	2.6	193
583	Murine models of hepatitis C: What can we look forward to?. Antiviral Research, 2014, 104, 15-22.	1.9	27
584	Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 2014, 46, 352-356.	9.4	938
585	Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgraduate Medical Journal, 2014, 90, 254-266.	0.9	12
586	Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 Diabetes. Hepatology, 2014, 59, 713-723.	3.6	567
587	Hepatitis C Virus. , 2014, , 859-877.		0
588	Review article: genetic factors that modify the outcome of viral hepatitis. Alimentary Pharmacology and Therapeutics, 2014, 39, 1059-1070.	1.9	50
589	<scp>PNPLA</scp>3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Alimentary Pharmacology and Therapeutics, 2014, 39, 532-539.	1.9	95
590	Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards nonâ€alcoholic steatohepatitis (<scp>NASH</scp>)?. Liver International, 2014, 34, e180-90.	1.9	93
591	Adiponutrin: A multimeric plasma protein. Biochemical and Biophysical Research Communications, 2014, 446, 1114-1119.	1.0	16
592	Chemical modulation of glycerolipid signaling and metabolic pathways. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 1060-1084.	1.2	27
593	Systems biology for hepatologists. Hepatology, 2014, 60, 736-743.	3.6	15
594	Phospholipases in Plant Signaling. Signaling and Communication in Plants, 2014, , .	0.5	12

#	Article	IF	Citations
595	The Genetics of Obesity. , 2014, , .		0
596	Living donor liver transplantation for nonâ€alcoholic steatohepatitis: A single center experience. Hepatology Research, 2014, 44, E3-E10.	1.8	18
597	Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. American Journal of Clinical Nutrition, 2014, 99, 869-874.	2.2	93
598	Targeted next-generation sequencing and fine linkage disequilibrium mapping reveals association of PNPLA3 and PARVB with the severity of nonalcoholic fatty liver disease. Journal of Human Genetics, 2014, 59, 241-246.	1.1	18
599	Metabolic profiling reveals that PNPLA3 induces widespread effects on metabolism beyond triacylglycerol remodeling in Huh-7 hepatoma cells. American Journal of Physiology - Renal Physiology, 2014, 307, G66-G76.	1.6	45
600	Metabolic Syndrome in Pediatrics. Advances in Clinical Chemistry, 2014, 65, 91-142.	1.8	19
601	Genetic Variants in the PNPLA3 Gene Are Associated with Nonalcoholic Steatohepatitis. Genetic Testing and Molecular Biomarkers, 2014, 18, 489-496.	0.3	6
602	TRIB1 downregulates hepatic lipogenesis and glycogenesis via multiple molecular interactions. Journal of Molecular Endocrinology, 2014, 52, 145-158.	1.1	49
603	Nonâ€alcoholic fatty liver disease: the role of nuclear receptors and circadian rhythmicity. Liver International, 2014, 34, 1133-1152.	1.9	56
604	Strain dependence of dietâ€induced <scp>NASH</scp> and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype. Liver International, 2014, 34, 1084-1093.	1.9	70
605	Circulating Triacylglycerol Signatures in Nonalcoholic Fatty Liver Disease Associated With the I148M Variant in PNPLA3 and With Obesity. Diabetes, 2014, 63, 312-322.	0.3	58
606	Ectopic Fat in Insulin Resistance, Dyslipidemia, and Cardiometabolic Disease. New England Journal of Medicine, 2014, 371, 1131-1141.	13.9	803
607	Genetic, anatomic, and clinical determinants of human serum sterol and vitamin D levels. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4006-14.	3.3	72
608	Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD. Trends in Endocrinology and Metabolism, 2014, 25, 576-585.	3.1	71
609	Hepatic patatin-like phospholipase domain-containing protein 3 sequence, single nucleotide polymorphism presence, protein confirmation, and responsiveness to energy balance in dairy cows. Journal of Dairy Science, 2014, 97, 5167-5175.	1.4	3
610	Whole-body MRI Screening. , 2014, , .		2
611	Treatment of the Obese Patient. , 2014, , .		3
612	Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. Metabolism: Clinical and Experimental, 2014, 63, 1542-1552.	1.5	88

#	Article	IF	Citations
614	PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans. Diabetologia, 2014, 57, 2103-2107.	2.9	41
615	Genetic insights on host and hepatitis B virus in liver diseases. Mutation Research - Reviews in Mutation Research, 2014, 762, 65-75.	2.4	18
616	Fatty Pancreas, Insulin Resistance, and Î²-Cell Function: A Population Study Using Fat-Water Magnetic Resonance Imaging. American Journal of Gastroenterology, 2014, 109, 589-597.	0.2	194
617	Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mammalian Genome, 2014, 25, 473-486.	1.0	32
618	PNPLA3 I148M polymorphism is associated with elevated alanine transaminase levels in Mexican Indigenous and Mestizo populations. Molecular Biology Reports, 2014, 41, 4705-4711.	1.0	25
619	Obesity and the liver: nonalcoholic fatty liver disease. Translational Research, 2014, 164, 312-322.	2.2	59
620	PNPLA3, the history of an orphan gene of the potato tuber protein family that found an organ: The liver. Hepatology, 2014, 59, 2068-2071.	3.6	16
621	Regulation of glucose and lipid homeostasis by adiponectin: Effects on hepatocytes, pancreatic Î²Âcells and adipocytes. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 43-58.	2.2	103
622	Development, External Validation, and Comparative Assessment of a New Diagnostic Score for Hepatic Steatosis. American Journal of Gastroenterology, 2014, 109, 1404-1414.	0.2	95
623	The Genetics of Nonalcoholic Fatty Liver Disease: Role of Diet as a Modifying Factor. Current Nutrition Reports, 2014, 3, 223-232.	2.1	6
624	Insights into obesity and diabetes at the intersection of mouse and human genetics. Trends in Endocrinology and Metabolism, 2014, 25, 493-501.	3.1	32
625	Shifts in dietary carbohydrate-lipid exposure regulate expression of the non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells. Metabolism: Clinical and Experimental, 2014, 63, 1352-1362.	1.5	25
626	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nature Communications, 2014, 5, 4309.	5.8	478
627	Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in obese adolescents: A looming marker of cardiac dysfunction. Hepatology, 2014, 59, 372-374.	3.6	12
628	Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes and Endocrinology,the, 2014, 2, 901-910.	5.5	938
629	Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 574-580.	1.2	153
630	Role of genetics in diagnosis and therapy of acquired liver disease. Molecular Aspects of Medicine, 2014, 37, 15-34.	2.7	6
631	Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. Journal of Hepatology, 2014, 61, 75-81.	1.8	431

#	Article	IF	Citations
632	Ethnic and Sex Differences in Fatty Liver on Cardiac Computed Tomography: The Multi-Ethnic Study of Atherosclerosis. Mayo Clinic Proceedings, 2014, 89, 493-503.	1.4	34
633	Host Genetic Variants in Obesity-Related Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2014, 18, 249-267.	1.0	8
634	Risk Factors for Fatty Liver in the Multicenter AIDS Cohort Study. American Journal of Gastroenterology, 2014, 109, 695-704.	0.2	106
635	The genetics of Mexico recapitulates Native American substructure and affects biomedical traits. Science, 2014, 344, 1280-1285.	6.0	420
636	Impact of <scp>PNPLA3</scp> polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis <scp>C</scp> virus infection. Hepatology Research, 2014, 44, E137-44.	1.8	20
637	Predicting Hepatic Steatosis in a Racially and Ethnically Diverse Cohort of Adolescent Girls. Journal of Pediatrics, 2014, 165, 319-325.e1.	0.9	30
638	The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis. American Journal of Gastroenterology, 2014, 109, 325-334.	0.2	270
639	A population-based study on the prevalence of NASH using scores validated against liver histology. Journal of Hepatology, 2014, 60, 839-846.	1.8	107
641	Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease. World Journal of Hepatology, 2014, 6, 570.	0.8	84
642	Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2014, 20, 475.	1.4	453
643	Association of polymorphisms in <i>GCKR</i> and <i>TRIB1</i> with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocrine Journal, 2014, 61, 683-689.	0.7	55
644	A 4â€Polymorphism Risk Score Predicts Steatohepatitis in Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 632-636.	0.9	74
645	Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C. Hepatology, 2014, 59, 453-460.	3.6	27
646	The Genetic Variant I148M inPNPLA3Is Associated With Increased Hepatic Retinyl-Palmitate Storage in Humans. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1568-E1574.	1.8	52
647	Genetic variants in adult liver diseases. Zeitschrift Fur Gastroenterologie, 2015, 53, 1436-1446.	0.2	14
648	Genetics of Alcoholic Liver Disease. Seminars in Liver Disease, 2015, 35, 361-374.	1.8	39
649	Patatinâ€like phospholipase domainâ€containing protein 3 and Liver Disease: Opportunities to Unravel Mechanisms Underlying Statistical Associations. Hepatology, 2015, 61, 18-20.	3.6	7
650	Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology, 2015, 61, 108-118.	3.6	297

#	Article	IF	Citations
651	Genetic analysis of nonalcoholic fatty liver disease within a Caribbeanâ€“Hispanic population. Molecular Genetics & Genomic Medicine, 2015, 3, 558-569.	0.6	14
652	Nonalcoholic fatty liver disease. Nature Reviews Disease Primers, 2015, 1, 15080.	18.1	612
653	Variant adiponutrin confers genetic protection against cholestatic itch. Scientific Reports, 2015, 4, 6374.	1.6	6
654	Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease. BMJ Open Gastroenterology, 2015, 2, e000019.	1.1	23
655	Alcoholic, Nonalcoholic, and Toxicant-Associated Steatohepatitis: Mechanistic Similarities and Differences. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 356-367.	2.3	64
656	Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. BMC Gastroenterology, 2015, 15, 175.	0.8	27
657	Heterogeneity of nonâ€alcoholic fatty liver disease. Liver International, 2015, 35, 2498-2500.	1.9	15
658	Identification of eQTLs for Hepatic Xbp1s and Socs3 Gene Expression in Mice Fed a High-Fat, High-Caloric Diet. G3: Genes, Genomes, Genetics, 2015, 5, 487-496.	0.8	3
659	Association of PNPLA3 rs738409 and TM6SF2 rs58542926 with health services utilization in a population-based study. BMC Health Services Research, 2015, 16, 41.	0.9	7
660	Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. Aids, 2015, 29, 1927-1935.	1.0	19
661	An overview of the genetics, mechanisms and management of NAFLD and ALD. Clinical Medicine, 2015, 15, s77-s82.	0.8	23
662	Hepatic lipid droplet biology: Getting to the root of fatty liver. Hepatology, 2015, 62, 964-967.	3.6	111
663	Nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 1154-1160.	0.8	23
664	Practical approach to nonâ€alcoholic fatty liver disease in patients with diabetes. Diabetic Medicine, 2015, 32, 1121-1133.	1.2	15
665	I148<scp>M</scp> variant in <scp>PNPLA</scp>3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver International, 2015, 35, 2537-2546.	1.9	27
667	GWASâ€identified Common Variants With Nonalcoholic Fatty Liver Disease in Chinese Children. Journal of Pediatric Gastroenterology and Nutrition, 2015, 60, 669-674.	0.9	33
668	Alcoholic hepatitis: The pivotal role of Kupffer cells. World Journal of Gastrointestinal Pathophysiology, 2015, 6, 90.	0.5	15
669	Genetic background in nonalcoholic fatty liver disease: A comprehensive review. World Journal of Gastroenterology, 2015, 21, 11088.	1.4	66

#	Article	IF	Citations
670	Problems of Long Survival Following Surgery in Patients with NonBNonC-HCC: Comparison with HBV and HCV Related-HCC. Journal of Cancer, 2015, 6, 438-447.	1.2	17
671	Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico. World Journal of Gastroenterology, 2015, 21, 11552.	1.4	48
672	Duplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C Patients. International Journal of Molecular Sciences, 2015, 16, 22223-22242.	1.8	4
673	Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance. Nutrients, 2015, 7, 9127-9138.	1.7	117
674	Assessment of Diet and Physical Activity in Paediatric Non-Alcoholic Fatty Liver Disease Patients: A United Kingdom Case Control Study. Nutrients, 2015, 7, 9721-9733.	1.7	23
675	Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. PLoS ONE, 2015, 10, e0137351.	1.1	22
676	Liver enzymes, metabolomics and genome-wide association studies: From systems biology to the personalized medicine. World Journal of Gastroenterology, 2015, 21, 711.	1.4	200
677	Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. BioMed Research International, 2015, 2015, 1-10.	0.9	116
678	The Frequent Adiponutrin (PNPLA3) Variant p.Ile148Met Is Associated with Early Liver Injury: Analysis of a German Pediatric Cohort. Gastroenterology Research and Practice, 2015, 2015, 1-6.	0.7	8
679	TM6SF2 E167K Variant, a Novel Genetic Susceptibility Variant, Contributing to Nonalcoholic Fatty Liver Disease. Journal of Clinical and Translational Hepatology, 2015, 3, 265-270.	0.7	27
680	Understanding the pathophysiological mechanisms in the pediatric non-alcoholic fatty liver disease: The role of genetics. World Journal of Hepatology, 2015, 7, 1439.	0.8	35
681	PNPLA3 I148M variant in nonalcoholic fatty liver disease: Demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis. World Journal of Gastroenterology, 2015, 21, 794.	1.4	35
682	Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: An open question. World Journal of Gastroenterology, 2015, 21, 4103.	1.4	135
683	Drug-induced fatty liver disease: An overview of pathogenesis and management. Annals of Hepatology, 2015, 14, 789-806.	0.6	81
684	Long-Term Outcomes of Nonalcoholic Fatty Liver Disease. Current Hepatology Reports, 2015, 14, 69-76.	0.4	13
685	PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease. American Journal of Gastroenterology, 2015, 110, 846-856.	0.2	120
686	Dyslipidemia: Relationship to Insulin Resistance, Fatty Liver, and Sub-Clinical Atherosclerosis. , 2015, , 65-79.		0
687	Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B. Digestive Diseases and Sciences, 2015, 60, 3005-3010.	1.1	10

#	Article	IF	Citations
688	Pathogenesis of Hepatocellular Carcinoma Development in Non-alcoholic Fatty Liver Disease. Current Hepatology Reports, 2015, 14, 119-127.	0.4	15
689	Noninvasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?. Current Hepatology Reports, 2015, 14, 109-118.	0.4	19
690	Elevated Aminotransferase Levels Among HIV-Infected Persons: What's Lurking Under the Surface?. Clinical Infectious Diseases, 2015, 60, 1579-81.	2.9	1
691	Different Mechanisms for Histone Acetylation by Ethanol and Its Metabolite Acetate in Rat Primary Hepatocytes. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 18-23.	1.3	17
692	PAEDIATRIC NON ALCOHOLIC FATTY LIVER DISEASE: AN EMERGING THREAT. Paediatrics Today, 2015, 11, 1-9.	0.1	6
693	Insulin resistance in clinical and experimental alcoholic liver disease. Annals of the New York Academy of Sciences, 2015, 1353, 1-20.	1.8	51
694	Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2015, 35, 375-391.	1.8	42
695	Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese. Nature Communications, 2015, 6, 10206.	5.8	86
696	Hepatocyte X-box binding protein 1 deficiency increases liver injury in mice fed a high-fat/sugar diet. American Journal of Physiology - Renal Physiology, 2015, 309, G965-G974.	1.6	47
697	PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease. Surgery for Obesity and Related Diseases, 2015, 11, 888-894.	1.0	18
698	Effect of PNPLA3 rs738409 variant (I148ÂM) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C. Journal of Gastroenterology, 2015, 50, 887-893.	2.3	18
699	New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis, 2015, 239, 483-495.	0.4	314
700	Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease. Hepatic Oncology, 2015, 2, 63-78.	4.2	2
701	The Progression of Non-alcoholic Fatty Liver Disease and Lifestyle Intervention in Older Adults. , 2015, , 85-97.		1
702	Prevalence of Suspected Nonalcoholic Fatty Liver Disease in Hispanic/Latino Individuals Differs by Heritage. Clinical Gastroenterology and Hepatology, 2015, 13, 569-576.	2.4	89
703	Liver Fat Content and Hepatic Insulin Sensitivity in Overweight Patients With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 607-616.	1.8	43
704	Isoleucine-to-methionine substitution at residue 148 variant of PNPLA3 gene and metabolic outcomes in gestational diabetes. American Journal of Clinical Nutrition, 2015, 101, 310-318.	2.2	6
705	Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology, 2015, 61, 515-525.	3.6	177

#	Article	IF	Citations
706	Genome-wide analysis of hepatic lipid content in extreme obesity. Acta Diabetologica, 2015, 52, 373-382.	1.2	47
707	<scp>PNPLA3</scp> polymorphisms (rs738409) and nonâ€alcoholic fatty liver disease risk and related phenotypes: a metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 821-829.	1.4	49
708	Metabolomic tissue signature in human nonâ€alcoholic fatty liver disease identifies protective candidate metabolites. Liver International, 2015, 35, 207-214.	1.9	28
709	Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clinical Journal of Gastroenterology, 2015, 8, 1-9.	0.4	69
710	Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. Journal of Hepatology, 2015, 62, 512-518.	1.8	30
711	<scp>PNPLA</scp>3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 139-146.	1.4	125
712	A concise review of non-alcoholic fatty liver disease. Atherosclerosis, 2015, 239, 192-202.	0.4	234
713	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology, 2015, 61, 506-514.	3.6	424
714	A genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity. Experimental and Molecular Pathology, 2015, 98, 178-183.	0.9	49
715	The <scp>UCP</scp>2 â€866ÂG>A promoter region polymorphism is associated with nonalcoholic steatohepatitis.. Liver International, 2015, 35, 1574-1580.	1.9	41
716	Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?. Molecular and Cellular Endocrinology, 2015, 418, 55-65.	1.6	244
717	Nonalcoholic Fatty Liver Disease. JAMA Pediatrics, 2015, 169, 170.	3.3	115
718	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Journal of Gastroenterology, 2015, 50, 364-377.	2.3	203
719	Ethnic Differences in Presentation and Severity of Alcoholic Liver Disease. Alcoholism: Clinical and Experimental Research, 2015, 39, 566-574.	1.4	69
720	Fatty acid desaturase 1 gene polymorphisms control human hepatic lipid composition. Hepatology, 2015, 61, 119-128.	3.6	67
721	Analysis of the liver lipidome reveals insights into the protective effect of exercise on high-fat diet-induced hepatosteatosis in mice. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E778-E791.	1.8	43
722	Muscle-Specific Deletion of Comparative Gene Identification-58 (CGI-58) Causes Muscle Steatosis but Improves Insulin Sensitivity in Male Mice. Endocrinology, 2015, 156, 1648-1658.	1.4	16
723	The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. Journal of Lipid Research, 2015, 56, 167-175.	2.0	41

#	Article	IF	Citations
724	White adipose tissue reference network: a knowledge resource for exploring health-relevant relations. Genes and Nutrition, 2015, 10, 439.	1.2	9
725	Hepatic steatosis in Wilson disease â€“ Role of copper and PNPLA3 mutations. Journal of Hepatology, 2015, 63, 156-163.	1.8	85
726	Lipid Management. , 2015, , .		1
727	PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients. SpringerPlus, 2015, 4, 83.	1.2	14
728	Fibrosis in Nonalcoholic Fatty Liver Disease: Mechanisms and Clinical Implications. Seminars in Liver Disease, 2015, 35, 132-145.	1.8	102
729	Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. American Journal of Gastroenterology, 2015, 110, 1306-1314.	0.2	240
730	P1239 : Assessment of diet and physical activity in paediatric non-alcoholic fatty liver disease patients: A UK case control study. Journal of Hepatology, 2015, 62, S821-S822.	1.8	0
731	The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. Journal of Clinical and Experimental Hepatology, 2015, 5, 147-158.	0.4	114
732	The TM6SF2 rs58542926 T allele is significantly associated with non-alcoholic fatty liver disease in Chinese. Journal of Hepatology, 2015, 62, 1438-1439.	1.8	45
733	The SRE Motif in the Human PNPLA3 Promoter (â^'97 to â^'88â€‰bp) Mediates Transactivational Effects of SREBPâ€1c. Journal of Cellular Physiology, 2015, 230, 2224-2232.	2.0	12
734	PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. Scientific Reports, 2015, 5, 11901.	1.6	9
735	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology, 2015, 149, 1226-1239.e4.	0.6	980
736	Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Digestive Diseases, 2015, 33, 598-607.	0.8	33
737	Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Progress in Lipid Research, 2015, 59, 106-125.	5.3	130
739	Management and diagnosis of fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2015, 9, 671-683.	1.4	11
740	TM6SF2: Catch-22 in the Fight Against Nonalcoholic Fatty Liver Disease and Cardiovascular Disease?. Gastroenterology, 2015, 148, 679-684.	0.6	75
741	NAFLD: A multisystem disease. Journal of Hepatology, 2015, 62, S47-S64.	1.8	2,037
742	Transplantation for Nonalcoholic Steatohepatitis. , 2015, , 250-255.		2

#	Article	IF	Citations
743	Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2015, 63, 494-502.	1.8	71
744	Genetics of liver disease: From pathophysiology to clinical practice. Journal of Hepatology, 2015, 62, S6-S14.	1.8	73
745	Non-alcoholic fatty liver disease: when to intervene and with what. Clinical Medicine, 2015, 15, 186-190.	0.8	17
746	The 148 M allele of the PNPLA3 is associated with plasma irisin levels in a population sample of Caucasian children: The PANIC Study. Metabolism: Clinical and Experimental, 2015, 64, 793-796.	1.5	19
747	Fibrosis â€" A Common Pathway to Organ Injury and Failure. New England Journal of Medicine, 2015, 372, 1138-1149.	13.9	942
748	<scp>PNPLA</scp>3 rs738409 I748M is associated with steatohepatitis in 434 nonâ€obese subjects with hepatitis C. Alimentary Pharmacology and Therapeutics, 2015, 41, 939-948.	1.9	18
749	Non-Alcoholic Fatty Liver Disease (NAFLD): The Lipid Disease of the Liver and the Effect of Statins. , 2015, , 149-173.		1
750	Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology, 2015, 149, 379-388.	0.6	608
752	Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Journal of Lipid Research, 2015, 56, 722-736.	2.0	264
753	Transcriptional networks implicated in human nonalcoholic fatty liver disease. Molecular Genetics and Genomics, 2015, 290, 1793-1804.	1.0	16
754	Evidenceâ€based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology Research, 2015, 45, 363-377.	1.8	149
755	Association of genetic variants with nonâ€alcoholic fatty liver disease in an urban Sri Lankan community. Liver International, 2015, 35, 676-679.	1.9	15
756	A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders, 2015, 13, 235-238.	0.5	27
758	Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2015, 35, 221-235.	1.8	278
759	Characterization of lipid metabolism in a novel immortalized human hepatocyte cell line. American Journal of Physiology - Endocrinology and Metabolism, 2015, 309, E511-E522.	1.8	24
760	Patatin-like phospholipase domain containing-3 gene (PNPLA3) I148M polymorphism and liver damage in chronic hepatitis C Egyptian patients. Egyptian Journal of Medical Human Genetics, 2015, 16, 333-341.	0.5	1
761	Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations. BMC Genetics, 2015, 16, 93.	2.7	25
762	Genetics of Cardiovascular Risk in Obesity. , 2015, , 1-30.		0

#	Article	IF	Citations
763	Epidemiology of NAFLD and Type 2 Diabetes: Health Disparities Among Persons of Hispanic Origin. Current Diabetes Reports, 2015, 15, 116.	1.7	30
764	Association Between Patatin-Like Phospholipase Domain Containing 3 Gene (PNPLA3) Polymorphisms and Nonalcoholic Fatty Liver Disease: A HuGE Review and Meta-Analysis. Scientific Reports, 2015, 5, 9284.	1.6	106
765	Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. Pharmacogenomics, 2015, 16, 1179-1188.	0.6	24
766	NAFLD incidence and remission: Only a matter of weight gain and weight loss?. Journal of Hepatology, 2015, 62, 15-17.	1.8	84
767	Associations of <scp>I148M</scp> variant in <scp>PNPLA3</scp> gene with plasma <scp>ALT</scp> levels during 2â€year followâ€up in normal weight and overweight children: the <scp>PANIC</scp> Study. Pediatric Obesity, 2015, 10, 84-90.	1.4	22
768	Childhood adiposity trajectories and risk of nonalcoholic fatty liver disease in adolescents. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 163-171.	1.4	106
769	A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nature Genetics, 2015, 47, 1443-1448.	9.4	435
770	Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2015, 35, 203-206.	1.8	6
771	The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Seminars in Liver Disease, 2015, 35, 270-290.	1.8	135
772	Nonalcoholic fatty liver disease â€“ current status and future directions. Journal of Digestive Diseases, 2015, 16, 541-557.	0.7	80
773	Molecular mechanisms of fatty liver in obesity. Frontiers of Medicine, 2015, 9, 275-287.	1.5	24
774	Caring for children with NAFLD and navigating their care into adulthood. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 617-628.	8.2	17
775	Calcium-independent phospholipases A2 and their roles in biological processes and diseases. Journal of Lipid Research, 2015, 56, 1643-1668.	2.0	151
776	Non-alcoholic fatty liver disease. Medicine, 2015, 43, 585-589.	0.2	6
777	Paradoxical Dissociation Between Hepatic Fat Content and De Novo Lipogenesis Due to PNPLA3 Sequence Variant. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E821-E825.	1.8	64
778	Differences in Cardiometabolic Risk between Insulin-Sensitive and Insulin-Resistant Overweight and Obese Children. Childhood Obesity, 2015, 11, 289-296.	0.8	9
779	Meta-analysis reveals a specific association of the PNPLA3 I148M polymorphism with ALT level in adolescents. Personalized Medicine, 2015, 12, 67-82.	0.8	1
780	Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial. Journal of Hepatology, 2015, 63, 1476-1483.	1.8	90

#	Article	IF	Citations
781	Is it worthy of switching to PegIFN alfa-2a in patients achieving virological suppression with entecavir?. Journal of Hepatology, 2015, 62, 1439-1440.	1.8	1
782	Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. Gastroenterology, 2015, 149, 1784-1793.	0.6	294
783	Pancreatic Lipid Content Is Not Associated with Beta Cell Dysfunction in Youth-Onset Type 2 Diabetes. Canadian Journal of Diabetes, 2015, 39, 398-404.	0.4	14
784	Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies. Metabolic Syndrome and Related Disorders, 2015, 13, 423-444.	0.5	670
785	A letter on ABCB4 from Iceland: On the highway to liver disease. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 655-658.	0.7	15
786	Leptin. , 2015, , .		4
787	Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy. Journal of Hepatology, 2015, 62, 182-189.	1.8	147
788	Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. Journal of Hepatology, 2015, 62, 657-663.	1.8	104
789	The impact of <scp>PNPLA</scp>3 (rs738409 C>G) polymorphisms on liver histology and longâ€term clinical outcome in chronic hepatitis B patients. Liver International, 2015, 35, 438-447.	1.9	29
790	From whole body to cellular models of hepatic triglyceride metabolism: man has got to know his limitations. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E1-E20.	1.8	30
791	Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. Journal of Hepatology, 2015, 62, 905-912.	1.8	89
792	Revisiting liver disease progression in HIV/HCVâ€coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Liver International, 2015, 35, 876-885.	1.9	32
793	Genetics in PBC: What Do the â€œRisk Genesâ€•Teach Us?. Clinical Reviews in Allergy and Immunology, 2015, 48, 176-181.	2.9	22
794	Significance of exercise in nonalcoholic fatty liver disease in men: a community-based large cross-sectional study. Journal of Gastroenterology, 2015, 50, 230-237.	2.3	19
795	Insulin Resistance in Nonalcoholic Fatty Liver Disease: Experience from Bangladesh. Bangladesh Critical Care Journal, 2016, 4, 86-91.	0.1	3
798	Nonalcoholic Fatty Liver Disease in Children: Role of the Gut Microbiota. , 2016, , .		0
799	Insulin resistance in development and progression of nonalcoholic fatty liver disease. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 211.	0.5	74
800	Association between adiponectin gene T45G polymorphism and nonalcoholic fatty liver disease risk: a meta-analysis. Genetics and Molecular Research, 2016, 15, .	0.3	4

#	Article	IF	Citations
801	The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. Journal of Clinical Investigation, 2016, 126, 12-22.	3.9	924
802	Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. International Journal of Molecular Sciences, 2016, 17, 367.	1.8	96
803	Nonalcoholic fatty liver disease as a multi-systemic disease. World Journal of Gastroenterology, 2016, 22, 4079.	1.4	100
804	Hepatokines and non-alcoholic fatty liver disease. Acta Biochimica Polonica, 2016, 63, .	0.3	32
805	The Immune Landscape in Nonalcoholic Steatohepatitis. Immune Network, 2016, 16, 147.	1.6	49
808	Recent advances in understanding ichthyosis pathogenesis. F1000Research, 2016, 5, 1497.	0.8	26
809	The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background. Gastroenterology Research and Practice, 2016, 2016, 1-13.	0.7	142
810	Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-7.	0.8	124
811	Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells. BioMed Research International, 2016, 2016, 1-11.	0.9	85
812	Non alcoholic fatty liver disease in Nigerian population with type II diabetes mellitus. Pan African Medical Journal, 2016, 24, 20.	0.3	17
813	Hedgehog signaling is a potent regulator of liver lipid metabolism and reveals a GLI-code associated with steatosis. ELife, 2016, 5, .	2.8	61
814	Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2016, 22, 8294.	1.4	81
815	A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. International Journal of Molecular Sciences, 2016, 17, 947.	1.8	129
818	How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?. Frontiers in Endocrinology, 2016, 7, 145.	1.5	19
819	Additive Effects of the Risk Alleles of PNPLA3 and TM6SF2 on Non-alcoholic Fatty Liver Disease (NAFLD) in a Chinese Population. Frontiers in Genetics, 2016, 7, 140.	1.1	54
820	Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infectionâ€"Liver: The â€œMusketeerâ€•in the Spotlight. International Journal of Molecular Sciences, 2016, 17, 355.	1.8	36
821	PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2016, 17, 630.	1.8	18
822	Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLDâ€"A Systematic Review. International Journal of Molecular Sciences, 2016, 17, 633.	1.8	114

#	Article	IF	Citations
823	The Natural Course of Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2016, 17, 774.	1.8	456
824	Molecular Pathogenesis of NASH. International Journal of Molecular Sciences, 2016, 17, 1575.	1.8	150
826	Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls. PLoS ONE, 2016, 11, e0163423.	1.1	32
827	Susceptibility of Different Mouse Wild Type Strains to Develop Diet-Induced NAFLD/AFLD-Associated Liver Disease. PLoS ONE, 2016, 11, e0155163.	1.1	62
828	Cirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central Obesity. PLoS ONE, 2016, 11, e0150978.	1.1	21
829	The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients. PLoS ONE, 2016, 11, e0168265.	1.1	15
830	Genetics of non-alcoholic fatty liver disease: From susceptibility and nutrient interactions to management. World Journal of Hepatology, 2016, 8, 827.	0.8	20
831	PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surgery for Obesity and Related Diseases, 2016, 12, 1838-1846.	1.0	60
832	GC Gene Polymorphism and Unbound Serum Retinol-Binding Protein 4 Are Related to the Risk of Insulin Resistance in Patients With Chronic Hepatitis C. Medicine (United States), 2016, 95, e3019.	0.4	13
833	Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes, Obesity and Metabolism, 2016, 18, 882-891.	2.2	175
834	PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes. Inflammatory Bowel Diseases, 2016, 22, 134-140.	0.9	27
835	Host genetic variants influencing the clinical course of hepatitis C virus infection. Journal of Medical Virology, 2016, 88, 185-195.	2.5	46
836	Non-alcoholic fatty liver disease and risk of type 2 diabetes. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 385-395.	2.2	110
837	Patatin-like phospholipase domain-containing protein 3 is involved in hepatic fatty acid and triglyceride metabolism through X-box binding protein 1 and modulation of endoplasmic reticulum stress in mice. Hepatology Research, 2016, 46, 584-592.	1.8	16
838	<scp>TM6SF2 G</scp>lu167<scp>L</scp>ys polymorphism is associated with low levels of <scp>LDL</scp>â€cholesterol and increased liver injury in obese children. Pediatric Obesity, 2016, 11, 115-119.	1.4	76
839	The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology, 2016, 64, 19-22.	3.6	174
840	Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease. Pharmacogenomics, 2016, 17, 1273-1288.	0.6	13
841	Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study. Hepatology, 2016, 64, 1547-1558.	3.6	64

#	Article	IF	Citations
842	Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort. Hepatology, 2016, 64, 1969-1977.	3.6	237
843	Interactions of a PPARGC1A Variant and a PNPLA3 Variant Affect Nonalcoholic Steatohepatitis in Severely Obese Taiwanese Patients. Medicine (United States), 2016, 95, e3120.	0.4	26
844	TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis. Nature, 2016, 535, 303-307.	13.7	72
845	The rs2294918 E434K variant modulates patatinâ€like phospholipase domainâ€containing 3 expression and liver damage. Hepatology, 2016, 63, 787-798.	3.6	93
846	Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, endoplasmic reticulum stress, and lipogenesis and is regulated by hepatocyte nuclear factor 4 alpha in mice. Hepatology, 2016, 63, 1860-1874.	3.6	97
847	Influence of the rs738409 polymorphism in patatinâ€like phospholipase 3 on the treatment efficacy of nonâ€alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatology Research, 2016, 46, E146-53.	1.8	19
848	<scp>TM</scp>6<scp>SF</scp>2 rs58542926 is not associated with steatosis and fibrosis in largeÂcohort of patients with genotype 1 chronic hepatitis C. Liver International, 2016, 36, 198-204.	1.9	15
849	Epigenetics in liver disease: from biology to therapeutics. Gut, 2016, 65, 1895-1905.	6.1	115
850	Hispanic health in the USA: a scoping review of the literature. Public Health Reviews, 2016, 37, 31.	1.3	306
851	Short-Term Hypocaloric High-Fiber and High-Protein Diet Improves Hepatic Steatosis Assessed by Controlled Attenuation Parameter. Clinical and Translational Gastroenterology, 2016, 7, e176.	1.3	29
852	Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. BMC Gastroenterology, 2016, 16, 141.	0.8	32
857	Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins. Journal of Biological Chemistry, 2016, 291, 10659-10676.	1.6	172
859	Clinical Applications and Systems Biomedicine. Translational Bioinformatics, 2016, , 323-335.	0.0	0
860	Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study. Hepatology, 2016, 63, 117-125.	3.6	106
861	DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology, 2016, 63, 418-427.	3.6	31
862	Childhood predictors of adult fatty liver. The Cardiovascular Risk in Young Finns Study. Journal of Hepatology, 2016, 65, 784-790.	1.8	51
863	Activation of the Constitutive Androstane Receptor induces hepatic lipogenesis and regulates Pnpla3 gene expression in a LXR-independent way. Toxicology and Applied Pharmacology, 2016, 303, 90-100.	1.3	23
864	Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. Journal of Lipid Research, 2016, 57, 1758-1770.	2.0	198

#	Article	IF	Citations
865	Alcoholic Liver Disease in Asia, Europe, and North America. Gastroenterology, 2016, 150, 1786-1797.	0.6	133
866	Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 451-496.	9.6	449
867	Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Digestive Diseases and Sciences, 2016, 61, 1214-1225.	1.1	130
868	PNPLA3 gene in liver diseases. Journal of Hepatology, 2016, 65, 399-412.	1.8	205
869	The Effects of Alcohol on Other Chronic Liver Diseases. Clinics in Liver Disease, 2016, 20, 581-594.	1.0	13
870	Exercise-based Interventions for Nonalcoholic Fatty Liver Disease: A Meta-analysis and Meta-regression. Clinical Gastroenterology and Hepatology, 2016, 14, 1398-1411.	2.4	159
871	Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therapeutic Advances in Gastroenterology, 2016, 9, 392-407.	1.4	100
872	Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan. Hepatology International, 2016, 10, 647-656.	1.9	35
873	The PNPLA3 rs738409 Câ€‰>â€‰G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scandinavian Journal of Gastroenterology, 2016, 51, 967-973.	0.6	20
874	Genetics in Common Liver Diseases: From Pathophysiology to Precise Treatment. Digestive Diseases, 2016, 34, 391-395.	0.8	5
875	The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH). BMC Medical Genetics, 2016, 17, 63.	2.1	29
876	Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. Alimentary Pharmacology and Therapeutics, 2016, 44, 1253-1264.	1.9	23
877	Nonalcoholic fatty liver disease and metabolic syndrome: Shared genetic basis of pathogenesis. Hepatology, 2016, 64, 1417-1420.	3.6	38
878	Mapping liver fat female-dependent quantitative trait loci in collaborative cross mice. Mammalian Genome, 2016, 27, 565-573.	1.0	20
879	Determinants of Racial/Ethnic Differences in Cardiorespiratory Fitness (from the Dallas Heart Study). American Journal of Cardiology, 2016, 118, 499-503.	0.7	21
880	Non-alcoholic fatty liver and the gut microbiota. Molecular Metabolism, 2016, 5, 782-794.	3.0	193
881	Endoplasmic reticulum proteostasis in hepatic steatosis. Nature Reviews Endocrinology, 2016, 12, 710-722.	4.3	149
882	The story of <scp>HCC</scp> in <scp>NAFLD</scp>: from epidemiology, across pathogenesis, to prevention and treatment. Liver International, 2016, 36, 317-324.	1.9	196

#	Article	IF	Citations
883	Review article: emerging antiâ€fibrotic therapies in the treatment of nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2016, 43, 1109-1123.	1.9	46
884	Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. Liver International, 2016, 36, 1563-1579.	1.9	126
885	Obesity, NASH, and HCC. , 2016, , 275-286.		0
886	Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction. Digestive Diseases, 2016, 34, 3-10.	0.8	29
887	Overnutrition, Ectopic Lipid and the Metabolic Syndrome. Journal of Investigative Medicine, 2016, 64, 1082-1086.	0.7	62
888	Changing epidemiology of chronic liver disease among ethnic groups in the United States. Hepatology, 2016, 64, 1843-1846.	3.6	3
890	PNPLA3 Polymorphism and Nonalcoholic Fatty Liver Disease. Exposure and Health, 2016, , 1-26.	2.8	0
891	Host â€“ hepatitis C viral interactions: The role of genetics. Journal of Hepatology, 2016, 65, S22-S32.	1.8	57
892	Ethnic differences in cardiometabolic risk among adolescents across the waistâ€“height ratio spectrum: National Health and Nutrition Examination Surveys (NHANES). International Journal of Cardiology, 2016, 222, 622-628.	0.8	15
893	Association between PNPLA3 rs738409 polymorphism and hepatocellular carcinoma risk: an updated meta-analysis. Genes and Genomics, 2016, 38, 831-839.	0.5	3
894	Variants in the autophagy-related gene IRGM confer susceptibility to non-alcoholic fatty liver disease by modulating lipophagy. Journal of Hepatology, 2016, 65, 1209-1216.	1.8	64
895	Association of MBOAT7 gene variant with plasma ALT levels in children: the PANIC study. Pediatric Research, 2016, 80, 651-655.	1.1	41
896	PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. Human Molecular Genetics, 2016, 25, ddw341.	1.4	86
897	Meta-analysis of the influence of TM6SF2 E167K variant on Plasma Concentration of Aminotransferases across different Populations and Diverse Liver Phenotypes. Scientific Reports, 2016, 6, 27718.	1.6	19
898	Nonalcoholic Fatty Liver Disease. Gastroenterology Clinics of North America, 2016, 45, 639-652.	1.0	202
899	Association between bilirubin and risk of Non-Alcoholic Fatty Liver Disease based on a prospective cohort study. Scientific Reports, 2016, 6, 31006.	1.6	39
900	Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults. Molecular Biology Reports, 2016, 43, 1359-1369.	1.0	16
901	Insufficiency of phosphatidylethanolamine N-methyltransferase is risk for lean non-alcoholic steatohepatitis. Scientific Reports, 2016, 6, 21721.	1.6	42

#	Article	IF	Citations
902	Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterology, 2016, 3, e000114.	1.1	21
903	Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clinical Medicine Insights Therapeutics, 2016, 8, CMT.S18885.	0.4	33
904	Early Detection of Steatohepatitis: Less Teeth NASHing and More Research?. Digestive Diseases and Sciences, 2016, 61, 1788-1789.	1.1	0
905	Noninvasive fatty liver markers predict liver disease mortality in the U.S. population. Hepatology, 2016, 63, 1170-1183.	3.6	76
906	Genomeâ€wide association study in mice identifies loci affecting liverâ€related phenotypes including Sel1l influencing serum bile acids. Hepatology, 2016, 63, 1943-1956.	3.6	2
907	I148M variant of PNPLA3 increases the susceptibility to nonâ€alcoholic fatty liver disease caused by obesity and metabolic disorders. Alimentary Pharmacology and Therapeutics, 2016, 43, 631-642.	1.9	30
908	Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. Journal of Hepatology, 2016, 65, 425-443.	1.8	366
909	Destined to develop NAFLD? The predictors of fatty liver from birth to adulthood. Journal of Hepatology, 2016, 65, 668-670.	1.8	18
910	Nighttime sleep duration and risk of nonalcoholic fatty liver disease: the Dongfeng-Tongji prospective study. Annals of Medicine, 2016, 48, 468-476.	1.5	19
911	Hepatology after Hepatitis C. Digestive Diseases, 2016, 34, 603-606.	0.8	2
912	Are genetic variations the most important risk factors for development of hepatocellular carcinoma?. Journal of Gastroenterology, 2016, 51, 404-405.	2.3	1
913	Entangled in a membranous web: ER and lipid droplet reorganization during hepatitis C virus infection. Current Opinion in Cell Biology, 2016, 41, 117-124.	2.6	30
914	Spectrum of Alcoholic Liver Disease. Clinics in Liver Disease, 2016, 20, 419-427.	1.0	78
915	Screening for rare variants in the PNPLA3 gene in obese liver biopsy patients. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 715-721.	0.7	3
916	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology, 2016, 64, 34-46.	3.6	83
917	Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease. Liver International, 2016, 36, 1213-1220.	1.9	31
918	Females, Hispanics and older individuals are at greatest risk of developing metabolic syndrome in the U.S.. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2016, 10, 230-233.	1.8	16
919	Novel phenotypes of prediabetes?. Diabetologia, 2016, 59, 1806-1818.	2.9	43

#	Article	IF	Citations
920	The intersection of nonalcoholic fatty liver disease and obesity. Science Translational Medicine, 2016, 8, 323rv1.	5.8	60
921	Obesity and Cancer: The Oil that Feeds the Flame. Cell Metabolism, 2016, 23, 48-62.	7.2	296
922	Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 1167-1175.	1.8	342
923	Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. Annual Review of Physiology, 2016, 78, 181-205.	5.6	302
924	The Role of Cholesterol in the Pathogenesis of NASH. Trends in Endocrinology and Metabolism, 2016, 27, 84-95.	3.1	347
925	Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Digestive Diseases and Sciences, 2016, 61, 1325-1336.	1.1	169
926	Alcoholic and Non-Alcoholic Fatty Liver Disease. , 2016, , .		5
927	Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2016, 150, 1798-1810.	0.6	129
928	Why do I treat my patients with mild hepatitis C?. Liver International, 2016, 36, 7-12.	1.9	20
929	Relationships Between Alanine Aminotransferase, Serum Triglycerides, Body Mass Index and Nonalcoholic Fatty Liver Disease in an Outpatient Pediatric Clinic Population. Journal of Pediatric Nursing, 2016, 31, 152-158.	0.7	7
930	Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. Gastroenterology, 2016, 150, 1728-1744.e7.	0.6	202
931	Pathogenesis of nonalcoholic steatohepatitis. Cellular and Molecular Life Sciences, 2016, 73, 1969-1987.	2.4	151
932	Pathogenesis of NAFLD and NASH. , 2016, , 71-101.		5
933	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology, 2016, 150, 1219-1230.e6.	0.6	506
934	Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2016, 65, 1161-1171.	1.5	68
935	Reduction of Caloric Intake Might Override the Prosteatotic Effects of the <i>PNPLA3</i> p.I148M and <i>TM6SF2</i> p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study. Digestion, 2016, 93, 139-148.	1.2	27
936	Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. Digestive Diseases and Sciences, 2016, 61, 1234-1245.	1.1	111
937	Genetics of Cardiovascular Risk in Obesity. , 2016, , 195-219.		0

#	Article	IF	Citations
938	The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or Ethnicities. Clinics in Liver Disease, 2016, 20, 215-224.	1.0	67
939	Non-alcoholic fatty liver disease and liver transplantation. Metabolism: Clinical and Experimental, 2016, 65, 1208-1223.	1.5	40
940	A â€œsystems medicineâ€•approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2016, 48, 333-342.	0.4	56
941	Genetic Basis of Alcoholic and Nonalcoholic Fatty Liver Disease. , 2016, , 147-163.		0
942	Genetic and epigenetic mechanisms of NASH. Hepatology International, 2016, 10, 394-406.	1.9	46
943	The Progression and Natural History of Pediatric Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2016, 20, 325-338.	1.0	117
944	The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Clinics in Liver Disease, 2016, 20, 225-243.	1.0	85
945	Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. Expert Review of Gastroenterology and Hepatology, 2016, 10, 393-403.	1.4	25
946	Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2016, 65, 1172-1182.	1.5	57
947	The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. Journal of Gastroenterology, 2016, 51, 370-379.	2.3	41
948	Genetics of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2016, 65, 1026-1037.	1.5	84
950	Tetra-primer ARMS-PCR identified four pivotal genetic variations in bovine PNPLA3 gene and its expression patterns. Gene, 2016, 575, 191-198.	1.0	1
952	Association study of PNPLA2 gene with histological parameters of NAFLD in an obese population. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 333-339.	0.7	7
953	Pathophysiology of lipid droplet proteins in liver diseases. Experimental Cell Research, 2016, 340, 187-192.	1.2	125
954	PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis. Digestive and Liver Disease, 2016, 48, 69-75.	0.4	73
955	Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Annual Review of Medicine, 2016, 67, 103-117.	5.0	535
956	Physiological Mechanisms of Weight Gainâ^'Induced Steatosis in People With Obesity. Gastroenterology, 2016, 150, 79-81.e2.	0.6	43
957	New Horizons in Pediatric Hepatology: A Glimpse of the Future. , 2016, , 897-904.		0

#	Article	IF	Citations
958	Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism: Clinical and Experimental, 2016, 65, 1136-1150.	1.5	190
959	Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. Critical Reviews in Clinical Laboratory Sciences, 2016, 53, 106-120.	2.7	37
960	The common <scp>PNPLA</scp>3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (<scp>CAP</scp>). Liver International, 2016, 36, 418-426.	1.9	24
961	Nonalcoholic Fatty Liver Disease in Latinos. Clinical Gastroenterology and Hepatology, 2016, 14, 5-12.	2.4	87
962	GCKR polymorphism influences liver fat content in patients with type 2 diabetes. Acta Diabetologica, 2016, 53, 237-242.	1.2	17
963	Clinicopathological characteristics of nonâ€B nonâ€C hepatocellular carcinoma without past hepatitis B virus infection. Hepatology Research, 2017, 47, 405-418.	1.8	30
964	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology, 2017, 65, 54-64.	3.6	260
965	Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology, 2017, 65, 2090-2099.	3.6	100
966	The interrelationship between bile acid and vitamin A homeostasis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2017, 1862, 496-512.	1.2	57
967	Early life programming and the risk of non-alcoholic fatty liver disease. Journal of Developmental Origins of Health and Disease, 2017, 8, 263-272.	0.7	23
968	The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology, 2017, 65, 1875-1890.	3.6	177
969	Genetics in liver diseases: From diagnostics to precise therapy. Clinical Liver Disease, 2017, 9, 1-4.	1.0	5
970	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Digestive and Liver Disease, 2017, 49, 471-483.	0.4	254
971	Analysis of Whole Exome Sequencing with Cardiometabolic Traits Using Family-Based Linkage and Association in the IRAS Family Study. Annals of Human Genetics, 2017, 81, 49-58.	0.3	6
972	Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs, 2017, 77, 131-144.	4.9	52
973	An extended fatty liver index to predict non-alcoholic fatty liver disease. Diabetes and Metabolism, 2017, 43, 229-239.	1.4	22
974	Genomeâ€Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. Clinical Pharmacology and Therapeutics, 2017, 102, 131-140.	2.3	50
975	Fat mass and obesityâ€associated gene variations are related to fatty liver disease in <scp>HIV</scp>â€infected patients. HIV Medicine, 2017, 18, 546-554.	1.0	6

#	Article	IF	Citations
976	Identification of core gene networks and hub genes associated with progression of nonâ€alcoholic fatty liver disease by RNA sequencing. Hepatology Research, 2017, 47, 1445-1458.	1.8	23
977	Impact of family history of metabolic traits on severity of nonâ€alcoholic steatohepatitis related cirrhosis: A crossâ€sectional study. Liver International, 2017, 37, 1397-1404.	1.9	19
978	Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. The Lancet Gastroenterology and Hepatology, 2017, 2, 211-223.	3.7	37
979	A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. Scientific Reports, 2017, 7, 43238.	1.6	41
980	Non-alcoholic fatty liver disease (NAFLD) â€“ pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metabolism Reviews, 2017, 49, 197-211.	1.5	414
981	Caspaseâ€cleaved keratinâ€18 fragments increase during alcohol withdrawal and predict liverâ€related death in patients with alcoholic liver disease. Hepatology, 2017, 66, 96-107.	3.6	59
982	Visceral fat is associated with the racial differences in liver fat between black and white adolescent boys with obesity. Pediatric Diabetes, 2017, 18, 660-663.	1.2	12
983	Hepatic nucleotide binding oligomerization domainâ€like receptors pyrin domainâ€containing 3 inflammasomes are associated with the histologic severity of nonâ€alcoholic fatty liver disease. Hepatology Research, 2017, 47, 1459-1468.	1.8	20
984	Nonâ€alcoholic fatty liver disease phosphoproteomics: A functional piece of the precision puzzle. Hepatology Research, 2017, 47, 1469-1483.	1.8	12
985	Lipid droplets and liver disease: from basic biology to clinical implications. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 343-355.	8.2	427
986	Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nature Genetics, 2017, 49, 842-847.	9.4	288
987	Depletion of TM6SF2 disturbs membrane lipid composition and dynamics in HuH7 hepatoma cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2017, 1862, 676-685.	1.2	26
988	Hepatocyte-specific depletion of ubiquitin regulatory X domain containing protein 8 accelerates fibrosis in a mouse non-alcoholic steatohepatitis model. Histochemistry and Cell Biology, 2017, 148, 219-227.	0.8	2
989	The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study. European Journal of Gastroenterology and Hepatology, 2017, 29, 441-447.	0.8	21
990	Mechanisms of hepatic stellate cell activation. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 397-411.	8.2	1,821
991	Systematic review with metaâ€analysis: risk factors for nonâ€alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Alimentary Pharmacology and Therapeutics, 2017, 46, 85-95.	1.9	161
992	Significant positive association of endotoxemia with histological severity in 237 patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 175-182.	1.9	58
993	Genetic Discoveries Highlight Environmental Factors as Key Drivers of Liver Disease. Digestive Diseases, 2017, 35, 323-333.	0.8	7

#	Article	IF	Citations
994	Fibronectin Type III Domainâ€“Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2660-2669.	1.8	42
995	Non-alcoholic fatty liver disease: A sign of systemic disease. Metabolism: Clinical and Experimental, 2017, 72, 94-108.	1.5	132
996	The management of childhood liver diseases in adulthood. Journal of Hepatology, 2017, 66, 631-644.	1.8	27
997	Genetics of Infectious and Inflammatory Diseases: Overlapping Discoveries from Association and Exome-Sequencing Studies. Annual Review of Immunology, 2017, 35, 1-30.	9.5	36
998	PPARs and nonalcoholic fatty liver disease. Biochimie, 2017, 136, 65-74.	1.3	210
999	The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology, 2017, 66, 1111-1124.	3.6	198
1000	New trends on obesity and NAFLD in Asia. Journal of Hepatology, 2017, 67, 862-873.	1.8	759
1001	Mutant PNPLA3 I148M protein as pharmacological target for liver disease. Hepatology, 2017, 66, 1026-1028.	3.6	25
1002	Incidence and risk factors for nonâ€alcoholic fatty liver disease: A 7â€year followâ€up study among urban, adult Sri Lankans. Liver International, 2017, 37, 1715-1722.	1.9	32
1003	Genetic determination of body fat distribution and the attributive influence on metabolism. Obesity, 2017, 25, 1277-1283.	1.5	15
1004	Ultraâ€highâ€field magnetic resonance spectroscopy in nonâ€alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in nonâ€alcoholic steatohepatitis and advanced fibrosis. Liver International, 2017, 37, 1544-1553.	1.9	35
1005	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clinical Gastroenterology and Hepatology, 2017, 15, 1604-1611.e1.	2.4	146
1007	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. Atherosclerosis, 2017, 262, 179-184.	0.4	19
1008	Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease. Digestive Diseases, 2017, 35, 282-287.	0.8	32
1009	De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. Clinics in Liver Disease, 2017, 21, 321-335.	1.0	23
1010	Vitamin A deficiency in chronic cholestatic liver disease: Is vitamin A therapy beneficial?. Liver International, 2017, 37, 1752-1758.	1.9	17
1011	Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease. Clinical Journal of Gastroenterology, 2017, 10, 201-207.	0.4	18
1012	Constitutional and functional genetics of human alcoholâ€related hepatocellular carcinoma. Liver International, 2017, 37, 1591-1601.	1.9	16

#	Article	IF	Citations
1013	Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis. Current Diabetes Reports, 2017, 17, 20.	1.7	26
1014	Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut, 2017, 66, 1138-1153.	6.1	807
1015	Binge alcohol alters PNPLA3 levels in liver through epigenetic mechanism involving histone H3 acetylation. Alcohol, 2017, 60, 77-82.	0.8	14
1016	Patatin-like phospholipase domain-containing protein 3 (PNPLA3): A potential role in the association between liver disease and bipolar disorder. Journal of Affective Disorders, 2017, 209, 93-96.	2.0	9
1018	Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver. Hepatology Communications, 2017, 1, 23-35.	2.0	56
1019	The size matters: regulation of lipid storage by lipid droplet dynamics. Science China Life Sciences, 2017, 60, 46-56.	2.3	65
1020	Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically- versus genetically-driven excess fat hepatic storage. Atherosclerosis, 2017, 257, 232-239.	0.4	39
1021	Genome-Wide Associations Related to Hepatic Histology in Nonalcoholic Fatty Liver Disease in Hispanic Boys. Journal of Pediatrics, 2017, 190, 100-107.e2.	0.9	38
1022	Association of single nucleotide polymorphism at PNPLA3 with fatty liver, steatohepatitis, and cirrhosis of liver. Indian Journal of Gastroenterology, 2017, 36, 366-372.	0.7	10
1023	Challenges in Patient Enrollment and Retention in Clinical Studies for Alcoholic Hepatitis: Experience of the TREAT Consortium. Alcoholism: Clinical and Experimental Research, 2017, 41, 2000-2006.	1.4	16
1024	Differences in bone structure and unloading-induced bone loss between C57BL/6N and C57BL/6J mice. Mammalian Genome, 2017, 28, 476-486.	1.0	29
1025	Influence of Dietary Macronutrients on Liver Fat Accumulation and Metabolism. Journal of Investigative Medicine, 2017, 65, 1102-1115.	0.7	104
1026	Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients. Digestive Diseases, 2017, 35, 521-530.	0.8	16
1027	LncRNA AK054921 and AK128652 are potential serum biomarkers and predictors of patient survival with alcoholic cirrhosis. Hepatology Communications, 2017, 1, 513-523.	2.0	40
1028	Epigenetics in Liver Fibrosis. Seminars in Liver Disease, 2017, 37, 219-230.	1.8	19
1030	Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease. Endocrine, 2017, 58, 246-252.	1.1	14
1031	The phospholipase PNPLA7 functions as a lysophosphatidylcholine hydrolase and interacts with lipid droplets through its catalytic domain. Journal of Biological Chemistry, 2017, 292, 19087-19098.	1.6	22
1032	Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma. Scientific Reports, 2017, 7, 11912.	1.6	28

#	Article	IF	Citations
1033	Is That Possible to Stop or Cease the NASH to Turn into HCC?. Journal of Gastrointestinal Cancer, 2017, 48, 250-255.	0.6	2
1034	Interferon lambda 4 rs368234815 TT>ÎŽG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology, 2017, 66, 1885-1893.	3.6	75
1035	A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease. Journal of Clinical Lipidology, 2017, 11, 1101-1105.	0.6	10
1036	Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metabolism, 2017, 26, 394-406.e6.	7.2	265
1037	Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum. Gastroenterology, 2017, 153, 621-625.e7.	0.6	24
1038	The Role of Fructose, and Specifically Sugar-Sweetened Beverages, in Pediatric Nonalcoholic Fatty Liver Disease. Topics in Clinical Nutrition, 2017, 32, 27-46.	0.2	0
1039	Lipid Droplet Biogenesis. Annual Review of Cell and Developmental Biology, 2017, 33, 491-510.	4.0	520
1040	The Role of Cholangiocyte Cell Death in the Development of Biliary Diseases. , 2017, , 23-38.		1
1041	Triglyceride Metabolism in the Liver. , 2017, 8, 1-22.		440
1042	Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C. Current Hepatology Reports, 2017, 16, 317-325.	0.4	1
1044	Non-alcoholic Fatty Liver Disease in Non-obese Patients. Current Hepatology Reports, 2017, 16, 382-390.	0.4	0
1045	Managing the Burden of Non-NASH NAFLD. Current Hepatology Reports, 2017, 16, 326-334.	0.4	3
1046	Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis. Digestive Disease Interventions, 2017, 01, 066-073.	0.3	0
1047	Predictors of Liver Fat and Stiffness in Non-Alcoholic Fatty Liver Disease (NAFLD) â€“ an 11-Year Prospective Study. Scientific Reports, 2017, 7, 14561.	1.6	18
1048	AQP3 is regulated by PPARÎ³ and JNK in hepatic stellate cells carrying PNPLA3 I148M. Scientific Reports, 2017, 7, 14661.	1.6	15
1049	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Scientific Reports, 2017, 7, 4492.	1.6	193
1050	Insulin resistance is associated with elevated transaminases and low aspartate aminotransferase/alanine aminotransferase ratio in young adults with normal weight. European Journal of Gastroenterology and Hepatology, 2017, 29, 435-440.	0.8	31
1051	The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population. Journal of Clinical Gastroenterology, 2017, 51, 160-166.	1.1	50

#	Article	IF	Citations
1052	Burden of hepatocellular carcinoma among hispanics in South Texas: a systematic review. Biomarker Research, 2017, 5, 15.	2.8	19
1053	Pediatric Nonalcoholic Fatty Liver Disease: the Rise of a Lethal Disease Among Mexican American Hispanic Children. Obesity Surgery, 2017, 27, 236-244.	1.1	25
1054	Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. Journal of Lipid Research, 2017, 58, 247-255.	2.0	159
1055	Development of hepatocellular carcinoma in Japanese patients with biopsyâ€proven nonâ€alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression. Hepatology Research, 2017, 47, 1083-1092.	1.8	61
1056	Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease. Protein and Cell, 2017, 8, 4-13.	4.8	23
1057	Metabolomics and Metabolic Diseases: Where Do We Stand?. Cell Metabolism, 2017, 25, 43-56.	7.2	539
1058	Metabolism disrupting chemicals and metabolic disorders. Reproductive Toxicology, 2017, 68, 3-33.	1.3	745
1059	Genetic and hormonal control of hepatic steatosis in female and male mice. Journal of Lipid Research, 2017, 58, 178-187.	2.0	46
1060	Weight loss induced by bariatric surgery restores adipose tissue <scp>PNPLA</scp>3 expression. Liver International, 2017, 37, 299-306.	1.9	13
1061	Nonobese Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 474-485.	2.4	262
1062	The genetics of alcohol dependence and alcohol-related liver disease. Journal of Hepatology, 2017, 66, 195-211.	1.8	127
1063	Gene polymorphisms of desaturase enzymes of polyunsaturated fatty acid metabolism and adiponutrin and the increased risk of nonalcoholic fatty liver disease. Meta Gene, 2017, 11, 152-156.	0.3	7
1064	Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health. Cell Biology and Toxicology, 2017, 33, 5-14.	2.4	11
1065	NAFLD and diabetes mellitus. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 32-42.	8.2	687
1066	Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. Journal of Trace Elements in Medicine and Biology, 2017, 39, 100-107.	1.5	28
1067	Magnetic Resonance Venography. , 2017, , 135-156.		0
1068	Concise Review: Current Status and Future Directions on Research Related to Nonalcoholic Fatty Liver Disease. Stem Cells, 2017, 35, 89-96.	1.4	48
1069	Gene-Targeted Next Generation Sequencing Identifies PNPLA1 Mutations in Patients with a Phenotypic Spectrum of Autosomal Recessive Congenital Ichthyosis: The Impact of Consanguinity. Journal of Investigative Dermatology, 2017, 137, 678-685.	0.3	28

#	Article	IF	Citations
1070	Association of the I148M/PNPLA3 (rs738409) polymorphism with premature coronary artery disease, fatty liver, and insulin resistance in type 2 diabetic patients and healthy controls. The GEA study. Immunobiology, 2017, 222, 960-966.	0.8	39
1071	Nonalcoholic fatty liver disease in Asia: emerging perspectives. Journal of Gastroenterology, 2017, 52, 164-174.	2.3	79
1074	In vitro cellular models of human hepatic fatty acid metabolism: differences between Huh7 and HepG2 cell lines in human and fetal bovine culturing serum. Physiological Reports, 2017, 5, e13532.	0.7	48
1075	Genetic and Epigenetic Associations of NAFLD: Focus on Clinical Decision Making. Current Hepatology Reports, 2017, 16, 335-345.	0.4	0
1076	Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. Journal of Clinical Investigation, 2017, 127, 2697-2704.	3.9	137
1077	Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Annals of Translational Medicine, 2017, 5, 270-270.	0.7	109
1078	New Thoughts on Pediatric Genetic Obesity: Pathogenesis, Clinical Characteristics and Treatment Approach. , 0, , .		0
1079	Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans. Thrombosis and Haemostasis, 2017, 117, 286-294.	1.8	18
1080	Redox Signaling in NASH. , 2017, , 169-180.		1
1081	Is Human Cirrhosis a Reversible Disease?. , 2017, , 259-265.		1
1082	Obesity and Hepatocellular Carcinoma. , 2017, , 267-277.		2
1083	The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-Î±. Nutrients, 2017, 9, 198.	1.7	29
1084	Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients, 2017, 9, 870.	1.7	102
1085	Pediatric Non-Alcoholic Fatty Liver Disease. Children, 2017, 4, 48.	0.6	41
1086	The Association between Pediatric NAFLD and Common Genetic Variants. Children, 2017, 4, 49.	0.6	8
1087	Insulin Resistance and NAFLD: A Dangerous Liaison beyond the Genetics. Children, 2017, 4, 74.	0.6	48
1088	A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2017, 18, 1534.	1.8	54
1089	Diabetes mellitus and non-alcoholic fatty liver disease: the thread of Ariadne. Minerva Endocrinology, 2017, 42, 109-121.	0.6	11

#	Article	IF	Citations
1090	Liver fibrosis: the 2017 state of art. Panminerva Medica, 2017, 59, 320-331.	0.2	53
1091	Non-alcoholic fatty liver disease: An expanded review. World Journal of Hepatology, 2017, 9, 715.	0.8	537
1093	Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART). PLoS ONE, 2017, 12, e0178685.	1.1	13
1094	The Serum Oxidative/Anti-oxidative Stress Balance Becomes Dysregulated in Patients with Non-alcoholic Steatohepatitis Associated with Hepatocellular Carcinoma. Internal Medicine, 2017, 56, 243-251.	0.3	23
1095	The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C. BMC Infectious Diseases, 2017, 17, 780.	1.3	19
1096	Genetic predisposition in nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 2017, 23, 1-12.	4.5	166
1097	Shorter Leukocyte Telomere Length in Relation to Presumed Nonalcoholic Fatty Liver Disease in Mexican-American Men in NHANES 1999â€“2002. International Journal of Hepatology, 2017, 2017, 1-7.	0.4	14
1098	Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease. Nutrients, 2017, 9, 1077.	1.7	12
1099	Lipoquality control by phospholipase A₂ enzymes. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2017, 93, 677-702.	1.6	49
1101	PNPLA3 expression and its impact on the liver: current perspectives. Hepatic Medicine: Evidence and Research, 2017, Volume 9, 55-66.	0.9	58
1102	Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2017, 23, 8263-8276.	1.4	514
1103	New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease. Internal Medicine, 2017, 56, 1459-1465.	0.3	2
1104	Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2017, 23, 7495-7504.	1.4	43
1105	Genetic and Epigenetic Profile of Patients With Alcoholic Liver Disease. Annals of Hepatology, 2017, 16, 490-500.	0.6	32
1106	The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population. Annals of Hepatology, 2017, 16, 909-915.	0.6	44
1107	Epidemiology of Nonalcoholic Fatty Liver Disease: Focusing on the Korean Genome Epidemiology Study (KoGES). Journal of Korean Diabetes, 2017, 18, 76.	0.1	1
1108	PNPLA3 Variant p.I148M and Bariatric Surgery. , 2017, , 389-396.		0
1109	Nonalcoholic Fatty Liver Disease in Children. Seminars in Liver Disease, 2018, 38, 001-013.	1.8	108

#	Article	IF	Citations
1110	Apixaban and RosuvasÂÂtatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 2018, 46, 485-492.	1.7	22
1111	Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers. Journal of Human Genetics, 2018, 63, 621-626.	1.1	29
1112	Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. Scientific Reports, 2018, 8, 3702.	1.6	59
1113	The genetic backgrounds in nonalcoholic fatty liver disease. Clinical Journal of Gastroenterology, 2018, 11, 97-102.	0.4	38
1114	Analysis of genotyping for predicting liver injury marker, procollagen <scp>III</scp> in persons at risk of nonâ€alcoholic fatty liver disease. Liver International, 2018, 38, 1832-1838.	1.9	2
1115	Heterogeneous expression of human PNPLA3 triggers algal lipid accumulation and lipid droplet enlargement. Algal Research, 2018, 31, 276-281.	2.4	18
1116	Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study. Digestive and Liver Disease, 2018, 50, 490-495.	0.4	25
1117	NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?. Current HIV/AIDS Reports, 2018, 15, 212-222.	1.1	9
1118	Functional relevance of synonymous alleles reflected in allele rareness in the population. Genomics, 2018, 110, 347-354.	1.3	4
1119	The rs4686434 variant in the fetuin B (FETUB) locus is associated with intrahepatic triglyceride content in obese Chinese adults. Journal of Diabetes, 2018, 10, 916-925.	0.8	2
1120	Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in Obese Adolescents: Findings From a Multiethnic Cohort. Hepatology, 2018, 68, 1376-1390.	3.6	75
1121	Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. Liver International, 2018, 38, 2060-2068.	1.9	72
1122	High frequency of the PNPLA3 rs738409 [G] singleâ€nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer, 2018, 124, 1583-1589.	2.0	16
1123	Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nature Genetics, 2018, 50, 559-571.	9.4	356
1124	Interaction between the patatinâ€like phospholipase domainâ€containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis. Hepatology Communications, 2018, 2, 29-34.	2.0	18
1125	NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects. Human Molecular Genetics, 2018, 27, 2214-2223.	1.4	95
1126	Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults. Advances in Nutrition, 2018, 9, 30-40.	2.9	68
1127	PNPLA3: A Determinant of Response to Low-Fructose Diet in Nonalcoholic Fatty Liver Disease. Gastroenterology, 2018, 154, 1207-1208.	0.6	7

#	Article	IF	Citations
1128	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. Annual Review of Pathology: Mechanisms of Disease, 2018, 13, 321-350.	9.6	387
1129	Disease Gene Identification. Methods in Molecular Biology, 2018, , .	0.4	2
1130	Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biology, 2018, 15, 467-479.	3.9	196
1131	Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A longâ€term followâ€up study. Hepatology Communications, 2018, 2, 48-57.	2.0	200
1132	Physiologic Interpretation of GWAS Signals for Type 2 Diabetes. Methods in Molecular Biology, 2018, 1706, 323-351.	0.4	2
1133	Relationship between genetic variation at PPP1R3B and levels of liver glycogen and triglyceride. Hepatology, 2018, 67, 2182-2195.	3.6	51
1134	Challenges in diagnosing and monitoring diabetes in patients with chronic liver diseases. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 431-440.	1.8	13
1135	Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. Journal of Internal Medicine, 2018, 283, 356-370.	2.7	256
1136	Thwart your destiny; effect of nonacoholic fatty liver disease genes on steatosis, liver injury and cirrhosis varies by body mass index. Hepatology, 2018, 68, 372-374.	3.6	0
1137	Genetic variants in COL13A1, ADIPOQ and SAMM50 , in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population. Experimental and Molecular Pathology, 2018, 104, 50-58.	0.9	25
1138	Genetic determinants of hepatic steatosis and serum cytokeratinâ€18 fragment levels in Taiwanese children. Liver International, 2018, 38, 1300-1307.	1.9	32
1139	Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279â€‰013 individuals. European Heart Journal, 2018, 39, 385-393.	1.0	152
1140	Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist. Hepatology Communications, 2018, 2, 561-570.	2.0	13
1141	Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2018, 155, 307-310.e2.	0.6	113
1142	Genetics of alcoholic liver disease and non-alcoholic steatohepatitis. Clinical Medicine, 2018, 18, s54-s59.	0.8	20
1143	The Membraneâ€bound Oâ€Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2018, 67, 69-74.	0.9	41
1144	Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. Clinical Gastroenterology and Hepatology, 2018, 16, 1511-1520.e5.	2.4	111
1145	A Protein-TruncatingHSD17B13Variant and Protection from Chronic Liver Disease. New England Journal of Medicine, 2018, 378, 1096-1106.	13.9	556

#	Article	IF	Citations
1146	Patatin-like phospholipase domainâ€“containing protein 3 promotes transfers of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. Journal of Biological Chemistry, 2018, 293, 6958-6968.	1.6	74
1147	Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. Molecular Aspects of Medicine, 2018, 64, 135-146.	2.7	103
1148	Polymorphism of receptorâ€type tyrosineâ€protein phosphatase delta gene in the development of nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 283-290.	1.4	15
1149	Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. Clinical Nutrition, 2018, 37, 37-55.	2.3	95
1150	Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2018, 52, 444-451.	1.1	11
1151	New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Protein and Cell, 2018, 9, 164-177.	4.8	92
1152	Sex differences between parental pregnancy characteristics and nonalcoholic fatty liver disease in adolescents. Hepatology, 2018, 67, 108-122.	3.6	51
1153	Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease. Journal of Gastroenterology, 2018, 53, 269-280.	2.3	73
1154	Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease. Journal of Gastroenterology, 2018, 53, 438-448.	2.3	24
1155	Lipid droplet proteins and metabolic diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1968-1983.	1.8	123
1156	A modified response of NAFLD patients with non-significant fibrosis in nutritional counseling according to GCKR rs1260326. European Journal of Nutrition, 2018, 57, 2227-2235.	1.8	11
1157	Effect of PNPLA3 I148M polymorphism on histologically proven nonâ€alcoholic fatty liver disease in liver transplant recipients. Hepatology Research, 2018, 48, E162-E171.	1.8	12
1158	Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. , 2018, 181, 108-125.		94
1159	Asiaâ€“Pacific Working Party on Nonâ€alcoholic Fatty Liver Disease guidelines 2017â€”Part 1: Definition, risk factors and assessment. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 70-85.	1.4	358
1160	Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2018, 16, 198-210.e2.	2.4	284
1161	The Genetics of Pediatric Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2018, 22, 59-71.	1.0	34
1162	Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics. Clinics in Liver Disease, 2018, 22, 39-57.	1.0	35
1163	Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation. Clinics in Liver Disease, 2018, 22, 213-227.	1.0	16

#	Article	IF	Citations
1164	Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study. Journal of the Formosan Medical Association, 2018, 117, 833-840.	0.8	12
1165	Nonalcoholic Fatty Liver Disease and Metabolic Syndrome. Clinics in Liver Disease, 2018, 22, 133-140.	1.0	153
1166	Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. Cell Metabolism, 2018, 27, 22-41.	7.2	496
1167	Nuclear lamina genetic variants, including a truncated LAP2, in twins and siblings with nonalcoholic fatty liver disease. Hepatology, 2018, 67, 1710-1725.	3.6	19
1168	Prevention of Diabetes: Countless Opportunities and Clear Challenges. American Journal of Lifestyle Medicine, 2018, 12, 25-29.	0.8	3
1169	Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. Journal of Gastroenterology, 2018, 53, 181-196.	2.3	61
1170	Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?. British Journal of Dermatology, 2018, 179, 16-29.	1.4	46
1171	Host genetic variations associated with disease progression in chronic hepatitis C virus infection. Hepatology Research, 2018, 48, 127-133.	1.8	18
1172	Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Clinics in Liver Disease, 2018, 22, 201-211.	1.0	65
1173	Association between urine retinolâ€binding protein levels and nonalcoholic fatty liver disease: A crossâ€sectional study in Chinese population. Journal of Clinical Laboratory Analysis, 2018, 32, e22359.	0.9	2
1174	Additive effects of PNPLA3 and TM6SF2 on the histological severity of nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1277-1285.	1.4	89
1175	Association of PNPLA3 rs738409 polymorphism with liver steatosis but not with cirrhosis in patients with HBV infection: Systematic review with metaâ€analysis. Journal of Gene Medicine, 2018, 20, e3001.	1.4	4
1176	The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. Journal of Hepatology, 2018, 68, 251-267.	1.8	116
1177	Genetics and epigenetics of NAFLD and NASH: Clinical impact. Journal of Hepatology, 2018, 68, 268-279.	1.8	670
1178	Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?. Journal of Hepatology, 2018, 68, 335-352.	1.8	495
1179	Risk factors for biopsyâ€proven advanced nonâ€alcoholic fatty liver disease in the Veterans Health Administration. Alimentary Pharmacology and Therapeutics, 2018, 47, 268-278.	1.9	33
1180	The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro. Pharmacogenomics Journal, 2018, 18, 487-493.	0.9	14
1181	Natural Extracts Abolished Lipid Accumulation in Cells Harbouring non-favourable PNPLA3 genotype. Annals of Hepatology, 2018, 17, 242-249.	0.6	10

#	Article	IF	Citations
1182	More Evidence for the Genetic Susceptibility of Mexican Population to Nonalcoholic Fatty Liver Disease through PNPLA3. Annals of Hepatology, 2018, 17, 250-255.	0.6	30
1183	Changing Etiology in Liver Cirrhosis in Sapporo, Japan. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 77-80.	0.1	7
1184	Hepatocellular Carcinoma Surveillance: Benefit of Serum Alfa-fetoprotein in Real-world Practice. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 83-87.	0.1	19
1185	Comparison of the Effectiveness of Probiotic, Chlorhexidine-based Mouthwashes, and Oil Pulling Therapy on Plaque Accumulation and Gingival Inflammation in 10- to 12-year-old Schoolchildren: A Randomized Controlled Trial. International Journal of Clinical Pediatric Dentistry, 2018, 11, 66-70.	0.3	13
1186	Nonalcoholic fatty liver disease: is the IFNL4 rs368234815 variant protective from liver damage?. Hepatobiliary Surgery and Nutrition, 2018, 7, 209-211.	0.7	0
1187	New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease. Hepatobiliary Surgery and Nutrition, 2018, 7, 372-381.	0.7	20
1188	Hepatitis B Virus Infection among Health Care Workers in Indonesia. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 88-92.	0.1	14
1189	Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity. World Journal of Gastroenterology, 2018, 24, 1601-1615.	1.4	60
1190	Non-alcoholic Fatty Liver Disease: What We Learn from Omics Studies. , 0, , .		0
1191	Diabetes and Cancer: Is there a Link?. , 2018, , .		1
1192	Nonalcoholic Fatty Liver Disease: Time to Take the Bull by the Horns. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 47-51.	0.1	10
1193	Natural Extracts as Modifiers of Intracellular Lipid Handling. Annals of Hepatology, 2018, 17, 180-181.	0.6	2
1194	PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease. Nutrients, 2018, 10, 1239.	1.7	14
1195	Influence of Storage Media and Duration of Fragment in the Media on the Bond Strength of the Reattached Tooth Fragment. International Journal of Clinical Pediatric Dentistry, 2018, 11, 83-88.	0.3	11
1196	Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis. Diabetes, 2018, 67, 2485-2493.	0.3	82
1197	A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2018, 2, 1467-1478.	2.0	9
1198	European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. Contemporary Clinical Trials, 2018, 75, 67-71.	0.8	16
1199	Non-alcoholic fatty liver disease: a narrative review of genetics. Journal of Biomedical Research, 2018, 32, 389.	0.7	38

#	Article	IF	Citations
1200	Hepatocellular Carcinoma in Malaysia and Its Changing Trend. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 54-56.	0.1	12
1201	Impact of Diabetes Mellitus Type 1 on Lebanese Familiesâ€™ Quality of Life. International Journal of Clinical Pediatric Dentistry, 2018, 11, 61-65.	0.3	4
1202	Determination of ABO Blood Groups and Rh Typing from Dry Salivary Samples. International Journal of Clinical Pediatric Dentistry, 2018, 11, 100-104.	0.3	4
1203	Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance. Cancers, 2018, 10, 481.	1.7	135
1204	Apple Pomace Consumption Favorably Alters Hepatic Lipid Metabolism in Young Female Sprague-Dawley Rats Fed a Western Diet. Nutrients, 2018, 10, 1882.	1.7	14
1205	Genetic and Epigenetic Modifiers of Alcoholic Liver Disease. International Journal of Molecular Sciences, 2018, 19, 3857.	1.8	75
1206	Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 57-62.	0.1	26
1207	Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 315-320.	1.2	11
1208	Advances in Pediatric Fatty Liver Disease. Gastroenterology Clinics of North America, 2018, 47, 949-968.	1.0	11
1209	Dissociation of Fatty Liver and Insulin Resistance in I148M PNPLA3 Carriers: Differences in Diacylglycerol (DAG) FA18:1 Lipid Species as a Possible Explanation. Nutrients, 2018, 10, 1314.	1.7	33
1210	Ectopic Fat Accumulation in Distinct Insulin Resistant Phenotypes; Targets for Personalized Nutritional Interventions. Frontiers in Nutrition, 2018, 5, 77.	1.6	71
1211	Effect of silibinin on CFLAR-JNK pathway in oleic acid-treated HepG2 cells. Biomedicine and Pharmacotherapy, 2018, 108, 716-723.	2.5	24
1212	Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From â€œtwo hit theoryâ€• to â€œmultiple hit modelâ€• World Journal of Gastroenterology, 2018, 24, 2974-2983.	1.4	237
1213	Analysis of Time-Series Gene Expression Data to Explore Mechanisms of Chemical-Induced Hepatic Steatosis Toxicity. Frontiers in Genetics, 2018, 9, 396.	1.1	22
1214	Genetic Variations Linked to Hepatocellular Carcinoma: Personalized Medicine Takes a Step Forward. American Journal of Gastroenterology, 2018, 113, 1435-1436.	0.2	3
1215	Role of Lipid Droplet Proteins in the Development of NAFLD and Hepatic Insulin Resistance. , 2018, , .		5
1216	Estimation of Salivary Glucose, Calcium, Phosphorus, Alkaline Phosphatase, and Immunoglobulin A among Diabetic and Nondiabetic Children: A Caseâ€“Control Study. International Journal of Clinical Pediatric Dentistry, 2018, 11, 71-78.	0.3	7
1219	AÂsystematic review of the present and future of non-alcoholic fatty liver disease. Clinical and Experimental Hepatology, 2018, 4, 165-174.	0.6	41

#	Article	IF	Citations
1220	Non-alcoholic fatty liver disease--a chronic disease of the 21st century. Journal of Biomedical Research, 2018, 32, 327-335.	0.7	15
1221	Alcohol and Cancer. Advances in Experimental Medicine and Biology, 2018, , .	0.8	0
1222	Suppressed Fat Mobilization Due to PNPLA3 rs738409 -Associated Liver Damage in Heavy Drinkers: The Liver Damage Feedback Hypothesis. Advances in Experimental Medicine and Biology, 2018, 1032, 153-172.	0.8	3
1223	Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis. Cellular and Molecular Gastroenterology and Hepatology, 2018, 6, 451-462.	2.3	58
1224	Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD. Journal of Nanobiotechnology, 2018, 16, 64.	4.2	48
1225	Manuka Honey: A Potent Cariostatic Agentâ€“Anin vitroStudy. International Journal of Clinical Pediatric Dentistry, 2018, 11, 105-109.	0.3	10
1226	Wholeâ€Exome Sequencing Study of Extreme Phenotypes of NAFLD. Hepatology Communications, 2018, 2, 1021-1029.	2.0	8
1227	Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches. Frontiers in Endocrinology, 2018, 9, 485.	1.5	49
1228	Role of Inflammasomes in the Development of Gastrointestinal Diseases. Experientia Supplementum (2012), 2018, 108, 235-268.	0.5	1
1229	Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. Journal of Clinical Lipidology, 2018, 12, 1390-1403.e4.	0.6	79
1230	Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease. , 0, , .		4
1231	PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC. PLoS ONE, 2018, 13, e0202942.	1.1	7
1232	Pathways and mechanisms linking dietary components to cardiometabolic disease: thinking beyond calories. Obesity Reviews, 2018, 19, 1205-1235.	3.1	60
1233	The Roles of Xenobiotic Receptors: Beyond Chemical Disposition. Drug Metabolism and Disposition, 2018, 46, 1361-1371.	1.7	86
1234	Dihydrocurcumin ameliorates the lipid accumulation, oxidative stress and insulin resistance in oleic acid-induced L02 and HepG2 cells. Biomedicine and Pharmacotherapy, 2018, 103, 1327-1336.	2.5	39
1235	IRGMGene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2018, 24, 2247-2257.	0.9	19
1236	Genetic and Epigenetic Culprits in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Journal of Clinical and Experimental Hepatology, 2018, 8, 390-402.	0.4	27
1237	Human-based systems: Mechanistic NASH modelling just around the corner?. Pharmacological Research, 2018, 134, 257-267.	3.1	38

#	Article	IF	Citations
1238	Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine, 2018, 24, 908-922.	15.2	2,392
1239	Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia, 2018, 61, 1923-1934.	2.9	256
1240	Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 831-841.	1.5	20
1241	Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. Advances in Experimental Medicine and Biology, 2018, 1061, 3-18.	0.8	22
1242	Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack?. Advances in Experimental Medicine and Biology, 2018, 1061, 63-77.	0.8	6
1243	Microbiota, Obesity and NAFLD. Advances in Experimental Medicine and Biology, 2018, 1061, 111-125.	0.8	63
1244	Obesity, Fatty Liver and Liver Cancer. Advances in Experimental Medicine and Biology, 2018, , .	0.8	17
1245	Impact of patatinâ€like phospholipase domain containing 3 rs738409ÂG/G genotype on hepatic decompensation and mortality in patients with portal hypertension. Alimentary Pharmacology and Therapeutics, 2018, 48, 451-459.	1.9	26
1246	Interaction of volatile organic compounds and underlying liver disease: a new paradigm for risk. Biological Chemistry, 2018, 399, 1237-1248.	1.2	45
1247	Mechanisms of Insulin Action and Insulin Resistance. Physiological Reviews, 2018, 98, 2133-2223.	13.1	1,502
1248	Establishment and characterization of an iPSC line from a 35â€¯years old high grade patient with nonalcoholic fatty liver disease (30â€“40% steatosis) with homozygous wildtype PNPLA3 genotype. Stem Cell Research, 2018, 31, 113-116.	0.3	6
1249	Evaluation of Antimicrobial Activity of Two Endodontic Sealers: Zinc Oxide with Thyme Oil and Zinc Oxide Eugenol against Root Canal Microorganismsâ€”Anin vitroStudy. International Journal of Clinical Pediatric Dentistry, 2018, 11, 79-82.	0.3	9
1250	Establishment and characterization of an iPSC line from a 58â€¯years old high grade patient with nonalcoholic fatty liver disease (70% steatosis) with homozygous wildtype PNPLA3 genotype. Stem Cell Research, 2018, 31, 131-134.	0.3	7
1251	Patatinâ€like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events. Hepatology Communications, 2018, 2, 798-806.	2.0	21
1252	Developmental and Inherited Liver Disease. , 2018, , 111-274.		4
1253	Drug-Induced Fatty Liver Disease. Current Hepatology Reports, 2018, 17, 260-269.	0.4	1
1254	Interactions between Genetics and Sugar-Sweetened Beverage Consumption on Health Outcomes: A Review of Geneâ€“Diet Interaction Studies. Frontiers in Endocrinology, 2017, 8, 368.	1.5	16
1255	Nonalcoholic Fatty Liver Disease in University Rugby Football Players. Frontiers in Endocrinology, 2018, 9, 341.	1.5	6

#	Article	IF	Citations
1256	The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania. Journal of Viral Hepatitis, 2018, 25, 1438-1445.	1.0	23
1257	Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD). International Journal of Molecular Sciences, 2018, 19, 911.	1.8	100
1258	Insights into the Role of PPARÎ²/Î´ in NAFLD. International Journal of Molecular Sciences, 2018, 19, 1893.	1.8	42
1259	Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients, 2018, 10, 29.	1.7	138
1260	Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors. Nutrients, 2018, 10, 649.	1.7	60
1261	Fatty Liver Disease. , 2018, , 308-371.		14
1262	Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. Gastroenterology, 2018, 155, 282-302.e8.	0.6	216
1263	Pharmacological intervention of liver triacylglycerol lipolysis: The good, the bad and the ugly. Biochemical Pharmacology, 2018, 155, 233-241.	2.0	58
1265	A Comparative Evaluation of Efficacy ofStreptococcus mutansCounts in Saliva: Anin vivoStudy. International Journal of Clinical Pediatric Dentistry, 2018, 11, 94-99.	0.3	6
1266	Triggering and resolution of inflammation in NASH. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 349-364.	8.2	560
1267	Arsenic exposure and risk of nonalcoholic fatty liver disease (NAFLD) among U.S. adolescents and adults: an association modified by race/ethnicity, NHANES 2005â€“2014. Environmental Health, 2018, 17, 6.	1.7	69
1268	Effect of high exposure of chlorogenic acid on lipid accumulation and oxidative stress in oleic acid-treated HepG2 cells. Chinese Herbal Medicines, 2018, 10, 199-205.	1.2	9
1269	Body composition and cardiometabolic health: the need for novel concepts. European Journal of Clinical Nutrition, 2018, 72, 638-644.	1.3	34
1270	Hepatic IRS1 and ÃŸ-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients. Journal of Gastroenterology, 2018, 53, 1261-1275.	2.3	25
1271	Lack of evidence supporting a role of TMC4-rs641738 missense variantâ€"MBOAT7- intergenic downstream variantâ€"in the Susceptibility to Nonalcoholic Fatty Liver Disease. Scientific Reports, 2018, 8, 5097.	1.6	48
1272	In a pilot study, reduced fatty acid desaturase 1 function was associated with nonalcoholic fatty liver disease and response to treatment in children. Pediatric Research, 2018, 84, 696-703.	1.1	10
1273	A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. Frontiers in Pharmacology, 2018, 9, 752.	1.6	23
1274	Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models. Hormone Molecular Biology and Clinical Investigation, 2020, 41, .	0.3	15

#	Article	IF	Citations
1276	Single-nucleotide rs738409 polymorphisms in the PNPLA3 gene are strongly associated with alcoholic liver disease in Han Chinese males. Hepatology International, 2018, 12, 429-437.	1.9	19
1277	Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis. PLoS ONE, 2018, 13, e0200568.	1.1	7
1278	Trichobezoar: Ravenous for Hair. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 97-98.	0.1	3
1279	Clinical Evaluation of Preventive Effect of Fissure Sealants on Initial Carious Lesion of Permanent Mandibular Molars Pretreated with and without Fluoride Varnish by Fluorescence Camera. International Journal of Clinical Pediatric Dentistry, 2018, 11, 89-93.	0.3	4
1280	Burden of nonâ€alcoholic fatty liver disease in Australia. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1-11.	1.4	39
1281	Non-alcoholic fatty liver disease. Clinical Medicine, 2018, 18, 245-250.	0.8	171
1283	Role of xenobiotics in the induction and progression of fatty liver disease. Toxicology Research, 2018, 7, 664-680.	0.9	22
1285	NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. American Journal of Gastroenterology, 2018, 113, 1649-1659.	0.2	401
1287	Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes. Cell Systems, 2018, 6, 709-721.e6.	2.9	52
1288	Pediatric Nonalcoholic Fatty Liver Disease in New York City: An Autopsy Study. Journal of Pediatrics, 2018, 200, 174-180.	0.9	32
1289	Risk Factors and Clinical Course for Liver Steatosis or Nonalcoholic Steatohepatitis After Living Donor Liver Transplantation. Transplantation, 2019, 103, 109-112.	0.5	15
1290	The role of PNPLA3 in health and disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 900-906.	1.2	71
1291	Lean non-alcoholic fatty liver disease. Clinical Nutrition, 2019, 38, 975-981.	2.3	77
1292	The role of IFN in the development of NAFLD and NASH. Cytokine, 2019, 124, 154519.	1.4	31
1293	Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2019, 17, 551-559.e1.	2.4	131
1294	Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Cells, 2019, 8, 845.	1.8	92
1295	Correlation of triglyceride to high-density lipoprotein cholesterol ratio with nonalcoholic fatty liver disease among the non-obese Chinese population with normal blood lipid levels: a retrospective cohort research. Lipids in Health and Disease, 2019, 18, 162.	1.2	42
1296	Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma. Frontiers in Oncology, 2019, 9, 762.	1.3	30

#	Article	IF	Citations
1297	NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. Frontiers in Pharmacology, 2019, 10, 877.	1.6	86
1298	PNPLA3 gene polymorphism in Brazilian patients with type 2 diabetes: A prognostic marker beyond liver disease?. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 965-971.	1.1	15
1299	Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease. International Journal of Environmental Research and Public Health, 2019, 16, 2755.	1.2	28
1300	Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism. Cell Metabolism, 2019, 30, 385-401.e9.	7.2	75
1301	Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective. Journal of Clinical and Experimental Hepatology, 2019, 9, 497-505.	0.4	24
1302	Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease. International Journal of Molecular Sciences, 2019, 20, 3987.	1.8	21
1303	Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. Journal of Hepatology, 2019, 71, 802-810.	1.8	39
1304	Highlights from the 87th EAS congress, 26â€“29th May 2019. Atherosclerosis, 2019, 287, 186-188.	0.4	1
1305	Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology, 2019, 70, 1424-1436.	3.6	73
1306	Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. Journal of Hepatology, 2019, 71, 823-833.	1.8	120
1307	Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes. Hepatology Communications, 2019, 3, 894-907.	2.0	41
1308	NAFLD in children: new genes, new diagnostic modalities and new drugs. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 517-530.	8.2	199
1309	NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?. Trends in Endocrinology and Metabolism, 2019, 30, 891-902.	3.1	80
1310	Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. International Journal of Molecular Sciences, 2019, 20, 5037.	1.8	98
1311	The complement system in liver diseases: Evidence-based approach and therapeutic options. Journal of Translational Autoimmunity, 2019, 2, 100017.	2.0	11
1312	Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?. Digestive Diseases and Sciences, 2019, 64, 3394-3401.	1.1	6
1313	Molecular prognosis in liver cirrhosis. , 2019, , 413-427.		0
1314	Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine . Journal of Hepatocellular Carcinoma, 2019, Volume 6, 151-166.	1.8	25

#	Article	IF	Citations
1315	Non-alcoholic fatty liver disease. Medicine, 2019, 47, 728-733.	0.2	5
1316	Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease. PLoS ONE, 2019, 14, e0224184.	1.1	13
1317	Lipid Related Genes Altered in NASH Connect Inflammation in Liver Pathogenesis Progression to HCC: A Canonical Pathway. International Journal of Molecular Sciences, 2019, 20, 5594.	1.8	20
1318	Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts. Current Pharmaceutical Design, 2019, 24, 4574-4586.	0.9	108
1319	Direct Conversion of Methane with Carbon Dioxide Mediated by RhVO₃^{â˜’} Cluster Anions. Angewandte Chemie, 2019, 131, 17447-17452.	1.6	14
1320	The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu. Journal of Molecular Medicine, 2019, 97, 1589-1600.	1.7	7
1321	Nonalcoholic Fatty Liver Disease in Nonobese Subjects of African Origin Has Atypical Metabolic Characteristics. Journal of the Endocrine Society, 2019, 3, 2051-2063.	0.1	3
1322	Cell type- and tissue-specific functions of ecto-5â€²-nucleotidase (CD73). American Journal of Physiology - Cell Physiology, 2019, 317, C1079-C1092.	2.1	71
1323	Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. International Journal of Environmental Research and Public Health, 2019, 16, 3104.	1.2	135
1324	The Liver in Children With Metabolic Syndrome. Frontiers in Endocrinology, 2019, 10, 514.	1.5	22
1326	Four-Week Omega-3 Supplementation in Carriers of the Prosteatotic <i>PNPLA3</i> p.I148M Genetic Variant: An Open-Label Study. Lifestyle Genomics, 2019, 12, 10-17.	0.6	4
1327	The Liver as an Endocrine Organâ€”Linking NAFLD and Insulin Resistance. Endocrine Reviews, 2019, 40, 1367-1393.	8.9	341
1328	Nonalcoholic Fatty Liver Disease (NAFLD), But not Its Susceptibility Gene Variants, Influences the Decrease of Kidney Function in Overweight/Obese Children. International Journal of Molecular Sciences, 2019, 20, 4444.	1.8	32
1329	PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age. PLoS ONE, 2019, 14, e0222609.	1.1	3
1330	Variations in hepatic lipid species of age-matched male mice fed a methionine-choline-deficient diet and housed in different animal facilities. Lipids in Health and Disease, 2019, 18, 172.	1.2	12
1331	The new liver epidemic. Nature Biotechnology, 2019, 37, 209-214.	9.4	10
1332	Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. International Journal of Environmental Research and Public Health, 2019, 16, 3570.	1.2	29
1333	Emerging Roles of Lipophagy in Health and Disease. Frontiers in Cell and Developmental Biology, 2019, 7, 185.	1.8	98

#	Article	IF	Citations
1334	Comparison of variation in frequency for SNPs associated with asthma or liver disease between Estonia, HapMap populations and the 1000 genome project populations. International Journal of Immunogenetics, 2019, 46, 49-58.	0.8	0
1335	A two gene-based risk score predicts alcoholic cirrhosis development in males with at-risk alcohol consumption. The Application of Clinical Genetics, 2019, Volume 12, 1-10.	1.4	13
1336	Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis, 2019, 282, 110-120.	0.4	68
1337	Obesity genetics and cardiometabolic health: Potential for risk prediction. Diabetes, Obesity and Metabolism, 2019, 21, 1088-1100.	2.2	24
1338	The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes. Diabetologia, 2019, 62, 644-654.	2.9	22
1339	Serum aldoâ€“keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis. Journal of Gastroenterology, 2019, 54, 549-557.	2.3	26
1340	The Association of Polymorphisms in Circadian Clock and Lipid Metabolism Genes With 2nd Trimester Lipid Levels and Preterm Birth. Frontiers in Genetics, 2019, 10, 540.	1.1	11
1341	Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis. Handbook of Experimental Pharmacology, 2019, 256, 325-357.	0.9	43
1342	Genomeâ€Wide Association Study Identifies Loci for Liver Enzyme Concentrations in Mexican Americans: The GUARDIAN Consortium. Obesity, 2019, 27, 1331-1337.	1.5	20
1343	A Systematic Review of NAFLD-Associated Extrahepatic Disorders in Youths. Journal of Clinical Medicine, 2019, 8, 868.	1.0	21
1344	Exome Sequencing in Clinical Hepatology. Hepatology, 2019, 70, 2185-2192.	3.6	19
1345	Diabetes in Liver Disease. , 2019, , 65-86.		0
1346	Non-Alcoholic Fatty Liver Disease in Non-Obese Individuals: Prevalence, Pathogenesis and Treatment. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 638-645.	0.7	33
1347	Quantitative digital pathology reveals association of cell-specific PNPLA3 transcription with NAFLD disease activity. JHEP Reports, 2019, 1, 199-202.	2.6	7
1348	Host Genetic Characters of Acute Exacerbation of Chronic Hepatitis B (AECHB). , 2019, , 159-221.		0
1349	Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity. Current Obesity Reports, 2019, 8, 243-254.	3.5	37
1350	Childhood and Adolescent Nonalcoholic Fatty Liver Disease: Is It Different from Adults?. Journal of Clinical and Experimental Hepatology, 2019, 9, 716-722.	0.4	21
1351	Genetic Insights for Drug Development in NAFLD. Trends in Pharmacological Sciences, 2019, 40, 506-516.	4.0	52

#	Article	IF	Citations
1352	Efficacy of a non-invasive model in predicting the cardiovascular morbidity and histological severity in non-alcoholic fatty liver disease. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 2272-2278.	1.8	21
1353	Alcoholic/Non-Alcoholic Digestive Diseases. , 2019, , .		0
1354	Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China. Annals of Hepatology, 2019, 18, 456-460.	0.6	19
1355	Metabolic Targets in Nonalcoholic Fatty Liver Disease. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 247-267.	2.3	91
1356	PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease. Adipocyte, 2019, 8, 201-208.	1.3	28
1357	Pediatric Liver Disease in theÂAfrican Continent. , 2019, , 699-741.		0
1358	Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. AIDS Patient Care and STDs, 2019, 33, 197-206.	1.1	10
1359	Lipase tug of war: PNPLA3 sequesters ABHD5 from ATGL. Nature Metabolism, 2019, 1, 505-506.	5.1	5
1360	Diagnosis and management of non-alcoholic fatty liver disease. Postgraduate Medical Journal, 2019, 95, 314-322.	0.9	70
1362	Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. International Journal of Molecular Sciences, 2019, 20, 1948.	1.8	127
1363	Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. Annals of Hepatology, 2019, 18, 466-471.	0.6	42
1364	Dynamic interactions of ABHD5 with PNPLA3 regulate triacylglycerol metabolism in brown adipocytes. Nature Metabolism, 2019, 1, 560-569.	5.1	79
1365	Lipid Droplet Formation and Lipophagy in Fatty Liver Disease. Seminars in Liver Disease, 2019, 39, 283-290.	1.8	30
1366	Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). Annals of Hepatology, 2019, 18, 518-535.	0.6	69
1367	Lipocalinâ€2 Protects Against Dietâ€Induced Nonalcoholic Fatty Liver Disease by Targeting Hepatocytes. Hepatology Communications, 2019, 3, 763-775.	2.0	22
1368	Epigenetic Markers and Microbiota/Metabolite-Induced Epigenetic Modifications in the Pathogenesis of Obesity, Metabolic Syndrome, Type 2 Diabetes, and Non-alcoholic Fatty Liver Disease. Current Diabetes Reports, 2019, 19, 31.	1.7	39
1369	The Gly385(388)Arg Polymorphism of the FGFR4 Receptor Regulates Hepatic Lipogenesis Under Healthy Diet. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2041-2053.	1.8	8
1370	Past, present and future perspectives in nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 377-386.	8.2	357

#	Article	IF	Citations
1371	Association of Bright Liver with the PNPLA3 I148M Gene Variant in 1-year-old Toddlers. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2163-2170.	1.8	6
1372	Non-alcoholic fatty liver disease in Africa: a hidden danger. Global Health, Epidemiology and Genomics, 2019, 4, e3.	0.2	16
1373	From NASH to HCC: current concepts and future challenges. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 411-428.	8.2	872
1374	Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9521-9526.	3.3	182
1375	Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease. Nutrients, 2019, 11, 677.	1.7	137
1376	Missense Mutant Patatinâ€Like Phospholipase Domain Containing 3 Alters Lipid Droplet Turnover in Partnership With CGIâ€58. Hepatology, 2019, 69, 2323-2325.	3.6	2
1377	A 17â€Betaâ€Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. Hepatology, 2019, 70, 231-240.	3.6	75
1378	Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. Expert Review of Gastroenterology and Hepatology, 2019, 13, 447-461.	1.4	67
1379	The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines (Basel, Switzerland), 2019, 6, 41.	0.7	80
1380	A small supernumerary marker chromosome resulting in mosaic partial tetrasomy 4q26-q31.21 in a foetus with multiple congenital malformations. Journal of Genetics, 2019, 98, 1.	0.4	2
1381	Evidence of bias during liver transplant evaluation of nonâ€alcoholic steatohepatitis cirrhosis patients. Liver International, 2019, 39, 1165-1173.	1.9	10
1382	Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2019, 156, 1264-1281.e4.	0.6	882
1383	Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World Journal of Hepatology, 2019, 11, 138-149.	0.8	122
1384	Meta-analysis of the association between MBOAT7 rs641738, TM6SF2 rs58542926 and nonalcoholic fatty liver disease susceptibility. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 533-541.	0.7	28
1385	Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD. Hepatology, 2019, 70, 142-153.	3.6	44
1386	Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics. Seminars in Liver Disease, 2019, 39, 124-140.	1.8	48
1387	Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis. Seminars in Liver Disease, 2019, 39, 153-162.	1.8	5
1388	The circadian clock and liver function in health and disease. Journal of Hepatology, 2019, 71, 200-211.	1.8	128

#	Article	IF	Citations
1389	Systems Genetics of Hepatic Metabolome Reveals Octopamine as a Target for Non-Alcoholic Fatty Liver Disease Treatment. Scientific Reports, 2019, 9, 3656.	1.6	11
1390	Differences in the genetic backgrounds of patients with alcoholic liver disease and nonâ€alcoholic fatty liver disease. JGH Open, 2019, 3, 17-24.	0.7	15
1391	Collagen Formation Assessed by Nâ€Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography. Hepatology, 2019, 70, 127-141.	3.6	21
1392	Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk?. Digestive Diseases and Sciences, 2019, 64, 903-909.	1.1	20
1393	Genetics of nonalcoholic fatty liver disease in Asian populations. Journal of Genetics, 2019, 98, 1.	0.4	18
1394	American Ancestry Is a Risk Factor for Suspected Nonalcoholic Fatty Liver Disease in Hispanic/Latino Adults. Clinical Gastroenterology and Hepatology, 2019, 17, 2301-2309.	2.4	23
1395	Omics: Potential Role in Early Phase Drug Development. , 2019, , 309-347.		0
1396	Genome-wide meta-analysis identifies multiple novel loci associated with serum uric acid levels in Japanese individuals. Communications Biology, 2019, 2, 115.	2.0	66
1397	Relationship Between Nonalcoholic Fatty Liver Disease Susceptibility Genes and Coronary Artery Disease. Hepatology Communications, 2019, 3, 587-596.	2.0	38
1398	Genetics of Nonalcoholic Fatty Liver Disease: A 2018 Update. Current Pharmaceutical Design, 2019, 24, 4566-4573.	0.9	30
1399	Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity. Medicine (United States), 2019, 98, e14324.	0.4	71
1400	An exploratory phenome wide association study linking asthma and liver disease genetic variants to electronic health records from the Estonian Biobank. PLoS ONE, 2019, 14, e0215026.	1.1	8
1401	From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis. Proceedings of the Nutrition Society, 2019, 78, 290-304.	0.4	36
1402	A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nature Communications, 2019, 10, 1406.	5.8	218
1403	PNPLA2 influences secretion of triglyceride-rich lipoproteins by human hepatoma cells. Journal of Lipid Research, 2019, 60, 1069-1077.	2.0	12
1405	Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 357-367.	1.1	34
1406	Circadian rhythms: a possible new player in non-alcoholic fatty liver disease pathophysiology. Journal of Molecular Medicine, 2019, 97, 741-759.	1.7	18
1407	PNPLA3, CGIâ€58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice. Hepatology, 2019, 69, 2427-2441.	3.6	129

#	Article	IF	Citations
1408	Genetic and metabolic predictors of hepatic fat content in a cohort of Italian children with obesity. Pediatric Research, 2019, 85, 671-677.	1.1	27
1409	The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD). Metabolites, 2019, 9, 25.	1.3	7
1410	Genetics of gallstone disease revisited. Current Opinion in Gastroenterology, 2019, 35, 82-87.	1.0	11
1411	Understanding susceptibility and targeting treatment in non-alcoholic fatty liver disease in children; moving the fulcrum. Proceedings of the Nutrition Society, 2019, 78, 362-371.	0.4	5
1412	Group VIA phospholipase A2 deficiency in mice chronically fed with high-fat-diet attenuates hepatic steatosis by correcting a defect of phospholipid remodeling. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 662-676.	1.2	17
1413	iPla2Î² deficiency in mice fed with MCD diet does not correct the defect of phospholipid remodeling but attenuates hepatocellular injury via an inhibition of lipid uptake genes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 677-687.	1.2	13
1414	A Novel Phosphoinositide-3-kinase Adapter Protein 1 Gene Missense Mutation in Familial Cirrhosis. Journal of Clinical and Experimental Hepatology, 2019, 9, 652-656.	0.4	0
1415	Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Molecular Metabolism, 2019, 22, 49-61.	3.0	140
1416	Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China. Lipids in Health and Disease, 2019, 18, 45.	1.2	10
1417	Identification of an intrinsic lysophosphatidic acid acyltransferase activity in the lipolytic inhibitor G 0 /G 1 switch gene 2 (G0S2). FASEB Journal, 2019, 33, 6655-6666.	0.2	15
1418	Lipoprotein metabolism in liver diseases. Current Opinion in Lipidology, 2019, 30, 30-36.	1.2	13
1421	The Role of Carbohydrate Response Elementâ€“Binding Protein in the Development of Liver Diseases. , 2019, , 263-274.		2
1422	Nutritional and Dietary Interventions for Nonalcoholic Fatty Liver Disease. , 2019, , 357-372.		3
1423	Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective. Journal of Clinical and Experimental Hepatology, 2019, 9, 491-496.	0.4	13
1424	Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. Diabetes and Metabolism, 2019, 45, 480-487.	1.4	36
1425	How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?. Annals of Internal Medicine, 2019, 171, 199.	2.0	4
1426	Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis. Journal of Clinical Gastroenterology, 2019, 53, 750-758.	1.1	13
1427	The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. International Journal of Molecular Sciences, 2019, 20, 5613.	1.8	39

#	Article	IF	Citations
1428	4. Genetik und Epigenetik alkoholischer Lebererkrankungen. , 2019, , 67-80.		2
1429	Using metabolomics to develop precision medicine strategies to treat nonalcoholic steatohepatitis. Expert Review of Precision Medicine and Drug Development, 2019, 4, 283-297.	0.4	1
1430	Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. Science Translational Medicine, 2019, 11, .	5.8	47
1431	Network Modeling Approaches and Applications to Unravelling Non-Alcoholic Fatty Liver Disease. Genes, 2019, 10, 966.	1.0	26
1432	Fat and Sugarâ€"A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease. Nutrients, 2019, 11, 2871.	1.7	14
1433	Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer?. Nutrients, 2019, 11, 2878.	1.7	47
1434	The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. , 0, , .		9
1435	Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. American Journal of Gastroenterology, 2019, 114, 579-590.	0.2	27
1436	PNPLA3 and IL 28B signature for predicting susceptibility to chronic hepatitis C infection and fibrosis progression. Archives of Physiology and Biochemistry, 2022, 128, 483-489.	1.0	12
1437	PNPLA3â€"A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease. Frontiers in Medicine, 2019, 6, 304.	1.2	49
1438	Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Molecular Aspects of Medicine, 2019, 65, 37-55.	2.7	628
1439	Parental nonâ€alcoholic fatty liver disease increases risk of nonâ€alcoholic fatty liver disease in offspring. Liver International, 2019, 39, 740-747.	1.9	26
1440	PNPLA3 variant M148 causes resistance to starvationâ€mediated lipid droplet autophagy in human hepatocytes. Journal of Cellular Biochemistry, 2019, 120, 343-356.	1.2	44
1441	High prevalence of non-alcoholic fatty liver disease and metabolic risk factors in Guatemala: A population-based study. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 191-200.	1.1	17
1442	Arid1a Loss Drives Nonalcoholic Steatohepatitis in Mice Through Epigenetic Dysregulation of Hepatic Lipogenesis and Fatty Acid Oxidation. Hepatology, 2019, 69, 1931-1945.	3.6	19
1443	Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. Gastroenterology, 2019, 156, 400-417.	0.6	35
1444	Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. Obesity Reviews, 2019, 20, 599-611.	3.1	59
1445	17â€Beta Hydroxysteroid Dehydrogenase 13ÂIs a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 69, 1504-1519.	3.6	200

#	Article	IF	Citations
1446	Metabolic factors affecting hepatocellular carcinoma in steatohepatitis. Liver International, 2019, 39, 531-539.	1.9	12
1447	Adult Non-alcoholic Fatty Liver Disease (NAFLD). , 2019, , 23-46.		0
1449	Genetic Aspects of Non-alcoholic Fatty Liver Disease (NAFLD). , 2019, , 195-206.		1
1450	Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?. Cell Metabolism, 2019, 29, 18-26.	7.2	169
1451	Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2019, 20, 298.	1.8	98
1452	NASH in Lean Individuals. Seminars in Liver Disease, 2019, 39, 086-095.	1.8	161
1453	Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2019, 13, 179-187.	1.4	51
1454	Hepatocellular carcinoma in the setting of alcohol-related liver disease. Journal of Hepatology, 2019, 70, 284-293.	1.8	221
1455	Clinical Epidemiology of Chronic Liver Diseases. , 2019, , .		2
1456	A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3â€²UTR. Journal of Hepatology, 2019, 70, 494-500.	1.8	67
1457	Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women. Journal of Hepatology, 2019, 70, 126-132.	1.8	44
1458	Polychlorinated biphenyl exposures differentially regulate hepatic metabolism and pancreatic function: Implications for nonalcoholic steatohepatitis and diabetes. Toxicology and Applied Pharmacology, 2019, 363, 22-33.	1.3	47
1459	Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease. Journal of Lipid Research, 2019, 60, 176-185.	2.0	105
1460	Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma. Journal of Gastroenterology, 2019, 54, 427-436.	2.3	30
1461	Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 117-125.	3.3	50
1462	Dynamics and functions of lipid droplets. Nature Reviews Molecular Cell Biology, 2019, 20, 137-155.	16.1	1,430
1463	Molecular and Pathological Events Involved in the Pathogenesis of Diabetes-Associated Nonalcoholic Fatty Liver Disease. Journal of Clinical and Experimental Hepatology, 2019, 9, 607-618.	0.4	45
1464	Clinical workup of fatty liver for the primary care provider. Postgraduate Medicine, 2019, 131, 19-30.	0.9	4

#	Article	IF	Citations
1465	PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. International Journal of Cancer, 2019, 144, 533-544.	2.3	72
1466	Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease. Liver International, 2019, 39, 250-256.	1.9	38
1467	Fish intake interacts with TM6SF2 gene variant to affect NAFLD risk: results of a caseâ€“control study. European Journal of Nutrition, 2019, 58, 1463-1473.	1.8	22
1468	NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis. Hepatology, 2020, 71, 1198-1212.	3.6	187
1469	Mechanisms, biomarkers and targets for therapy in alcohol-associated liver injury: From Genetics to nutrition: Summary of the ISBRA 2018 symposium. Alcohol, 2020, 83, 105-114.	0.8	17
1470	High Risk of Fatty Liver Disease Amplifies the Alanine Transaminaseâ€“Lowering Effect of a HSD17B13 Variant. Hepatology, 2020, 71, 56-66.	3.6	60
1471	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 935-944.e3.	2.4	102
1472	Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis. Journal of Gastroenterology, 2020, 55, 330-341.	2.3	20
1473	Association of Fetuin-B with Subclinical Atherosclerosis in Obese Chinese Adults. Journal of Atherosclerosis and Thrombosis, 2020, 27, 418-428.	0.9	6
1474	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocrine Reviews, 2020, 41, 66-117.	8.9	134
1475	Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 40-52.	8.2	203
1476	Natural History of Simple Steatosis or Nonalcoholic Fatty Liver. Journal of Clinical and Experimental Hepatology, 2020, 10, 255-262.	0.4	43
1477	Î²-Klotho gene variation is associated with liver damage in children with NAFLD. Journal of Hepatology, 2020, 72, 411-419.	1.8	48
1478	The Underpinnings of PNPLA3â€Mediated Fatty Liver Emerge. Hepatology, 2020, 71, 375-377.	3.6	8
1479	Liver Disease, Nonalcoholic Fatty. , 2020, , 408-413.		1
1480	Hepatobiliary Diseases. , 2020, , 27-33.		0
1481	Pathology of liver disease: advances in the last 50 years. Human Pathology, 2020, 95, 78-98.	1.1	18
1482	Patatinâ€Like Phospholipase Domainâ€Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population. Hepatology, 2020, 71, 820-834.	3.6	58

#	Article	IF	Citations
1483	Risk of chemotherapy-associated liver injury (CALI) in PNPLA3 p.148M allele carriers: Preliminary results of a transient elastography-based study. Digestive and Liver Disease, 2020, 52, 102-106.	0.4	1
1484	Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia, 2020, 63, 253-260.	2.9	95
1485	PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. Liver International, 2020, 40, 107-119.	1.9	67
1486	Association of rs780094 polymorphism of glucokinase regulatory protein with non-alcoholic fatty liver disease. BMC Research Notes, 2020, 13, 26.	0.6	10
1487	Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease. Cell Metabolism, 2020, 31, 35-45.	7.2	130
1488	Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis. Expert Opinion on Investigational Drugs, 2020, 29, 125-133.	1.9	40
1489	Race affects the association of obesity measures with insulin sensitivity. American Journal of Clinical Nutrition, 2020, 111, 515-525.	2.2	19
1490	Liver fat accumulation assessed by computed tomography is an independent risk factor for diabetes mellitus in a population-based study: SESSA (Shiga Epidemiological Study of Subclinical) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 4	1	
1491	A Comprehensive Analysis of Liver Transplantation Outcomes Among Ethnic Minorities in the United States. Journal of Clinical Gastroenterology, 2020, 54, 263-270.	1.1	21
1492	Circulating MicroRNAâ€122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD. Hepatology Communications, 2020, 4, 66-76.	2.0	9
1493	A Microphysiological System for Studying Nonalcoholic Steatohepatitis. Hepatology Communications, 2020, 4, 77-91.	2.0	41
1494	Epidemiological differences of common liver conditions between Asia and the West. JGH Open, 2020, 4, 332-339.	0.7	18
1495	Risk factors for histological progression of nonâ€alcoholic steatohepatitis analyzed from repeated biopsy cases. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1412-1419.	1.4	10
1496	Genetic variations associated with spleen-yang deficiency pattern of non-alcoholic fatty liver disease: A candidate gene study. European Journal of Integrative Medicine, 2020, 33, 101044.	0.8	0
1497	Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals. Frontline Gastroenterology, 2020, 11, 478-483.	0.9	11
1498	Screening and Early Detection. , 2020, , 375-398.e7.		1
1499	PNPLA3 I148M mediates the regulatory effect of NFâ€kB on inflammation in PAâ€treated HepG2 cells. Journal of Cellular and Molecular Medicine, 2020, 24, 1541-1552.	1.6	27
1500	Imaging of triglycerides in tissues using nanospray desorption electrospray ionization (Nano-DESI) mass spectrometry. International Journal of Mass Spectrometry, 2020, 448, 116269.	0.7	26

#	Article	IF	Citations
1501	Donor PNPLA3 and TM6SF2 Variant Alleles Confer Additive Risks for Graft Steatosis After Liver Transplantation. Transplantation, 2020, 104, 526-534.	0.5	16
1502	Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. Cells, 2020, 9, 37.	1.8	85
1503	Alcohol and Liver Clock Disruption Increase Small Droplet Macrosteatosis, Alter Lipid Metabolism and Clock Gene mRNA Rhythms, and Remodel the Triglyceride Lipidome in Mouse Liver. Frontiers in Physiology, 2020, 11, 1048.	1.3	8
1504	Playing Jekyll and Hydeâ€"The Dual Role of Lipids in Fatty Liver Disease. Cells, 2020, 9, 2244.	1.8	4
1505	The association of genetic polymorphisms with nonalcoholic fatty liver disease in a longitudinal study. BMC Gastroenterology, 2020, 20, 344.	0.8	2
1506	Characterization of essential domains in HSD17B13 for cellular localization and enzymatic activity. Journal of Lipid Research, 2020, 61, 1400-1409.	2.0	17
1507	The pharmacological treatment of nonalcoholic fatty liver disease in children. Expert Review of Clinical Pharmacology, 2020, 13, 1219-1227.	1.3	3
1508	Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. Diabetes Research and Clinical Practice, 2020, 170, 108487.	1.1	48
1509	Discovery and Targeting of the Signaling Controls of PNPLA3 to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD/NASH Settings. Cells, 2020, 9, 2247.	1.8	26
1511	Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population. Clinical Gastroenterology and Hepatology, 2021, 19, 2606-2614.e4.	2.4	7
1512	Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Molecular Metabolism, 2020, 42, 101092.	3.0	197
1513	Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells, 2020, 9, 1638.	1.8	76
1514	Current Trends of Essential Trace Elements in Patients with Chronic Liver Diseases. Nutrients, 2020, 12, 2084.	1.7	39
1515	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158765.	1.2	10
1516	Pathogenesis of Insulin Resistance. , 0, , .		1
1517	Influence of LGALS3 and PNPLA3 genes in non-alcoholic steatohepatitis (NASH) in patients undergone bariatric surgery. Obesity Research and Clinical Practice, 2020, 14, 326-332.	0.8	3
1518	Plasma Lipidome, PNPLA3 polymorphism and hepatic steatosis in hereditary hemochromatosis. BMC Gastroenterology, 2020, 20, 230.	0.8	7
1519	A Low Ï‰-6 to Ï‰-3 PUFA Ratio (nâ€“6:nâ€“3 PUFA) Diet to Treat Fatty Liver Disease in Obese Youth. Journal of Nutrition, 2020, 150, 2314-2321.	1.3	52

#	Article	IF	Citations
1521	Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Molecular Metabolism, 2021, 50, 101122.	3.0	135
1522	EZH2 as a Potential Target for NAFLD Therapy. International Journal of Molecular Sciences, 2020, 21, 8617.	1.8	17
1523	Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease. International Journal of Molecular Sciences, 2020, 21, 8761.	1.8	27
1524	Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. Journal of Clinical Medicine, 2020, 9, 3843.	1.0	10
1525	Zucker Lean Rats With Hepatic Steatosis Recapitulate Asymptomatic Metabolic Syndrome and Exhibit Greater Sensitivity to Drug-Induced Liver Injury Compared With Standard Nonclinical Sprague-Dawley Rat Model. Toxicologic Pathology, 2020, 48, 994-1007.	0.9	2
1526	iPSC-derived hepatocytes generated from NASH donors provide a valuable platform for disease modeling and drug discovery. Biology Open, 2020, 9, .	0.6	18
1527	Modeling Non-Alcoholic Fatty Liver Disease (NAFLD) Using â€œGood-Fitâ€•Genome-Editing Tools. Cells, 2020, 9, 2572.	1.8	4
1528	The PNPLA3 rs738409 variant can increase the risk of liver toxicity in multiple sclerosis patients treated with beta-interferon. Clinical Neurology and Neurosurgery, 2020, 197, 106166.	0.6	1
1529	Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD. Molecular Metabolism, 2021, 50, 101115.	3.0	106
1530	Hepatic Fatâ€”Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs. Hepatology, 2020, 72, 1912-1923.	3.6	48
1531	Disruption of the ERLINâ€“TM6SF2â€“APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease. PLoS Genetics, 2020, 16, e1008955.	1.5	32
1533	Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination. Alimentary Pharmacology and Therapeutics, 2020, 52, 866-876.	1.9	20
1534	The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2020, 111, 154320.	1.5	68
1535	Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2103-2110.	1.1	7
1536	Insights into genetic variants associated with NASH-fibrosis from metabolite profiling. Human Molecular Genetics, 2020, 29, 3451-3463.	1.4	27
1537	Updating Phospholipase A2 Biology. Biomolecules, 2020, 10, 1457.	1.8	117
1538	PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication. Journal of Gastroenterology, 2020, 55, 1162-1170.	2.3	9
1539	Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination. Scientific Reports, 2020, 10, 18345.	1.6	19

#	Article	IF	Citations
1540	High prevalence of elevated serum liver enzymes in Chinese children suggests metabolic syndrome as a common risk factor. Journal of Paediatrics and Child Health, 2020, 56, 1590-1596.	0.4	1
1541	Fatty Liver Disease in Human Immunodeficiency Virusâ€“Hepatitis B Virus Coinfection: A Cause for Concern. Clinical Infectious Diseases, 2021, 73, e3286-e3287.	2.9	2
1542	Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes. Pharmaceuticals, 2020, 13, 222.	1.7	23
1543	Rescue of Hepatic Phospholipid Remodeling Defect in iPLA2Î²-Null Mice Attenuates Obese but Not Non-Obese Fatty Liver. Biomolecules, 2020, 10, 1332.	1.8	8
1544	Exploring the genetic basis of fatty liver development in geese. Scientific Reports, 2020, 10, 14279.	1.6	4
1545	Difference in lifestyle and metabolic profile of non-alcoholic fatty liver disease with raised alanine amino-transferases between obese and non-overweight subjects. Scientific Reports, 2020, 10, 15232.	1.6	5
1546	Genetic variant rs72613567 of HSD17B13 gene reduces alcoholâ€related liver disease risk in Chinese Han population. Liver International, 2020, 40, 2194-2202.	1.9	13
1547	Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program. PLoS ONE, 2020, 15, e0237430.	1.1	15
1548	FTO Polymorphisms are Associated with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Susceptibility in the Older Chinese Han Population . Clinical Interventions in Aging, 2020, Volume 15, 1333-1341.	1.3	12
1549	Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers. Disease Markers, 2020, 2020, 1-16.	0.6	26
1550	High-Risk Groups for Non-alcoholic Fatty Liver and Non-alcoholic Steatohepatitis Development and Progression. Current Hepatology Reports, 2020, 19, 412-419.	0.4	4
1551	ALT Trends through Childhood and Adolescence Associated with Hepatic Steatosis at 24 Years: A Population-Based UK Cohort Study. Children, 2020, 7, 117.	0.6	4
1552	Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinology, Diabetes and Metabolism, 2020, 3, e00179.	1.0	10
1553	Validating candidate biomarkers for different stages of non-alcoholic fatty liver disease. Medicine (United States), 2020, 99, e21463.	0.4	3
1554	Racial Disparities in Diagnosis and Prognosis of Nonalcoholic Fatty Liver Disease. Clinical Liver Disease, 2020, 16, 66-72.	1.0	26
1555	MARC1 and HNRNPUL1: Two Novel Players in Alcohol-related Liver Disease. Gastroenterology, 2020, 159, 1231-1232.	0.6	1
1556	An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase. American Journal of Physiology - Renal Physiology, 2020, 319, G469-G480.	1.6	26
1557	Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children: a meta-analysis. BMC Medical Genetics, 2020, 21, 163.	2.1	13

#	Article	IF	Citations
1558	Metabolic Footprint, towards Understanding Type 2 Diabetes beyond Glycemia. Journal of Clinical Medicine, 2020, 9, 2588.	1.0	11
1559	Identifying High-Risk NASH Patients: What We Know so Far . Hepatic Medicine: Evidence and Research, 2020, Volume 12, 125-138.	0.9	18
1560	History of Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2020, 21, 5888.	1.8	74
1561	Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. Frontiers in Pharmacology, 2020, 11, 603926.	1.6	115
1562	Metabolic drivers of non-alcoholic fatty liver disease. Molecular Metabolism, 2021, 50, 101143.	3.0	99
1563	FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Frontiers in Endocrinology, 2020, 11, 601290.	1.5	111
1564	New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease. Frontiers in Pediatrics, 2020, 8, 603654.	0.9	23
1565	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). Biomedicines, 2020, 8, 625.	1.4	21
1566	National and Global Ethnicity Differences in Non-alcoholic Fatty Liver Disease. Current Hepatology Reports, 2020, 19, 429-436.	0.4	1
1567	Genetic Variants Associated with Non-Alcoholic Fatty Liver Disease Do Not Associate with Measures of Sub-Clinical Atherosclerosis: Results from the IMPROVE Study. Genes, 2020, 11, 1243.	1.0	5
1568	Ethnicity Strongly Influences Body Fat Distribution Determining Serum Adipokine Profile and Metabolic Derangement in Childhood Obesity. Frontiers in Pediatrics, 2020, 8, 551103.	0.9	12
1569	Genetic and epigenetic factors determining NAFLD risk. Molecular Metabolism, 2021, 50, 101111.	3.0	74
1570	Friend or Foe: Lipid Droplets as Organelles for Protein and Lipid Storage in Cellular Stress Response, Aging and Disease. Molecules, 2020, 25, 5053.	1.7	39
1571	Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease. Clinical and Translational Gastroenterology, 2020, 11, e00165.	1.3	4
1572	Differential Associations of Circulating MicroRNAs With Pathogenic Factors in NAFLD. Hepatology Communications, 2020, 4, 670-680.	2.0	19
1573	The PNPLA3â€I148M variant increases polyunsaturated triglycerides in human adipose tissue. Liver International, 2020, 40, 2128-2138.	1.9	17
1574	Review article: the emerging role of genetics in precision medicine for patients with nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 1305-1320.	1.9	103
1575	Immunity-related GTPase induces lipophagy to prevent excess hepatic lipid accumulation. Journal of Hepatology, 2020, 73, 771-782.	1.8	34

#	Article	IF	Citations
1576	Combined alcoholic and non-alcoholic steatohepatitis. JHEP Reports, 2020, 2, 100101.	2.6	42
1577	The Morbidity and Comorbidity of Nonalcoholic Fatty Liver Disease and Different Glucose Intolerance Strata in a Community-Based Chinese Population. Metabolic Syndrome and Related Disorders, 2020, 18, 284-290.	0.5	2
1578	Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma. Nutrients, 2020, 12, 1576.	1.7	38
1579	Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis. BMC Gastroenterology, 2020, 20, 186.	0.8	20
1580	Impact of PNPLA3 (rs738409â€C) polymorphism on postâ€transplant outcomes after liver transplantation for alcoholâ€related liver disease. Clinical Transplantation, 2020, 34, e14011.	0.8	0
1581	Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. Cancers, 2020, 12, 1422.	1.7	41
1582	The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2020, 21, 3863.	1.8	118
1583	How do genetic variants affect our interpretation of nonâ€invasive tests for nonâ€alcoholic fatty liver disease?. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 915-916.	1.4	0
1584	Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. Gastroenterology, 2020, 159, 1276-1289.e7.	0.6	53
1585	Prevalence of NAFLD in Guatemala following exposure to a protein-energy nutrition intervention in early life. Annals of Hepatology, 2020, 19, 373-379.	0.6	1
1586	APOC3 rs2854116 , PNPLA3 rs738409, and TM6SF2 rs58542926 polymorphisms might influence predisposition of NAFLD : A metaâ€analysis. IUBMB Life, 2020, 72, 1757-1764.	1.5	7
1587	Liver fibrogenesis: un update on established and emerging basic concepts. Archives of Biochemistry and Biophysics, 2020, 689, 108445.	1.4	15
1588	The Role of Bone Morphogenetic Protein Signaling in Non-Alcoholic Fatty Liver Disease. Scientific Reports, 2020, 10, 9831.	1.6	10
1589	Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3575-e3585.	1.8	51
1590	Role of Patatin-Like Phospholipase Domainâ€“Containing 3 Gene for Hepatic Lipid Content and Insulin Resistance in Diabetes. Diabetes Care, 2020, 43, 2161-2168.	4.3	45
1591	Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology. Hepatology, 2020, 72, 330-346.	3.6	75
1592	Western diet induces severe nonalcoholic steatohepatitis, ductular reaction, and hepatic fibrosis in liver CGI-58 knockout mice. Scientific Reports, 2020, 10, 4701.	1.6	17
1593	Beneficial effects of Chinese herbs in the treatment of fatty liver diseases. Journal of Traditional and Complementary Medicine, 2020, 10, 260-267.	1.5	7

#	Article	IF	Citations
1594	Childhood obesity and the associated rise in cardiometabolic complications. Nature Metabolism, 2020, 2, 223-232.	5.1	92
1595	Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population. Hepatology, 2020, 72, 845-856.	3.6	132
1596	Nonalcoholic Fatty Liver Disease. Handbook of Experimental Pharmacology, 2020, , 1.	0.9	6
1597	Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011â€“2016. Journal of Internal Medicine, 2020, 287, 711-722.	2.7	50
1598	Identification of key pathways and genes in nonalcoholic fatty liver disease using bioinformatics analysis. Archives of Medical Science, 2020, 16, 374-385.	0.4	19
1599	Epidemiology of non-alcoholic fatty liver disease in Asia. Indian Journal of Gastroenterology, 2020, 39, 1-8.	0.7	39
1600	Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. Journal of Hepatology, 2020, 73, 263-276.	1.8	137
1601	A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. Journal of Hepatology, 2020, 72, 1070-1081.	1.8	35
1602	Genetic Risk for Hepatic Fat among an Ethnically Diverse Cohort of Youth: The Exploring Perinatal Outcomes among Children Study. Journal of Pediatrics, 2020, 220, 146-153.e2.	0.9	10
1603	Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges. Gastroenterology, 2020, 158, 1967-1983.e1.	0.6	75
1604	Clinical and Genetic Markers of Nonalcoholic Fatty Liver Disease and Prediction of Liver Disease Mortality: Ready for Population Screening?. Gastroenterology, 2020, 158, 1838-1840.	0.6	2
1605	PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1789-1794.	1.4	10
1606	Update on NAFLD genetics: From new variants to the clinic. Journal of Hepatology, 2020, 72, 1196-1209.	1.8	234
1607	PNPLA3I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings. Liver International, 2020, 40, 1130-1141.	1.9	33
1608	Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis. Cells, 2020, 9, 590.	1.8	38
1609	The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development, 2020, 5, 253-263.	0.4	0
1610	The hepatic lipidome: From basic science to clinical translation. Advanced Drug Delivery Reviews, 2020, 159, 180-197.	6.6	37
1611	Approach to prevention of non-alcoholic fatty liver disease after liver transplantation. Translational Gastroenterology and Hepatology, 2020, 5, 51-51.	1.5	7

#	Article	IF	Citations
1612	Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease. Cancers, 2020, 12, 1714.	1.7	28
1613	Genomeâ€Wide Association Study of Liver Fat: The Multiethnic Cohort Adiposity Phenotype Study. Hepatology Communications, 2020, 4, 1112-1123.	2.0	21
1614	PNPLA3 and nonalcoholic fatty liver disease: towards personalized medicine for fatty liver. Hepatobiliary Surgery and Nutrition, 2020, 9, 353-356.	0.7	11
1615	Association between PNPLA3 rs738409 G variant and MRI cerebrovascular disease biomarkers. Journal of the Neurological Sciences, 2020, 416, 116981.	0.3	4
1616	Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. SAGE Open Medicine, 2020, 8, 205031212093380.	0.7	12
1617	The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 990-1002.	1.8	101
1618	Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology, 2020, 158, 1913-1928.	0.6	346
1619	Effect of the patatinâ€like phospholipase domain containing 3 gene (PNPLA3) I148M polymorphism on the risk and severity of nonalcoholic fatty liver disease and metabolic syndromes: A metaâ€analysis of paediatric and adolescent individuals. Pediatric Obesity, 2020, 15, e12615.	1.4	11
1620	The metabolic basis of nonalcoholic steatohepatitis. Endocrinology, Diabetes and Metabolism, 2020, 3, e00112.	1.0	64
1621	Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease. Lipids in Health and Disease, 2020, 19, 29.	1.2	18
1622	Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 1525.	1.8	66
1623	Phenotypic Response and Personalized Medicine in Liver Cancer and Transplantation: Approaches to Complex Systems. Advanced Therapeutics, 2020, 3, 1900167.	1.6	2
1624	The Patatinâ€Like Phospholipase Domain Containing Protein 7 Facilitates VLDL Secretion by Modulating ApoE Stability. Hepatology, 2020, 72, 1569-1585.	3.6	19
1625	Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. PLoS ONE, 2020, 15, e0219412.	1.1	17
1626	NAFLD and NASH. , 2020, , .		1
1627	Human genetics of HCV infection phenotypes in the era of direct-acting antivirals. Human Genetics, 2020, 139, 855-863.	1.8	7
1629	Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2020, 111, 154183.	1.5	39
1630	Development and Validation of a Scoring System, Based on Genetic and Clinical Factors, to Determine Risk of Steatohepatitis in Asian Patients with Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 2592-2599.e10.	2.4	32

#	Article	IF	Citations
1631	Short-term high-fat diet intake leads to exacerbation of concanavalin A-induced liver injury through the induction of procoagulation state. Biochemistry and Biophysics Reports, 2020, 22, 100736.	0.7	5
1632	Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. EBioMedicine, 2020, 52, 102658.	2.7	71
1633	Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis. Gastroenterology Clinics of North America, 2020, 49, 25-44.	1.0	21
1634	Burden of Disease due to Nonalcoholic Fatty Liver Disease. Gastroenterology Clinics of North America, 2020, 49, 1-23.	1.0	53
1636	PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD. Diabetes and Metabolism, 2020, 46, 496-503.	1.4	5
1637	Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH. Liver International, 2020, 40, 1098-1110.	1.9	21
1638	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	0.6	1,840
1639	NAFLD Preclinical Models: More than a Handful, Less of a Concern?. Biomedicines, 2020, 8, 28.	1.4	33
1640	Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond. Gastroenterology, 2020, 158, 1865-1880.e1.	0.6	76
1641	Generation of new hepatocyte-like in vitro models better resembling human lipid metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158659.	1.2	2
1642	Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?. Frontiers in Pharmacology, 2019, 10, 1413.	1.6	17
1643	Association of metabolic syndrome and patatinâ€like phospholipase 3 â€“ rs738409 gene variant in nonâ€alcoholic fatty liver disease among a Chennaiâ€based south Indian population. Journal of Gene Medicine, 2020, 22, e3160.	1.4	7
1644	Advances in molecular classification and precision oncology in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 215-229.	1.8	311
1645	PNPLA3 Genotype and Risk of Liver and Allâ€Cause Mortality. Hepatology, 2020, 71, 777-779.	3.6	23
1646	Metabolomics in genetic testing. Advances in Clinical Chemistry, 2020, 94, 85-153.	1.8	15
1647	Pathogenesis of Nonalcoholic Steatohepatitis: An Overview. Hepatology Communications, 2020, 4, 478-492.	2.0	243
1648	Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis. Trends in Pharmacological Sciences, 2020, 41, 199-208.	4.0	68
1649	The endothelial function biomarker soluble Eâ€selectin is associated with nonalcoholic fatty liver disease. Liver International, 2020, 40, 1079-1088.	1.9	17

#	Article	IF	Citations
1650	Mechanisms of liver fibrosis and its role in liver cancer. Experimental Biology and Medicine, 2020, 245, 96-108.	1.1	183
1651	Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis. Scientific Reports, 2020, 10, 1148.	1.6	39
1654	Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with nonâ€alcoholic fatty liver disease. Liver International, 2020, 40, 1686-1692.	1.9	21
1655	Nutrition and Genetics in NAFLD: The Perfect Binomium. International Journal of Molecular Sciences, 2020, 21, 2986.	1.8	60
1656	Lipid Droplet Contacts With Autophagosomes, Lysosomes, and Other Degradative Vesicles. Contact (Thousand Oaks (Ventura County, Calif)), 2020, 3, 251525642091089.	0.4	16
1657	Correlation between insulin resistance and liver histology in patients with nonalcoholic steatohepatitis with and without obesity. Indian Journal of Gastroenterology, 2020, 39, 42-49.	0.7	5
1658	PNPLA3 rs738409 is not associated with the risk of hepatocellular carcinoma and persistent infection of hepatitis B virus (HBV) in HBV-related subjects: A case-control study and meta-analysis on Asians. Gene, 2020, 742, 144585.	1.0	2
1659	HSD17B13 as a promising therapeutic target against chronic liver disease. Liver International, 2020, 40, 756-757.	1.9	9
1660	Noninvasive Diagnosis of NAFLD and NASH. Cells, 2020, 9, 1005.	1.8	145
1661	The PNPLA3 rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 1160-1168.	1.9	17
1662	Omicsâ€derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. Hepatology Research, 2020, 50, 817-830.	1.8	13
1663	Genetic Variation atPPP1R3BIncreases Hepatic CT Attenuation and Interacts With Prandial Status on Plasma Glucose. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1963-1972.	1.8	6
1664	A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. PLoS Genetics, 2020, 16, e1008629.	1.5	101
1665	The Lipolysomeâ€"A Highly Complex and Dynamic Protein Network Orchestrating Cytoplasmic Triacylglycerol Degradation. Metabolites, 2020, 10, 147.	1.3	15
1666	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohortâ˜†. Journal of Hepatology, 2020, 73, 505-515.	1.8	279
1667	Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut, 2020, 69, 1855-1866.	6.1	75
1668	Nonalcoholic fatty liver disease experiences accumulation of hepatic liquid crystal associated with increasing lipophagy. Cell and Bioscience, 2020, 10, 55.	2.1	7
1669	CAP: a Novel Era to Better Quantitate Fatty Liver?. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 11-13.	0.5	4

#	Article	IF	Citations
1670	Epidemiology of Hepatocellular Carcinoma. Hepatology, 2021, 73, 4-13.	3.6	1,007
1671	Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. Digestive Diseases and Sciences, 2021, 66, 912-916.	1.1	19
1672	Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity. Hepatology, 2021, 73, 14-26.	3.6	66
1673	Non-alcoholic fatty liver disease and childhood obesity. Archives of Disease in Childhood, 2021, 106, 3-8.	1.0	57
1674	Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases. Clinical Gastroenterology and Hepatology, 2021, 19, 996-1008.e6.	2.4	33
1675	Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 751-757.	1.4	4
1676	17â€Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury. Hepatology, 2021, 73, 1701-1716.	3.6	38
1677	Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. Gastroenterology, 2021, 160, 219-231.e1.	0.6	167
1678	Diabetes and cardiometabolic risk in South Asian youth: A review. Pediatric Diabetes, 2021, 22, 52-66.	1.2	21
1679	Outcomes of Japanese patients with non-alcoholic fatty liver disease according to genetic background and lifestyle-related diseases. Annals of Hepatology, 2021, 21, 100260.	0.6	4
1680	Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis. Journal of Hepatology, 2021, 74, 511-521.	1.8	23
1681	Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opinion on Drug Discovery, 2021, 16, 125-134.	2.5	3
1682	The Genetic Architecture of Carbon Tetrachloride-Induced Liver Fibrosis in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 199-220.	2.3	19
1683	The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e300-e315.	1.8	17
1684	Immunological mechanisms and therapeutic targets of fatty liver diseases. Cellular and Molecular Immunology, 2021, 18, 73-91.	4.8	98
1685	A review of nonâ€alcoholic fatty liver disease in nonâ€obese and lean individuals. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1497-1507.	1.4	43
1686	Serum aromatic and branchedâ€chain amino acids associated with NASH demonstrate divergent associations with serum lipids. Liver International, 2021, 41, 754-763.	1.9	23
1687	The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. The Lancet Gastroenterology and Hepatology, 2021, 6, 65-72.	3.7	108

#	Article	IF	Citations
1688	Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism: Clinical and Experimental, 2021, 116, 154457.	1.5	62
1689	Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Geneâ€“Environment Interaction Study. Gastroenterology, 2021, 160, 1620-1633.e13.	0.6	68
1690	The relationship between excessive dietary fructose consumption and paediatric fatty liver disease. Pediatric Obesity, 2021, 16, e12759.	1.4	23
1691	Metabolicâ€associated fatty liver disease (MAFLD) in coeliac disease. Liver International, 2021, 41, 788-798.	1.9	15
1692	Non-alcoholic fatty liver disease: Not time for an obituary just yet!. Journal of Hepatology, 2021, 74, 972-974.	1.8	24
1693	A Noncoding Variant Near PPP1R3B Promotes Liver Glycogen Storage and MetS, but Protects Against Myocardial Infarction. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 372-387.	1.8	12
1694	Mitochondrial haplogroup G is associated with nonalcoholic fatty liver disease, while haplogroup A mitigates the effects of PNPLA3. Endocrinology, Diabetes and Metabolism, 2021, 4, e00187.	1.0	2
1695	Hepatocyte Nuclear Factor 4Î± Prevents the Steatosisâ€toâ€NASH Progression by Regulating p53 and Bile Acid Signaling (in mice). Hepatology, 2021, 73, 2251-2265.	3.6	40
1696	PCSK9 rs11591147 R46L lossâ€ofâ€function variant protects against liver damage in individuals with NAFLD. Liver International, 2021, 41, 321-332.	1.9	26
1697	Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatinâ€Like Phospholipase Domain Containing 3â€“Mediated Acceleration of Steatohepatitis. Hepatology, 2021, 73, 1290-1306.	3.6	37
1698	A case of symmetric lipomatosis of the tongue arising in a patient with alcoholic liver cirrhosis presenting with macroglossia. Oral Science International, 2021, 18, 94-98.	0.3	0
1699	OligonucleotideâBased Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases. Hepatology, 2021, 73, 1581-1593.	3.6	4
1700	Genomeâ€wide Association Study and Metaâ€analysis on Alcoholâ€Associated Liver Cirrhosis Identifies Genetic Risk Factors. Hepatology, 2021, 73, 1920-1931.	3.6	54
1701	Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). Translational Gastroenterology and Hepatology, 2021, 6, 2-2.	1.5	46
1702	IPSC-derived 3D human fatty liver models. , 2021, , 271-291.		0
1703	Research progress, challenges and perspectives on PNPLA3 and its variants in Liver Diseases. Journal of Cancer, 2021, 12, 5929-5937.	1.2	5
1704	Lean NAFLD: an underrecognized and challenging disorder in medicine. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 351-366.	2.6	40
1705	Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry. Translational Gastroenterology and Hepatology, 2021, 6, 5-5.	1.5	6

#	Article	IF	Citations
1706	PNPLA3 gene polymorphism and severity of liver steatosis and fibrosis. Archives of Medical Science - Civilization Diseases, 2021, 6, 31-35.	0.1	1
1707	Nutrition in Chronic Liver Disease: Consensus Statement of the Indian National Association for Study of the Liver. Journal of Clinical and Experimental Hepatology, 2021, 11, 97-143.	0.4	36
1708	NAFLD-related HCC. Advances in Cancer Research, 2021, 149, 143-169.	1.9	13
1709	Genetics of Polygenic Metabolic Liver Disease. , 2021, , 409-419.		0
1710	Reduction of fatty liver in rats by nicotinamide via the regeneration of the methionine cycle and the inhibition of aldehyde oxidase. Journal of Toxicological Sciences, 2021, 46, 31-42.	0.7	5
1711	Insights Into Metabolic Mechanisms and Their Application in the Treatment of NASH. Clinical Liver Disease, 2021, 17, 29-32.	1.0	4
1712	Association between obesity profile and non-alcoholic fatty liver by race/ethnicity. Annals of Clinical Endocrinology and Metabolism, 2021, 5, 001-010.	0.3	1
1713	Hepatic deletion of Mboat7 (LPIAT1) causes activation of SREBP-1c and fatty liver. Journal of Lipid Research, 2021, 62, 100031.	2.0	39
1714	Electronic Health Record-Based Genome-Wide Meta-Analysis Provides New Insights on the Genetic Architecture of Non-Alcoholic Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	2
1715	The PNPLA3 rs738409 Variant but not MBOAT7 rs641738 is a Risk Factor for Nonalcoholic Fatty Liver Disease in Obese U.S. Children of Hispanic Ethnicity. Pediatric Gastroenterology, Hepatology and Nutrition, 2021, 24, 455.	0.4	9
1716	A perspective on RNA interference-based therapeutics for metabolic liver diseases. Expert Opinion on Investigational Drugs, 2021, 30, 237-244.	1.9	7
1718	Epigenetic mechanisms of hepatocellular carcinoma progression: Potential therapeutic opportunities. , 2021, , 279-296.		0
1721	Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis. Saudi Journal of Gastroenterology, 2021, 27, 64.	0.5	2
1722	Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice. International Journal of Molecular Sciences, 2021, 22, 2126.	1.8	3
1723	Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma. Biomedicines, 2021, 9, 184.	1.4	23
1724	RORÎ± regulates hepatic lipolysis by inducing transcriptional expression of PNPLA3 in mice. Molecular and Cellular Endocrinology, 2021, 522, 111122.	1.6	3
1725	The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C. BMC Gastroenterology, 2021, 21, 81.	0.8	6
1726	The Impact of Macronutrient Intake on Non-alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories?. Frontiers in Nutrition, 2021, 8, 640557.	1.6	44

#	Article	IF	Citations
1727	Pharmacogenetics of novel glucose-lowering drugs. Diabetologia, 2021, 64, 1201-1212.	2.9	28
1728	Interferon lambda 4 genotype and pathway in alcoholic hepatitis. Scandinavian Journal of Gastroenterology, 2021, 56, 304-311.	0.6	0
1729	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 413-414.	2.4	0
1730	Fat mass to fat-free mass ratio and the risk of non-alcoholic fatty liver disease and fibrosis in non-obese and obese individuals. Nutrition and Metabolism, 2021, 18, 21.	1.3	16
1732	Greater liver PNPLA3 protein abundance in vivo and in vitro supports lower triglyceride accumulation in dairy cows. Scientific Reports, 2021, 11, 2839.	1.6	17
1733	From the origin of NASH to the future of metabolic fatty liver disease. Gut, 2021, 70, 1570-1579.	6.1	43
1734	Targeting the ileal bile salt transporter in the treatment of non-alcoholic fatty liver disease. Hepatology International, 2021, 15, 283-286.	1.9	0
1735	Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications. Current Diabetes Reports, 2021, 21, 8.	1.7	27
1736	Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. Biomedicines, 2021, 9, 145.	1.4	20
1737	Recent Epidemiology of Nonalcoholic Fatty Liver Disease. Gut and Liver, 2021, 15, 206-216.	1.4	54
1738	Association of LDLR rs1433099 with the Risk of NAFLD and CVD in Chinese Han Population. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	2
1739	PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center. Journal of Personalized Medicine, 2021, 11, 165.	1.1	6
1740	Nonalcoholic fatty liver disease or metabolic dysfunctionâ€associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. European Journal of Clinical Investigation, 2021, 51, e13519.	1.7	32
1741	The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. EBioMedicine, 2021, 65, 103249.	2.7	11
1742	Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. Metabolites, 2021, 11, 155.	1.3	44
1743	Hepatic Fat in Participants With and Without Incident Diabetes in the Diabetes Prevention Program Outcome Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4746-e4765.	1.8	4
1744	Flavin Adenine Dinucleotide Depletion Caused by electron transfer flavoprotein subunit alpha Haploinsufficiency Leads to Hepatic Steatosis and Injury in Zebrafish. Hepatology Communications, 2021, 5, 976-991.	2.0	3
1745	Pediatric Nonâ€Alcoholic Fatty Liver Disease Is Affected by Genetic Variants Involved in Lifespan/Healthspan. Journal of Pediatric Gastroenterology and Nutrition, 2021, 73, 161-168.	0.9	4

#	Article	IF	Citations
1746	Hepatic Steatosis in the Pediatric Population: An Overview of Pathophysiology, Genetics, and Diagnostic Workup. Clinical Liver Disease, 2021, 17, 191-195.	1.0	3
1747	Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD. Journal of Clinical Lipidology, 2021, 15, 275-291.	0.6	8
1748	Dietary Oxysterol, 7-Ketocholesterol Accelerates Hepatic Lipid Accumulation and Macrophage Infiltration in Obese Mice. Frontiers in Endocrinology, 2020, 11, 614692.	1.5	11
1749	Nonalcoholic Fatty Liver Disease: A Global Perspective. Clinical Therapeutics, 2021, 43, 473-499.	1.1	38
1750	Catch-up growth in juvenile rats, fat expansion, and dysregulation of visceral adipose tissue. Pediatric Research, 2021, , .	1.1	4
1751	Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study. Clinical and Translational Gastroenterology, 2021, 12, e00321.	1.3	6
1752	Advances in the Epidemiology, Diagnosis, and Management of Pediatric Fatty Liver Disease. Clinical Therapeutics, 2021, 43, 438-454.	1.1	8
1753	STE20â€Type Protein Kinase MST4 Controls NAFLD Progression by Regulating Lipid Droplet Dynamics and Metabolic Stress in Hepatocytes. Hepatology Communications, 2021, 5, 1183-1200.	2.0	13
1754	Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis. Nutrition Research, 2021, 88, 34-43.	1.3	5
1755	Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. Pharmacological Research, 2021, 166, 105517.	3.1	16
1756	NAFLD: a multi-faceted morbid spectrum with uncertain diagnosis and complicated management. Minerva Surgery, 2021, 76, 450-466.	0.1	2
1757	Nonalcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Riskâ€"A Single-Center Cross-Sectional Study. Clinical and Translational Gastroenterology, 2021, 12, e00326.	1.3	28
1758	Undiagnosed liver diseases. Translational Gastroenterology and Hepatology, 2021, 6, 28-28.	1.5	11
1759	Associations between Free Sugar and Sugary Beverage Intake in Early Childhood and Adult NAFLD in a Population-Based UK Cohort. Children, 2021, 8, 290.	0.6	4
1760	Exome-wide scan identifies significant association of rs4788084 in IL27 promoter with increase in hepatic fat content among Indians. Gene, 2021, 775, 145431.	1.0	13
1761	Update on cardiovascular risk in nonalcoholic fatty liver disease. Current Opinion in Cardiology, 2021, 36, 478-486.	0.8	5
1762	Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis. Alcoholism: Clinical and Experimental Research, 2021, 45, 709-719.	1.4	8
1763	Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes. Frontiers in Endocrinology, 2021, 12, 639548.	1.5	35

#	Article	IF	Citations
1765	Silencing of STE20â€type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates dietâ€induced nonalcoholic fatty liver disease. FASEB Journal, 2021, 35, e21567.	0.2	15
1766	Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides. Current Opinion in Lipidology, 2021, 32, 200-206.	1.2	10
1767	Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. International Journal of Molecular Sciences, 2021, 22, 4459.	1.8	30
1768	Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. World Journal of Gastroenterology, 2021, 27, 1738-1750.	1.4	8
1769	Characteristics and prognosis of patients with large well-differentiated hepatocellular carcinoma who have undergone resection. American Journal of Surgery, 2022, 223, 339-345.	0.9	1
1770	Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions. International Journal of Molecular Sciences, 2021, 22, 3899.	1.8	20
1771	Emerging Metabolic and Transcriptomic Signature of PNPLA3â€Associated NASH. Hepatology, 2021, 73, 1248-1250.	3.6	3
1772	The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD. Genes, 2021, 12, 645.	1.0	41
1773	Allele-specific variation atAPOEincreases nonalcoholic fatty liver disease and obesity but decreases risk of Alzheimerâ€™s disease and myocardial infarction. Human Molecular Genetics, 2021, 30, 1443-1456.	1.4	20
1775	Role of Insulin Resistance in MAFLD. International Journal of Molecular Sciences, 2021, 22, 4156.	1.8	131
1776	What considerations are there for the pharmacotherapeutic management of nonalcoholic steatohepatitis?. Expert Opinion on Pharmacotherapy, 2021, 22, 1217-1220.	0.9	4
1777	Heterozygosity of the Alpha 1â€Antitrypsin Pi*Z Allele and Risk of Liver Disease. Hepatology Communications, 2021, 5, 1348-1361.	2.0	15
1778	The influence of PM2.5 exposure on non-alcoholic fatty liver disease. Life Sciences, 2021, 270, 119135.	2.0	30
1779	Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR-based lipoprotein profiling. Journal of Hepatology, 2021, 74, 974-977.	1.8	26
1780	Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sciences, 2021, 271, 119220.	2.0	38
1781	Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. Journal of Personalized Medicine, 2021, 11, 281.	1.1	5
1782	A PNPLA3 Polymorphism Confers Lower Susceptibility to Incident Diabetes Mellitus in Subjects With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 682-691.e8.	2.4	10
1783	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. Gastroenterology, 2021, 160, 1634-1646.e7.	0.6	82

#	Article	IF	Citations
1784	Obesity and Liver Cancer in Japan: A Comprehensive Review. Anticancer Research, 2021, 41, 2227-2237.	0.5	5
1785	Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. Frontiers in Endocrinology, 2021, 12, 665987.	1.5	17
1786	Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?. Journal of Clinical Medicine, 2021, 10, 2040.	1.0	6
1787	The impact of genetic risk on liver fibrosis in nonâ€alcoholic fatty liver disease as assessed by magnetic resonance elastography. Alimentary Pharmacology and Therapeutics, 2021, 54, 68-77.	1.9	18
1788	The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers, 2021, 13, 2621.	1.7	15
1789	Hemostatic alterations linked to body fat distribution, fatty liver, and insulin resistance. Molecular Metabolism, 2021, 53, 101262.	3.0	9
1790	Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives. Nutrients, 2021, 13, 1679.	1.7	14
1791	Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. International Journal of Environmental Research and Public Health, 2021, 18, 5227.	1.2	109
1793	PNPLA3 Genotype, Arachidonic Acid Intake, and Unsaturated Fat Intake Influences Liver Fibrosis in Hispanic Youth with Obesity. Nutrients, 2021, 13, 1621.	1.7	8
1794	Disproportionate Vitamin A Deficiency in Women of Specific Ethnicities Linked to Differences in Allele Frequencies of Vitamin A-Related Polymorphisms. Nutrients, 2021, 13, 1743.	1.7	8
1795	The influence of RS738409 I148M polymorphism of patatin-like phospholipase domain containing 3 gene on the susceptibility of non-alcoholic fatty liver disease. Medicine (United States), 2021, 100, e25893.	0.4	8
1796	Metabolic-associated Fatty Liver Disease as Assessed by the Fatty Liver Index Among Migrant and Non-migrant Ghanaian Populations. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	4
1797	Role of non-alcoholic fatty liver disease in the evolution of renal function in patients with diabetes mellitus. Nephrology Dialysis Transplantation, 2022, 37, 1125-1131.	0.4	10
1798	Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 2021, 184, 2537-2564.	13.5	757
1799	Genetic risk score prediction of leg fat and insulin sensitivity differs by race/ethnicity in early pubertal children. Pediatric Obesity, 2021, 16, e12828.	1.4	2
1800	Reply to: â€œPolygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver diseaseâ€. Journal of Hepatology, 2021, 74, 1494-1496.	1.8	9
1801	Genomeâ€wide association analysis of serum alanine and aspartate aminotransferase, and the modifying effects of BMI in 388kÂEuropean individuals. Genetic Epidemiology, 2021, 45, 664-681.	0.6	9
1802	Genetic architecture of 11 organ traits derived from abdominal MRI using deep learning. ELife, 2021, 10, .	2.8	102

#	Article	IF	Citations
1803	Clinically Actionable Findings Derived From Predictive Genomic Testing Offered in a Medical Practice Setting. Mayo Clinic Proceedings, 2021, 96, 1407-1417.	1.4	6
1804	Lipid nanoparticle formulations for targeting leukocytes with therapeutic RNA in liver fibrosis. Advanced Drug Delivery Reviews, 2021, 173, 70-88.	6.6	6
1805	Non-alcoholic fatty liver disease. Lancet, The, 2021, 397, 2212-2224.	6.3	1,035
1806	Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD â€“ Reconciling the present with the past. JHEP Reports, 2021, 3, 100261.	2.6	31
1807	Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. Hepatology International, 2021, 15, 922-933.	1.9	14
1809	Adipokines in patients with hypertensive disease with obesity in the dynamics of combined antihypertensive therapy. Regulatory Mechanisms in Biosystems, 2021, 12, 362-368.	0.5	0
1810	Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches. Nutrients, 2021, 13, 1977.	1.7	17
1811	Secure and optimized detection of PNPLA3 rs738409 genotype by an improved PCRâ€“restriction fragment length polymorphismÂmethod. BioTechniques, 2021, 70, 345-349.	0.8	0
1812	Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank. JHEP Reports, 2021, 3, 100262.	2.6	15
1813	Optimization enzymatic degradation of chitosan into amphiphilic chitooligosaccharides for application in mitigating liver steatosis and cholesterol regulation. European Polymer Journal, 2021, 153, 110507.	2.6	7
1814	Metabolic Risk Profiles for Hepatic Steatosis Differ by Race/Ethnicity: An Elastography-Based Study of US Adults. Digestive Diseases and Sciences, 2022, 67, 3340-3355.	1.1	6
1815	Diagnosis and management of secondary causes of steatohepatitis. Journal of Hepatology, 2021, 74, 1455-1471.	1.8	56
1816	The pathogenic oralâ€“gutâ€“liver axis: new understandings and clinical implications. Expert Review of Clinical Immunology, 2021, 17, 727-736.	1.3	18
1817	Association of Genetic Risk Score With NAFLD in An Ethnically Diverse Cohort. Hepatology Communications, 2021, 5, 1689-1703.	2.0	22
1818	Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Reports, 2021, 3, 100284.	2.6	28
1819	Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic Target. Journal of Personalized Medicine, 2021, 11, 619.	1.1	8
1820	A human liver chimeric mouse model for non-alcoholic fatty liver disease. JHEP Reports, 2021, 3, 100281.	2.6	27
1821	Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease. Nucleic Acid Therapeutics, 2021, 31, 324-340.	2.0	9

#	Article	IF	Citations
1822	Sphingolipids in metabolic disease: The good, the bad, and the unknown. Cell Metabolism, 2021, 33, 1293-1306.	7.2	109
1823	Assessing Interactions between PNPLA3 and Dietary Intake on Liver Steatosis in Mexican-Origin Adults. International Journal of Environmental Research and Public Health, 2021, 18, 7055.	1.2	4
1824	Mutations of NRG4 Contribute to the Pathogenesis of Nonalcoholic Fatty Liver Disease and Related Metabolic Disorders. Diabetes, 2021, 70, 2213-2224.	0.3	13
1825	Risk for hepatic and extraâ€hepatic outcomes in nonalcoholic fatty liver disease. Journal of Internal Medicine, 2022, 292, 177-189.	2.7	11
1826	Dietary carbohydrates and fats in nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 770-786.	8.2	108
1827	The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcoholâ€Associated Hepatitis. Liver Transplantation, 2021, 27, 1382-1391.	1.3	4
1828	MAFLD-Epidemiology, Natural History, Outcomes and Prevention. European Journal of Medical and Health Sciences, 2021, 3, 12-17.	0.1	1
1829	PNPLA3 is the dominant SNP linked to liver disease severity at time of first referral to a tertiary center. Digestive and Liver Disease, 2022, 54, 84-90.	0.4	4
1830	Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Digestive and Liver Disease, 2022, 54, 154-163.	0.4	15
1831	CD8+ T Cells Involved in Metabolic Inflammation in Visceral Adipose Tissue and Liver of Transgenic Pigs. Frontiers in Immunology, 2021, 12, 690069.	2.2	8
1832	Genetic Variation in the Mitochondrial Glycerolâ€3â€Phosphate Acyltransferase Is Associated With Liver Injury. Hepatology, 2021, 74, 3394-3408.	3.6	9
1833	Reassessment of the Hispanic Disparity: Hepatic Steatosis Is More Prevalent in Mexican Americans Than Other Hispanics. Hepatology Communications, 2021, 5, 2068-2079.	2.0	12
1834	NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. Liver International, 2021, 41, 2712-2719.	1.9	6
1835	Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. Hepatology Communications, 2021, 5, 1833-1847.	2.0	54
1836	Biochemical Mechanisms Associating Alcohol Use Disorders with Cancers. Cancers, 2021, 13, 3548.	1.7	9
1837	Relationship between AGT rs2493132 polymorphism and the risk of coronary artery disease in patients with NAFLD in the Chinese Han population. Journal of International Medical Research, 2021, 49, 030006052110192.	0.4	2
1838	Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort. Clinical and Molecular Hepatology, 2021, 27, 486-498.	4.5	20
1839	Waitlist mortality and transplant free survival in Hispanic patients listed for liver transplant using the UNOS database. Annals of Hepatology, 2021, 23, 100304.	0.6	9

#	Article	IF	Citations
1840	GWAS of serum ALT and AST reveals an association of SLC30A10 Thr95Ile with hypermanganesemia symptoms. Nature Communications, 2021, 12, 4571.	5.8	26
1841	Organ-on-chip applications in drug discovery: an end user perspective. Biochemical Society Transactions, 2021, 49, 1881-1890.	1.6	22
1842	Targeting miRNA by Natural Products: A Novel Therapeutic Approach for Nonalcoholic Fatty Liver. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-16.	0.5	11
1843	Hepatocyteâ€specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatinâ€like) Tj ETQq1 1 0.784314 rgBT /Ove 2022, 75, 125-139.	3.6	25
1844	Associations of Dietary Lipid-Soluble Micronutrients with Hepatic Steatosis among Adults in the United States. Biomedicines, 2021, 9, 1093.	1.4	2
1845	Cancer and hepatic steatosis. ESMO Open, 2021, 6, 100185.	2.0	9
1846	We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases. Hepatology, 2021, 74, 2876-2887.	3.6	7
1847	Genetic and Environmental Susceptibility to Alcoholic Hepatitis. Clinics in Liver Disease, 2021, 25, 517-535.	1.0	5
1848	Multi-omics profiling: the way toward precision medicine in metabolic diseases. Journal of Molecular Cell Biology, 2021, , .	1.5	16
1849	Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille?. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	3
1850	Sex hormoneâ€“binding globulin: biomarker and hepatokine?. Trends in Endocrinology and Metabolism, 2021, 32, 544-553.	3.1	30
1851	Metabolic dysfunctionâ€“associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. Hepatology, 2022, 75, 419-429.	3.6	64
1852	NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. Cells, 2021, 10, 2034.	1.8	20
1853	Metabolic disorders and the risk of cholangiocarcinoma. Expert Review of Gastroenterology and Hepatology, 2021, 15, 999-1007.	1.4	9
1854	The Risk of Type 2 Diabetes and Coronary Artery Disease in Non-obese Patients With Non-alcoholic Fatty Liver Disease: A Cohort Study. Frontiers in Cardiovascular Medicine, 2021, 8, 680664.	1.1	7
1855	Identification of 90 NAFLD GWAS loci and establishment of NAFLD PRS and causal role of NAFLD in coronary artery disease. Human Genetics and Genomics Advances, 2022, 3, 100056.	1.0	10
1856	Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	17
1857	Lipid Droplet-Associated Factors, PNPLA3, TM6SF2, and HSD17B Proteins in Hepatopancreatobiliary Cancer. Cancers, 2021, 13, 4391.	1.7	13

#	Article	IF	Citations
1858	Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. Nutrients, 2021, 13, 2830.	1.7	27
1859	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. EBioMedicine, 2021, 70, 103521.	2.7	11
1860	Hepatic sexual dimorphism â€" implications for non-alcoholic fatty liver disease. Nature Reviews Endocrinology, 2021, 17, 662-670.	4.3	41
1861	Variants in the <i>PNPLA1</i> Gene in Families with Autosomal Recessive Congenital Ichthyosis Reveal Clinical Significance. Molecular Syndromology, 2021, 12, 351-361.	0.3	6
1862	Biomarkers in Fatty Liver Diseaseâ€"Here is the Skinny. Journal of Clinical and Experimental Hepatology, 2021, 11, 637-640.	0.4	0
1863	Metabolic-associated fatty liver disease and lipoprotein metabolism. Molecular Metabolism, 2021, 50, 101238.	3.0	195
1864	Human Three-Dimensional Hepatic Models: Cell Type Variety and Corresponding Applications. Frontiers in Bioengineering and Biotechnology, 2021, 9, 730008.	2.0	12
1865	The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD. Clinical and Translational Gastroenterology, 2021, 12, e00400.	1.3	12
1866	Drug-induced Fatty Liver Disease: Pathogenesis and Treatment. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	6
1867	Alcoholic liver disease: Current insights into cellular mechanisms. World Journal of Biological Chemistry, 2021, 12, 87-103.	1.7	15
1868	Influence of Nonalcoholic Fatty Liver Disease on the Occurrence and Severity of Chronic Kidney Disease. Journal of Clinical and Translational Hepatology, 2022, 10, 164-173.	0.7	9
1869	Steatotic Hepatocytes Release Mature VLDL Through Methionine and Tyrosine Metabolism in a Keap1â€Nrf2â€"Dependent Manner. Hepatology, 2021, 74, 1271-1286.	3.6	16
1870	Characterization and Pharmacological Validation of a Preclinical Model of NASH in GÃ¶ttingen Minipigs. Journal of Clinical and Experimental Hepatology, 2022, 12, 293-305.	0.4	2
1871	The CYTOLD and ERTOLD pathways for lipid dropletâ€"protein targeting. Trends in Biochemical Sciences, 2022, 47, 39-51.	3.7	40
1872	Effects of <scp>PNPLA3</scp>, <scp>TM6SF2</scp> and <scp>SAMM50</scp> on the development and severity of nonâ€alcoholic fatty liver disease in children. Pediatric Obesity, 2022, 17, e12852.	1.4	12
1873	To Be or Not to Be: The Quest for Patatinâ€Like Phospholipase Domain Containing 3 p.I148M Function. Hepatology, 2021, 74, 2942-2944.	3.6	1
1874	Association of elevated serum aminotransferase levels with chronic kidney disease measures: hispanic community health study/study of latinos. BMC Nephrology, 2021, 22, 302.	0.8	3
1875	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Journal of Gastroenterology, 2021, 56, 951-963.	2.3	114

#	Article	IF	Citations
1876	Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. The Lancet Gastroenterology and Hepatology, 2021, 6, 1036-1046.	3.7	23
1877	Hepatocytic Activating Transcription Factor 3 Protects Against Steatohepatitis via Hepatocyte Nuclear Factor 4Î±. Diabetes, 2021, 70, 2506-2517.	0.3	8
1878	Single nucleotide polymorphisms in PNPLA3, ADAR-1 and IFIH1 are associated with advanced liver fibrosis in patients co-infected with HIV-1//hepatitis C virus. Aids, 2021, 35, 2497-2502.	1.0	6
1879	Genetics Is of the Essence to Face NAFLD. Biomedicines, 2021, 9, 1359.	1.4	30
1880	Changing clinical management of NAFLD in Asia. Liver International, 2022, 42, 1955-1968.	1.9	18
1881	Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD. Hepatology, 2021, 74, 2241-2250.	3.6	41
1882	Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World Journal of Hepatology, 2021, 13, 1107-1121.	0.8	4
1883	Modeling PNPLA3â€Associated NAFLD Using Humanâ€Induced Pluripotent Stem Cells. Hepatology, 2021, 74, 2998-3017.	3.6	35
1884	Evidenceâ€based clinicalÂpractice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatology Research, 2021, 51, 1013-1025.	1.8	58
1886	Recent advances in the epidemiology of nonalcoholic fatty liver disease in children. Pediatric Obesity, 2021, 16, e12849.	1.4	21
1887	Dietary Patterns Influence Target Gene Expression through Emerging Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease. Biomedicines, 2021, 9, 1256.	1.4	14
1888	Genomeâ€Wide Association Study of NAFLD Using Electronic Health Records. Hepatology Communications, 2022, 6, 297-308.	2.0	33
1889	Antioxidant Role of Kaempferol in Prevention of Hepatocellular Carcinoma. Antioxidants, 2021, 10, 1419.	2.2	43
1890	Screening for nonalcoholic fatty liver disease-when, who and how?. World Journal of Gastroenterology, 2021, 27, 5803-5821.	1.4	18
1891	TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease. Hepatology Communications, 2022, 6, 448-460.	2.0	51
1892	Associations of Nutrient Intake Changes During Childhood with Adolescent Hepatic Fat: The Exploring Perinatal Outcomes Among CHildrenÂStudy. Journal of Pediatrics, 2021, 237, 50-58.e3.	0.9	3
1893	Genetic risk scores and personalization of care in fatty liver disease. Current Opinion in Pharmacology, 2021, 61, 6-11.	1.7	13
1894	Integrative analysis of transcriptomic and metabolomic profiles reveal the complex molecular regulatory network of meat quality in Enshi black pigs. Meat Science, 2022, 183, 108642.	2.7	32

#	Article	IF	Citations
1895	Structure and function of lipid droplets. , 2021, , 357-394.		0
1896	The lipidome in nonalcoholic fatty liver disease: actionable targets. Journal of Lipid Research, 2021, 62, 100073.	2.0	14
1897	Pleiotropy within gene variants associated with nonalcoholic fatty liver disease and traits of the hematopoietic system. World Journal of Gastroenterology, 2021, 27, 305-320.	1.4	6
1899	Shifting perspectives â€“ interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals. World Journal of Hepatology, 2021, 13, 80-93.	0.8	1
1900	Hepatic steatosis relates to gastrointestinal microbiota changes in obese girls with polycystic ovary syndrome. PLoS ONE, 2021, 16, e0245219.	1.1	14
1901	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, 6.	18.1	2,757
1902	Management of non-alcoholic fatty liver disease. BMJ, The, 2021, 372, m4747.	3.0	99
1903	Effect of a Low-Fat Vegan Diet on Body Weight, Insulin Sensitivity, Postprandial Metabolism, and Intramyocellular and Hepatocellular Lipid Levels in Overweight Adults. JAMA Network Open, 2020, 3, e2025454.	2.8	85
1906	Alcoholâ€Associated Liver Disease: East Versus West. Clinical Liver Disease, 2020, 16, 231-235.	1.0	8
1907	Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. Advances in Experimental Medicine and Biology, 2020, 1307, 417-440.	0.8	21
1908	Periodontitis and Liver Diseases. Oxidative Stress in Applied Basic Research and Clinical Practice, 2014, , 197-209.	0.4	2
1909	Obesity and the Pathogenesis of Nonalcoholic Fatty Liver Disease. , 2014, , 121-135.		2
1911	Epidemiology and Risk Factors for Alcoholic Liver Disease. , 2016, , 1-20.		2
1912	Nonalcoholic Fatty Liver Disease in Children. , 2016, , 339-362.		1
1914	Insulin Resistance, Obesity and Lipotoxicity. Advances in Experimental Medicine and Biology, 2017, 960, 277-304.	0.8	304
1915	Clinical Epidemiology of NAFLD. , 2019, , 211-227.		3
1916	The Natural History of NAFLD: Environmental vs. Genetic Risk Factors. , 2020, , 129-145.		2
1917	pPLA: Patatin-Related Phospholipase As with Multiple Biological Functions. Signaling and Communication in Plants, 2014, , 93-108.	0.5	9

#	Article	IF	Citations
1918	CGI-58: Versatile Regulator of Intracellular Lipid Droplet Homeostasis. Advances in Experimental Medicine and Biology, 2020, 1276, 197-222.	0.8	17
1919	Accounting for the Placebo Effect and Optimizing Outcomes in Clinical Trials of Nonalcoholic Steatohepatitis (NASH). Current Hepatology Reports, 2020, 19, 63-69.	0.4	7
1920	NASH in HIV. Current HIV/AIDS Reports, 2020, 17, 601-614.	1.1	23
1921	Pathophysiological mechanisms underlying MAFLD. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1875-1887.	1.8	75
1922	PNPLA3 L148M (rs738409) polymorphism as a risk for new onset diabetes mellitus and obesity in non-NASH/cryptogenic living related donor liver transplant recipients. Gene Reports, 2020, 19, 100607.	0.4	1
1923	Hepatic lipid droplet homeostasis and fatty liver disease. Seminars in Cell and Developmental Biology, 2020, 108, 72-81.	2.3	88
1924	Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics. Biochemical Journal, 2020, 477, 985-1008.	1.7	116
1925	African Americans have a distinct clinical and histologic profile with lower prevalence of NASH and advanced fibrosis relative to Caucasians. European Journal of Gastroenterology and Hepatology, 2021, 33, 388-398.	0.8	8
1933	PNPLA3 as a liver steatosis risk factor following livingâ€donor liver transplantation for hepatitis C. Hepatology Research, 2018, 48, E335-E339.	1.8	12
1934	Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. JCI Insight, 2020, 5, .	2.3	38
1935	Science, serendipity, and the single degree. Journal of Clinical Investigation, 2018, 128, 4218-4223.	3.9	2
1936	Nuclear envelopeâ€"localized torsinA-LAP1 complex regulates hepatic VLDL secretion and steatosis. Journal of Clinical Investigation, 2019, 129, 4885-4900.	3.9	52
1937	Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. Journal of Clinical Investigation, 2012, 122, 4130-4144.	3.9	221
1938	Tribbles-1 regulates hepatic lipogenesis through posttranscriptional regulation of C/EBPÎ±. Journal of Clinical Investigation, 2015, 125, 3809-3818.	3.9	84
1939	Insights from human genetic studies of lung and organ fibrosis. Journal of Clinical Investigation, 2018, 128, 36-44.	3.9	31
1940	The role of NAFLD in cardiometabolic disease: an update. F1000Research, 2018, 7, 170.	0.8	15
1941	Recent advances in understanding/management of non-alcoholic steatohepatitis. F1000prime Reports, 2015, 7, 28.	5.9	8
1942	Role of genetic polymorphisms in hepatitis C virus chronic infection. World Journal of Clinical Cases, 2015, 3, 807.	0.3	18

#	Article	IF	Citations
1943	PNPLA3 rs139051 is associated with phospholipid metabolite profile and hepatic inflammation in nonalcoholic fatty liver disease. World Journal of Clinical Cases, 2018, 6, 355-364.	0.3	10
1944	PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease. World Journal of Clinical Cases, 2018, 6, 167-175.	0.3	25
1945	The PNPLA3 rs738409 148M/M Genotype Is a Risk Factor for Liver Cancer in Alcoholic Cirrhosis but Shows No or Weak Association in Hepatitis C Cirrhosis. PLoS ONE, 2011, 6, e27087.	1.1	108
1946	The Association of PNPLA3 Variants with Liver Enzymes in Childhood Obesity Is Driven by the Interaction with Abdominal Fat. PLoS ONE, 2011, 6, e27933.	1.1	78
1947	A Common Variant of PNPLA3 (p.I148M) Is Not Associated with Alcoholic Chronic Pancreatitis. PLoS ONE, 2012, 7, e29433.	1.1	15
1948	Genetic Polymorphisms of the Human PNPLA3 Gene Are Strongly Associated with Severity of Non-Alcoholic Fatty Liver Disease in Japanese. PLoS ONE, 2012, 7, e38322.	1.1	228
1949	Gene Expression Profiling Unravels Cancer-Related Hepatic Molecular Signatures in Steatohepatitis but Not in Steatosis. PLoS ONE, 2012, 7, e46584.	1.1	97
1950	Genetic Variants in PNPLA3 and Risk of Non-Alcoholic Fatty Liver Disease in a Han Chinese Population. PLoS ONE, 2012, 7, e50256.	1.1	46
1951	Frequency of Rare Allelic Variation in Candidate Genes among Individuals with Low and High Urinary Calcium Excretion. PLoS ONE, 2013, 8, e71885.	1.1	23
1952	PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e75982.	1.1	42
1953	Genome-Wide Analysis of Copy Number Variation Identifies Candidate Gene Loci Associated with the Progression of Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e95604.	1.1	30
1954	Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C. PLoS ONE, 2014, 9, e106022.	1.1	9
1955	The Impact of PNPLA3 rs738409 Genetic Polymorphism and Weight Gain â‰¥10 kg after Age 20 on Non-Alcoholic Fatty Liver Disease in Non-Obese Japanese Individuals. PLoS ONE, 2015, 10, e0140427.	1.1	64
1956	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. PLoS ONE, 2015, 10, e0143429.	1.1	23
1957	A Combination of Mitochondrial Oxidative Stress and Excess Fat/Calorie Intake Accelerates Steatohepatitis by Enhancing Hepatic CC Chemokine Production in Mice. PLoS ONE, 2016, 11, e0146592.	1.1	17
1958	Influence of Ethnicity on the Accuracy of Non-Invasive Scores Predicting Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0160526.	1.1	26
1959	Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. PLoS ONE, 2018, 13, e0185490.	1.1	104
1960	Aberrant hepatic lipid storage and metabolism in canine portosystemic shunts. PLoS ONE, 2017, 12, e0186491.	1.1	7

#	Article	IF	Citations
1961	PNPLA3 as a Genetic Determinant of Risk for and Severity of Non-alcoholic Fatty Liver Disease Spectrum. Journal of Clinical and Translational Hepatology, 2016, 4, 175-191.	0.7	29
1962	Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications. Journal of Clinical and Translational Hepatology, 2017, XX, 1-8.	0.7	73
1963	Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft. Journal of Clinical and Translational Hepatology, 2018, 6, 1-5.	0.7	20
1964	The Genetics of Clinical Liver Diseases: Insight into the TM6SF2 E167K Variant. Journal of Clinical and Translational Hepatology, 2018, 6, 1-6.	0.7	12
1965	Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally. Journal of Clinical and Translational Hepatology, 2020, 000, 1-10.	0.7	13
1966	Single Nucleotide Polymorphisms Associated With Alimentary Fatty Liver Disease Are Not Genetic Risk Factors For Treatment-associated Hepatic Steatosis In HIV Patients On HAART.. Journal of Clinical Research in HIV AIDS and Prevention, 2013, 1, 1-4.	0.1	2
1967	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. American Journal of Gastroenterology, 2021, 116, 984-993.	0.2	25
1968	Impact of the Association Between PNPLA3 Genetic Variation and Dietary Intake on the Risk of Significant Fibrosis in Patients With NAFLD. American Journal of Gastroenterology, 2021, 116, 994-1006.	0.2	30
1969	Hereditary Persistence of Alpha-Fetoprotein Is Associated with the â€”119G>A Polymorphism in AFP Gene. ACG Case Reports Journal, 2017, 4, e33.	0.2	3
1970	The role of PNPLA3 (rs738409) c>g variant on histological progression of non-alcoholic fatty liver disease. Hepatology Forum, 0, , .	0.3	3
1971	Fighting liver fat. Endocrine Connections, 2020, 9, R173-R186.	0.8	4
1972	Healthy PNPLA3 Risk Allele Carriers Present with Unexpected Body Fat Composition. A Study of One ousand Subjects. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 33-37.	0.5	5
1973	Risk Factor Prevalence and Their Relative Influence on Fatty Liver and Gallstone Disease: A Cross-Ethnic Study Comparing Two High-Risk Populations from Chile and Northeast Germany. Epidemiology - Open Journal, 2016, 1, 40-52.	0.4	1
1974	Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease. Revista Espanola De Enfermedades Digestivas, 2018, 110, 634-640.	0.1	12
1975	The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome. Current Opinion in Gynecology and Obstetrics, 2018, 1, 24-33.	0.0	16
1976	Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans. Aging, 2016, 9, 26-40.	1.4	11
1977	The association of variants in PNPLA3 and GRP78 and the risk of developing hepatocellular carcinoma in an Italian population. Oncotarget, 2016, 7, 86791-86802.	0.8	16
1978	Genetic variation in long noncoding RNAs and the risk of nonalcoholic fatty liver disease. Oncotarget, 2017, 8, 22917-22926.	0.8	27

#	Article	IF	Citations
1979	Genetic factors associated with risk of metabolic syndrome and hepatocellular carcinoma. Oncotarget, 2017, 8, 35403-35411.	0.8	18
1980	The additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on lipid metabolism. Oncotarget, 2017, 8, 74209-74216.	0.8	15
1981	Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. Hepatoma Research, 2020, 2020, .	0.6	11
1982	Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States. Annals of Gastroenterology, 2019, 32, 504-513.	0.4	15
1984	Risk of Kidney Dysfunction IN Nafld. Current Pharmaceutical Design, 2020, 26, 1045-1061.	0.9	12
1985	The link between Hepatic Vitamin A Metabolism and Nonalcoholic Fatty Liver Disease. Current Drug Targets, 2015, 16, 1281-1292.	1.0	20
1986	Non-Alcoholic Fatty Liver Disease and Vascular Disease. Current Vascular Pharmacology, 2020, 19, 269-279.	0.8	12
1987	Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges. Caspian Journal of Internal Medicine, 2020, 11, 346-354.	0.1	3
1988	Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma. Hepatic Oncology, 2020, 7, HEP36.	4.2	12
1989	Factores de riesgo asociados a hÃgado graso de origen no alcohÃ³lico en una poblaciÃ³n del Caribe Colombiano. Revista Colombiana De Gastroenterologia, 2017, 31, 89.	0.1	2
1990	Molecular Genetics of Keratinization Disorders â€“ Whatâ€™s New About Ichthyosis. Acta Dermato-Venereologica, 2020, 100, adv00095-185.	0.6	17
1991	Helicobacter pylori and non-alcoholic fatty liver disease. Minerva Gastroenterologica E Dietologica, 2020, 66, 267-279.	2.2	13
1992	PNPLA3 Polymorphisms and Liver Aminotransferase Levels in a Mexican American Population. Clinical and Investigative Medicine, 2012, 35, 237.	0.3	33
1993	JSH Consensus Kobe 2009; Diagnosis and Treatment of NASH. Acta Hepatologica Japonica, 2009, 50, 741-747.	0.0	10
1994	Molecular genetic studies in chronic diff use liver diseases. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2020, , 96-100.	0.1	3
1995	Predictive factors of non-alcoholic steatohepatitis: relationship with metabolic syndrome. Nutricion Hospitalaria, 2015, 31, 2496-502.	0.2	13
1996	Association between rs2303861 polymorphism in CD82 gene and non-alcoholic fatty liver disease: a preliminary case-control study. Croatian Medical Journal, 2019, 60, 361-368.	0.2	9
1997	Recent research trends and updates on nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 2019, 25, 1-11.	4.5	74

#	Article	IF	Citations
1998	Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology. Clinical and Molecular Hepatology, 2020, 26, 461-475.	4.5	39
1999	Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights. Clinical and Molecular Hepatology, 2020, 26, 728-735.	4.5	27
2000	Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. Cancers, 2020, 12, 1290.	1.7	20
2001	Genetic Susceptibility to Chronic Liver Disease in Individuals from Pakistan. International Journal of Molecular Sciences, 2020, 21, 3558.	1.8	8
2002	Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events. Middle East Journal of Digestive Diseases, 2020, 12, 65-88.	0.2	6
2003	PNPLA3 gene and kidney disease. , 2020, 1, 42-50.		32
2004	Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. Exploration of Medicine, 2020, 1, 218-243.	1.5	4
2005	Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. Exploration of Medicine, 2020, 1, .	1.5	37
2006	Genome-wide association studies - A summary for theclinical gastroenterologist. World Journal of Gastroenterology, 2009, 15, 5377.	1.4	14
2007	Adiponectin, a key adipokine in obesity related liver diseases. World Journal of Gastroenterology, 2011, 17, 2801-11.	1.4	201
2008	Patatin-like phospholipase domain containing-3gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World Journal of Gastroenterology, 2012, 18, 2813.	1.4	50
2009	Multicausality in fatty liver disease: Is there a rationale to distinguish between alcoholic and non-alcoholic origin?. World Journal of Gastroenterology, 2012, 18, 3492.	1.4	60
2010	PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2012, 18, 6018.	1.4	53
2011	Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2012, 18, 6546.	1.4	73
2012	Favorable effect of modest alcohol consumption to fatty liver disease. World Journal of Gastroenterology, 2013, 19, 5393.	1.4	1
2013	PNPLA3 I148M polymorphism and progressive liver disease. World Journal of Gastroenterology, 2013, 19, 6969.	1.4	207
2014	Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. World Journal of Gastroenterology, 2013, 19, 7055.	1.4	8
2015	Non-alcoholic fatty liver disease and liver transplantation: Outcomes and advances. World Journal of Gastroenterology, 2013, 19, 9146.	1.4	36

#	Article	IF	Citations
2016	Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population. World Journal of Gastroenterology, 2014, 20, 3655.	1.4	31
2017	NAFLD prevalence differs among hispanic subgroups: The multi-ethnic study of atherosclerosis. World Journal of Gastroenterology, 2014, 20, 4987.	1.4	99
2018	Liver transplantation for nonalcoholic fatty liver disease: New challenges and new opportunities. World Journal of Gastroenterology, 2014, 20, 5320.	1.4	96
2019	Pediatric fatty liver disease: Role of ethnicity and genetics. World Journal of Gastroenterology, 2014, 20, 7347.	1.4	64
2020	Proteomic and genomic studies of non-alcoholic fatty liver disease - clues in the pathogenesis. World Journal of Gastroenterology, 2014, 20, 8325.	1.4	33
2021	Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?. World Journal of Gastroenterology, 2014, 20, 9072-89.	1.4	118
2022	Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World Journal of Gastroenterology, 2014, 20, 12082.	1.4	155
2023	Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. World Journal of Gastroenterology, 2014, 20, 12945.	1.4	117
2024	Non-invasive diagnosis of alcoholic liver disease. World Journal of Gastroenterology, 2014, 20, 14626.	1.4	112
2025	Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World Journal of Gastroenterology, 2015, 21, 8293.	1.4	24
2026	LinkedPNPLA3polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B. World Journal of Gastroenterology, 2015, 21, 8605.	1.4	21
2027	Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. World Journal of Gastroenterology, 2016, 22, 6742.	1.4	74
2028	Mechanisms of intrahepatic triglyceride accumulation. World Journal of Gastroenterology, 2016, 22, 1664.	1.4	87
2029	Genetic polymorphism inCD14gene, a co-receptor of TLR4 associated with non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2016, 22, 9346.	1.4	22
2030	Glycosyltransferases and non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2016, 22, 2483.	1.4	17
2031	Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play. World Journal of Gastroenterology, 2016, 22, 2494.	1.4	45
2032	Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables. World Journal of Gastroenterology, 2018, 24, 4835-4845.	1.4	31
2033	Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management. World Journal of Gastroenterology, 2020, 26, 6514-6528.	1.4	25

#	Article	IF	Citations
2034	Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Endocrinology and Metabolism, 2020, 35, 243-259.	1.3	23
2035	Abnormal metabolic processes involved in the pathogenesis of nonâ€'alcoholic fatty liver disease (Review). Experimental and Therapeutic Medicine, 2020, 20, 1-1.	0.8	37
2036	InÂvitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism. Molecular Medicine Reports, 2020, 23, .	1.1	5
2037	PNPLA3 genetic variation in alcoholic steatosis and liver disease progression. Hepatobiliary Surgery and Nutrition, 2015, 4, 152-60.	0.7	8
2038	Immunoregulation by lipids during the development of non-alcoholic steatohepatitis. Hepatobiliary Surgery and Nutrition, 2015, 4, 11-23.	0.7	21
2039	Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. Diabetes and Metabolism Journal, 2020, 44, 382.	1.8	46
2040	Non-Alcoholic Fatty Liver Disease: Current Perspectives and Future Direction in Disease pathogenesis, Treatment and Diagnosis. , 2012, 2, .		2
2041	PNPLA3 and TNF-<i>Î±</i> G238A Genetic Polymorphisms in Egyptian Patients with Different Grades of Severity of NAFLD. Open Journal of Gastroenterology, 2016, 06, 53-64.	0.1	3
2042	Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research. World Journal of Hepatology, 2018, 10, 231-245.	0.8	18
2043	PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. World Journal of Hepatology, 2020, 12, 792-806.	0.8	22
2044	Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population. World Journal of Hepatology, 2020, 12, 1228-1238.	0.8	9
2045	Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis. World Journal of Hepatology, 2020, 12, 506-518.	0.8	11
2046	Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge. World Journal of Hepatology, 2010, 2, 275.	0.8	41
2047	â€œWeighing the riskâ€• Obesity and outcomes following liver transplantation. World Journal of Hepatology, 2015, 7, 1484.	0.8	15
2048	Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease. World Journal of Hepatology, 2015, 7, 2749.	0.8	15
2049	Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful?. World Journal of Hepatology, 2015, 7, 968.	0.8	78
2050	Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World Journal of Hepatology, 2015, 7, 1192.	0.8	8
2051	Primary liver injury and delayed resolution of liver stiffness after alcohol detoxification in heavy drinkers with thePNPLA3variant I148M. World Journal of Hepatology, 2016, 8, 1547.	0.8	21

#	Article	IF	Citations
2052	PNPLA3polymorphism increases risk for and severity of chronic hepatitis C liver disease. World Journal of Hepatology, 2016, 8, 1584.	0.8	4
2053	Regional differences in genetic susceptibility to non-alcoholic liver disease in two distinct Indian ethnicities. World Journal of Hepatology, 2017, 9, 1101.	0.8	18
2054	Fatty liver without a large â€œbellyâ€: Magnified review of non-alcoholic fatty liver disease in non-obese patients. World Journal of Gastrointestinal Pathophysiology, 2017, 8, 100.	0.5	25
2055	Management of Hepatocellular Carcinoma: Bangladesh Perspective. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 52-53.	0.1	8
2056	Liver Disease in Singapore. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 66-68.	0.1	6
2057	Epidemiology of Chronic Hepatitis B in Turkey. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 73-74.	0.1	20
2058	Burden of Alcoholic Liver Disease: Bhutan Scenario. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 81-82.	0.1	4
2059	F-18 Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography Findings of Isolated Gastric Tuberculosis mimicking Gastric Cancer and Lymphoma. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 93-96.	0.1	10
2060	Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan. Gut and Liver, 2016, 10, 437-45.	1.4	29
2061	PNPLA3 rs738409 Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis. Gut and Liver, 2016, 10, 456-63.	1.4	28
2062	Genetic Polymorphisms of PNPLA3 and SAMM50 Are Associated with Nonalcoholic Fatty Liver Disease in a Korean Population. Gut and Liver, 2018, 12, 316-323.	1.4	45
2063	Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression. Clinical and Experimental Hepatology, 2020, 6, 289-294.	0.6	20
2064	New Perspectives in Pediatric Nonalcoholic Fatty Liver Disease: Epidemiology, Genetics, Diagnosis, and Natural History. Pediatric Gastroenterology, Hepatology and Nutrition, 2019, 22, 501.	0.4	15
2065	ÂMonozygotic twins with NASH cirrhosis: cumulative effect of multiple single nucleotide polymorphisms?. Annals of Hepatology, 2016, 15, 277-82.	0.6	6
2066	Pediatric Nonalcoholic Fatty Liver Disease. , 0, , .		1
2067	Synonymous Codon Usage Controls Various Molecular Aspects. Genomics and Informatics, 2017, 15, 123-127.	0.4	15
2068	Correlation Between Patatin-Like Phospholipase Domain-Containing Protein 3 Gene Polymorphisms and Liver Cirrhosis in a Chinese Han Population With Chronic Hepatitis B. Hepatitis Monthly, 2014, 14, e18943.	0.1	9
2069	Association of PNPLA3 Polymorphism with Hepatocellular Carcinoma Development and Prognosis in Viral and Non-Viral Chronic Liver Diseases. Asian Pacific Journal of Cancer Prevention, 2016, 16, 8377-8382.	0.5	16

#	Article	IF	Citations
2070	The genetic architecture of NAFLD among inbred strains of mice. ELife, 2015, 4, e05607.	2.8	96
2071	Expression of SREBP-1c Requires SREBP-2-mediated Generation of a Sterol Ligand for LXR in Livers of Mice. ELife, 2017, 6, .	2.8	82
2072	Low Birth Weight Associated with a High Risk of Lifestyle-related Diseases: Fetal Programing During the Developmental Stage. Juntendo Medical Journal, 2021, 67, .	0.1	0
2073	Lrp6 Genotype affects Individual Susceptibility to Nonalcoholic Fatty Liver Disease and Silibinin Therapeutic Response via Wnt/Î²-catenin-Cyp2e1 Signaling. International Journal of Biological Sciences, 2021, 17, 3936-3953.	2.6	2
2074	Main Risk Factors of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. Journal of Oncology, 2021, 2021, 1-10.	0.6	8
2075	Genetic predictors and pathophysiological features of non-alcoholic fat liver disease. Meditsinskiy Sovet, 2021, , 78-87.	0.1	1
2077	Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of nonâ€alcoholic steatohepatitis. European Journal of Clinical Investigation, 2022, 52, e13695.	1.7	24
2078	Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 526-535.	1.8	80
2079	Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico. Lipids in Health and Disease, 2021, 20, 136.	1.2	6
2080	Hepatic Steatosis in the Mouse Model of Wilson Disease Coincides with a Muted Inflammatory Response. American Journal of Pathology, 2022, 192, 146-159.	1.9	5
2081	Clinically silent LINE 1 insertion in the PNPLA3 gene may impede genotyping of the p.I148M variant. Scientific Reports, 2021, 11, 20924.	1.6	0
2082	The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2021, 22, 11128.	1.8	58
2083	Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response. Medicina (Lithuania), 2021, 57, 1153.	0.8	1
2084	Novel therapeutic targets for cholestatic and fatty liver disease. Gut, 2022, 71, 194-209.	6.1	84
2085	Leveraging health systems data to characterize a large effect variant conferring risk for liver disease in Puerto Ricans. American Journal of Human Genetics, 2021, 108, 2099-2111.	2.6	4
2086	STE20-type kinase TAOK3 regulates hepatic lipid partitioning. Molecular Metabolism, 2021, 54, 101353.	3.0	10
2089	PNPLA3 rs738409 C>G Variant Influences the Association Between Visceral Fat and Significant Fibrosis in Biopsy-proven Nonalcoholic Fatty Liver Disease. Journal of Clinical and Translational Hepatology, 2022, 10, 439-448.	0.7	1
2090	Referral care paths for nonâ€alcoholic fatty liver diseaseâ€”Gearing up for an ever more prevalent and severe liver disease. United European Gastroenterology Journal, 2021, 9, 903-909.	1.6	8

#	Article	IF	Citations
2091	Association of genetic variations with NAFLD in lean individuals. Liver International, 2022, 42, 149-160.	1.9	33
2092	Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metabolism: Clinical and Experimental, 2022, 126, 154911.	1.5	31
2095	The Role of Liver Transplantation in theTreatment of Alcoholic Liver Disease. , 0, , .		0
2096	The Role of Inflammatory Mediators in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Pediatric Gastroenterology, Hepatology and Nutrition, 2012, 15, 74.	0.4	2
2097	Two male study groups with adiposity and hypertriglyceridemia were at risk for hypertension and alcohol use declined renal endothelium. Health, 2012, 04, 1390-1395.	0.1	2
2098	The Liver in Metabolic Syndrome. , 2014, , 27-61.		1
2099	Genetic Pleiotropies of Obesity. , 2014, , 93-111.		0
2102	Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. , 2014, , 351-370.		0
2105	Obesity and the Pathogenesis of Nonalcoholic Fatty Liver Disease. , 2014, , 121-135.		0
2106	Women with overweight, mixed hyperlipidemia, intolerance to glucose and diastolic hypertension. Health, 2014, 06, 454-467.	0.1	2
2107	Cryptogenic cirrhosis and NASH: entities in evolution and involution. Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation, 2014, 35, 65-70.	0.0	2
2108	Clinical Aspects of Nonalcoholic Fatty Liver Disease. Oxidative Stress and Disease, 2014, , 3-24.	0.3	0
2110	Association of PNPLA3 I148M Variant With Chronic Viral Hepatitis, Autoimmune Liver Diseases and Outcomes of Liver Transplantation. Hepatitis Monthly, 2015, 15, e26459.	0.1	2
2111	The Association of Low Free Testosterone with Histological Severity of Nonalcoholic Fatty Liver Disease in Japanese Men. Gastroenterology & Hepatology (Bartlesville, Okla), 2015, 2, .	0.0	2
2115	A Meta-Analysis of the Association Between the I148M Variant of Patatin-Like Phospholipase Domain Containing 3 Gene and the Presence of Chronic Hepatitis C. Hepatitis Monthly, 2015, 15, e31987.	0.1	0
2116	LDL-Related Intolerance to Glucose, Diastolic Hypertension and Additive Effects of Smoking Were Found with Three Female Study Groups. Health, 2016, 08, 230-250.	0.1	0
2118	21.ÂChronic Liver Disease. , 2016, , .		0
2119	Oxidative Stress in Nonalcoholic Steatohepatitis. , 2016, , 349-361.		0

#	Article	IF	Citations
2120	Pediatric Nonalcoholic Fatty Liver Disease. , 2016, , 293-307.		0
2123	PNPLA3 Polymorphism and Nonalcoholic Fatty Liver Disease. Biomarkers in Disease, 2017, , 667-692.	0.0	0
2124	Lipotoxicity in Non-parenchymal Liver Cells. , 2017, , 1-21.		0
2126	Pancreatic steatosis in children. Part 1. Etiology, epidemiology and pathogenesis. Gastroenterologia, 2017, 51, 46-55.	0.0	0
2128	Which Method is Superior in the Diagnosis of Nonalcoholic Fatty Liver and Steatohepatatis in Children?. Hepatitis Monthly, 2017, 17, .	0.1	0
2129	ApolipoproteinC3 Gene Variants in Nonalcoholic Fatty Liver Disease in Egypt. American Journal of Biochemistry and Molecular Biology, 2017, 8, 16-22.	0.6	1
2130	Molecular and Genetics-Based Diagnostics. , 2018, , 127-135.e2.		0
2131	Reviewing of Research Finding of Hepatitis B Virus Infection in Lao People's Democratic Republic. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 75-76.	0.1	0
2132	Natural History and Cofactors of Alcoholic Liver Disease. , 2018, , 345-350.e3.		1
2133	Multi-Omic Predictors of Steatohepatitis and Advanced Fibrosis in Children. SSRN Electronic Journal, 0, , .	0.4	0
2134	Non-Alcoholic Fatty Liver Disease. The Egyptian Journal of Hospital Medicine, 2018, 70, 570-576.	0.0	0
2135	Epidemiology, Natural History, and Evaluation of Nonalcoholic Fatty Liver Disease. , 2018, , 391-405.e3.		1
2136	Nonalcoholic Fatty Liver Disease: Identifying the Disease Burden in Sri Lanka. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 69-72.	0.1	4
2137	Postobstructive Cyst Formation in Pancreatic Duct affecting Surgical Approach. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 99-100.	0.1	0
2138	Liver Cancer in Nepal. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 63-65.	0.1	4
2139	Hepatocellular Carcinoma: Known and Emerging Risk Factors. Journal of Cancer Therapy, 2018, 09, 417-437.	0.1	0
2140	Clinical Manifestations of Liver Disease in Diabetes Mellitus. Clinical Gastroenterology, 2018, , 275-315.	0.0	0
2141	Effects of theÂPNPLA3â€“SNPÂrs738409 on Serum Transaminase levels are modified by body mass index and alcohol consumption. Biometrics & Biostatistics International Journal, 2018, 7, .	0.2	0

#	Article	IF	Citations
2142	Frontiers and prospects of pharmacotherapy for non-alcoholic fatty liver disease. World Chinese Journal of Digestology, 2019, 27, 73-79.	0.0	1
2143	Genetic Aspects of Non-Alcoholic Fatty Liver Disease. Voprosy Sovremennoi Pediatrii - Current Pediatrics, 2019, 17, 442-448.	0.1	5
2146	Detection of patatin-like phospholipase domain-containing protein 3 in nonalcoholic fatty liver disease among egyptian patients. The Egyptian Journal of Internal Medicine, 2019, 31, 273-280.	0.3	0
2147	Serum markers in diagnostics of steatohepatitis. Vnitrni Lekarstvi, 2019, 65, 577-582.	0.1	2
2148	Automated phenotyping of patients with non-alcoholic fatty liver disease reveals clinically relevant disease subtypes. , 2019, , .		4
2150	The lipid droplet as a signaling node. , 2020, , 157-172.		2
2151	Low real-world eligibility rates for nonalcoholic steatohepatitis patients for phase 3 clinical trial criteria application in a large academic health system. European Journal of Gastroenterology and Hepatology, 2021, 33, 424-429.	0.8	2
2155	Role of molecular genetic factors in pathogenesis and diagnosis of non-alcoholic fatty liver disease (literature review and own data). Medical Alphabet, 2020, , 13-19.	0.0	1
2156	Portable Ultrasonography to Assess Adult Hepatosteatosis in Rural Ecuador. Journal of Osteopathic Medicine, 2020, 120, 553-559.	0.4	0
2157	The diagnostic conundrum in non-alcoholic fatty liver disease. Exploration of Medicine, 2020, 1, .	1.5	6
2158	What Do We Know about Inequalities in NAFLD Distribution and Outcomes? A Scoping Review. Journal of Clinical Medicine, 2021, 10, 5019.	1.0	23
2160	Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review. Journal of Gastroenterology, 2021, 56, 1045-1061.	2.3	18
2161	Liver Transplantation and NAFLD/NASH. , 2020, , 343-362.		0
2162	Pathogenesis of Nonalcoholic Fatty Liver Disease in Children and Adolescents. Advances in Clinical Medicine, 2020, 10, 360-366.	0.0	0
2163	Obesity and NAFLD: Same Problem?. , 2020, , 1-14.		0
2165	Alternative Approaches to Ameliorate Nonalcoholic Fatty Liver Disease: Phyllanthus niruri Clinicopathological Significance; A review. Zagazig Veterinary Journal, 2020, 48, 399-413.	0.1	0
2167	Genes and NAFLD/NASH Progression. , 2020, , 29-47.		0
2168	Mechanisms of Fibrogenesis in NASH. , 2020, , 97-127.		0

#	Article	IF	Citations
2169	Nonalcoholic Fatty Liver Disease: A Wide Spectrum Disease. , 2020, , 273-284.		3
2170	HCC in Patients with NAFLD/NASH. , 2020, , 191-203.		0
2171	Biomarkers in Pediatric NAFLD. , 2020, , 69-88.		0
2172	Extracellular Vesicles in Non-alcoholic Fatty Liver Disease: Key Players in Disease Pathogenesis and Promising Biomarker Tools. , 2020, , 157-180.		0
2173	Genetic Confounders of Liver Stiffness and Controlled Attenuation Parameter. , 2020, , 277-295.		1
2174	PNPLA3 and TM6SF2, but Not MBOAT7, Are Associated with Steatosis and HBV Viral Persistence in Pakistani Population. Jundishapur Journal of Microbiology, 2020, 13, .	0.2	0
2175	Liver Cirrhosis as the Outcome of Non-Alcoholic Fatty Liver Disease Associated with PNPLA3 Gene RS738409 Polymorphism. Russian Archives of Internal Medicine, 2020, 10, 148-154.	0.0	1
2176	Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. Cell Reports Medicine, 2021, 2, 100437.	3.3	56
2177	Metabolic dysfunctionâ€associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middleâ€aged and older US population. Hepatology Research, 2022, 52, 176-186.	1.8	8
2178	Association of <i>PNPLA3</i> I148M with Liver Disease Biomarkers in Latinos. Human Heredity, 2021, 86, 21-27.	0.4	4
2179	The Role of Inflammatory Mediators in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Pediatric Gastroenterology, Hepatology and Nutrition, 2012, 15, 74.	0.4	0
2180	Liver Cirrhosis as the Outcome of Non-Alcoholic Fatty Liver Disease Associated with PNPLA3 Gene RS738409 Polymorphism. Russian Archives of Internal Medicine, 2020, 10, 148-154.	0.0	0
2182	Phenotypic Differences Between Polygenic and Monogenic Hypobetalipoproteinemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, e63-e71.	1.1	12
2183	WOMEN IN THE AGE GROUP OF 20 TO 50 YEARS ARE LESS PRONE TO DEVELOP NAFLD IN KERALA, SOUTH INDIA: A POPULATION BASED STUDY. , 2020, , 1-4.		0
2184	Genome-Wide Association Studies: "SNPing" Away at Liver Disease. Gastroenterology and Hepatology, 2011, 7, 407-9.	0.2	0
2186	Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterology and Hepatology, 2012, 8, 661-8.	0.2	30
2187	Genetic variation I148M in patatin-like phospholipase 3 gene and risk of non-alcoholic fatty liver disease among Filipinos. International Journal of Clinical and Experimental Medicine, 2014, 7, 2129-36.	1.3	10
2188	Association between PNPLA3 rs738409 polymorphisms and risk of hepatocellular carcinoma and its development in patients with cirrhosis: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 6638-49.	1.3	4

#	Article	IF	Citations
2189	The prevalence and adverse profiles of fatty liver disease among different ethnic public servants in Urumqi of Xinjiang Uygur Autonomous Region in China. International Journal of Clinical and Experimental Medicine, 2015, 8, 9218-28.	1.3	0
2190	Overexpression of variant PNPLA3 gene at I148M position causes malignant transformation of hepatocytes via IL-6-JAK2/STAT3 pathway in low dose free fatty acid exposure: a laboratory investigation in vitro and in vivo. American Journal of Translational Research (discontinued), 2016, 8, 1319-38.	0.0	7
2191	Topological and functional analysis of nonalcoholic steatohepatitis through protein interaction mapping. Gastroenterology and Hepatology From Bed To Bench, 2016, 9, S23-S28.	0.6	2
2193	The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome. , 2018, 1, 24-33.		3
2194	NASH: The Emerging Most Common Form of Chronic Liver Disease. Missouri Medicine, 2018, 115, 225-229.	0.3	21
2195	Genetic Factors Involved in the Development and Progression of Nonalcoholic Fatty Liver Disease. Current Health Sciences Journal, 2015, 41, 297-301.	0.2	0
2197	Fatty liver disease in persons with HIV infection. Topics in Antiviral Medicine, 2019, 27, 75-82.	0.1	16
2198	Non-Alcoholic Fatty Liver Disease, an Overview. Integrative Medicine, 2019, 18, 42-49.	0.1	8
2199	Implications of Nonalcoholic Fatty Liver Disease on Pregnancy and Maternal and Child Outcomes. Gastroenterology and Hepatology, 2019, 15, 221-228.	0.2	3
2200	Automated phenotyping of patients with non-alcoholic fatty liver disease reveals clinically relevant disease subtypes. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2020, 25, 91-102.	0.7	4
2201	Current Management and Future Treatment of Alcoholic Hepatitis. Gastroenterology and Hepatology, 2020, 16, 178-189.	0.2	1
2202	Genetics of Nonalcoholic Steatohepatitis. Gastroenterology and Hepatology, 2020, 16, 651-653.	0.2	0
2203	Correlations between PNPLA3 Gene Polymorphisms and NAFLD in Type 2 Diabetic Patients. Medicina (Lithuania), 2021, 57, 1249.	0.8	5
2204	Network Pharmacology Exploration Reveals Anti-Apoptosis as a Common Therapeutic Mechanism for Non-Alcoholic Fatty Liver Disease Treated with Blueberry Leaf Polyphenols. Nutrients, 2021, 13, 4060.	1.7	7
2205	Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers, 2021, 13, 5844.	1.7	27
2206	The Neglected Role of Bile Duct Epithelial Cells in NASH. Seminars in Liver Disease, 2022, 42, 034-047.	1.8	8
2207	Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. Frontiers in Immunology, 2021, 12, 667354.	2.2	7
2208	An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis. Molecular Therapy, 2022, 30, 1329-1342.	3.7	18

#	Article	IF	Citations
2209	New Horizons in Paediatric Hepatology: A Glimpse of the Future. , 2022, , 1063-1069.		0
2210	Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World Journal of Hepatology, 2021, 13, 1584-1610.	0.8	20
2211	Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nature Reviews Endocrinology, 2022, 18, 55-66.	4.3	82
2212	Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE). PLoS ONE, 2021, 16, e0260320.	1.1	10
2213	Lipolysis: cellular mechanisms for lipid mobilization from fat stores. Nature Metabolism, 2021, 3, 1445-1465.	5.1	208
2214	Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease. Nutrients, 2021, 13, 4077.	1.7	5
2215	Linking liver metabolic and vascular disease via bile acid signaling. Trends in Molecular Medicine, 2022, 28, 51-66.	3.5	16
2216	Genetic susceptibility to hepatocellular carcinoma in chromosome 22q13.31, findings of a genomeâ€wide association study. JGH Open, 2021, 5, 1363-1372.	0.7	9
2217	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in InÂVitro Models. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 759-788.	2.3	44
2218	Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. Clinical and Molecular Hepatology, 2022, 28, 183-195.	4.5	6
2219	Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chinese Medical Journal, 2021, 134, 2911-2921.	0.9	21
2220	Sex-Specific Differences in the Association Between Race/Ethnicity and NAFLD Among US Population. Frontiers in Medicine, 2021, 8, 795421.	1.2	12
2221	InÂvitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications. IScience, 2022, 25, 103549.	1.9	44
2222	Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. Cells, 2021, 10, 3401.	1.8	17
2223	Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metabolism Open, 2021, 12, 100149.	1.4	54
2225	Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by metaâ€analysis: Focusing on the nonâ€overlap groups. Liver International, 2022, 42, 277-287.	1.9	60
2226	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. Lancet Oncology, The, 2022, 23, 161-171.	5.1	36
2227	The metabolic triad of nonâ€alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. Diabetes, Obesity and Metabolism, 2022, 24, 15-27.	2.2	24

#	Article	IF	Citations
2228	Metabolic dysfunctionâ€“associated fatty liver disease and the risk of 24 specific cancers. Metabolism: Clinical and Experimental, 2022, 127, 154955.	1.5	34
2229	Potentialities of nanomaterials for the management and treatment of metabolic syndrome: A new insight. Materials Today Advances, 2022, 13, 100198.	2.5	25
2230	An Overview on Diagnosis and Management of Non-alcoholic Fatty Liver Disease. International Journal of Pharmaceutical Research and Allied Sciences, 2021, 10, 144-148.	0.1	0
2231	PNPLA3 downregulation exacerbates the fibrotic response in human hepatic stellate cells. PLoS ONE, 2021, 16, e0260721.	1.1	3
2232	Association of lifestyle behaviors with non-alcoholic fatty liver disease and advanced fibrosis detected by transient elastography among Hispanic/Latinos adults in the U.S.. Ethnicity and Health, 2023, 28, 299-312.	1.5	10
2233	Phenome-Wide Association Analysis Reveals Novel Links Between Genetically Determined Levels of Liver Enzymes and Disease Phenotypes. Phenomics, 2022, 2, 295-311.	0.9	9
2234	PSD3 downregulation confers protection against fatty liver disease. Nature Metabolism, 2022, 4, 60-75.	5.1	15
2236	HSD17B13: A Potential Therapeutic Target for NAFLD. Frontiers in Molecular Biosciences, 2021, 8, 824776.	1.6	18
2237	Healthy dietary patterns and metabolic dysfunction-associated fatty liver disease in less-developed ethnic minority regions: a large cross-sectional study. BMC Public Health, 2022, 22, 118.	1.2	8
2238	Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis. Biomolecules, 2022, 12, 105.	1.8	23
2239	Non-invasive tests of non-alcoholic fatty liver disease. Chinese Medical Journal, 2022, 135, 532-546.	0.9	17
2240	Hepatic TM6SF2 Is Required for Lipidation of VLDL in a Pre-Golgi Compartment in Mice and Rats. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 879-899.	2.3	36
2241	Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2022, , 1-11.	1.4	8
2242	NAFLDâ€related gene polymorphisms and allâ€cause and causeâ€specific mortality in an Asian population: the Shanghai Changfeng Study. Alimentary Pharmacology and Therapeutics, 2022, 55, 705-721.	1.9	17
2243	Liver specific, systemic and genetic contributors to alcohol-related liver disease progression. Zeitschrift Fur Gastroenterologie, 2022, 60, 36-44.	0.2	2
2244	Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. Clinical Gastroenterology and Hepatology, 2023, 21, 370-379.	2.4	30
2245	Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown. Nutrients, 2022, 14, 556.	1.7	10
2246	Clinical, Laboratory, and Histologic Correlates of Serum Antinuclear Antibody in Hispanic Pediatric Patients With Nonalcoholic Fatty Liver Disease. American Journal of Clinical Pathology, 2022, 158, 221-227.	0.4	2

#	Article	IF	Citations
2247	Non-alcoholic fatty liver disease (NAFLD) in Filipino North American patients: Results from a multi-ethnic cohort. Canadian Liver Journal, 2022, 5, 4-13.	0.3	2
2248	The influence of host genetics on liver microbiome composition in patients with NAFLD. EBioMedicine, 2022, 76, 103858.	2.7	13
2249	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). Canadian Liver Journal, 2022, 5, 61-90.	0.3	7
2250	Association between rs738408, rs738409 and rs139051polymorphisms in PNPLA3 gene and non-alcoholic fatty liver disease. Gene Reports, 2022, 26, 101472.	0.4	2
2251	Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-stratification in Patients with Hepatitis C Cirrhosis.. Clinical and Translational Gastroenterology, 2022, Publish Ahead of Print, .	1.3	2
2252	A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2022, 6, 1032-1044.	2.0	6
2253	The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease. Hepatology Research, 2022, 52, 508-521.	1.8	1
2254	Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics, 2022, 12, 407.	1.3	22
2255	Single Nucleotide Polymorphism of Genes Associated with Metabolic Fatty Liver Disease. Journal of Oncology, 2022, 2022, 1-6.	0.6	7
2257	Effects of Moderate Alcohol Consumption in Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2022, 11, 890.	1.0	7
2258	Perturbation of Wnt/Î²â€catenin signaling and sexual dimorphism in nonâ€alcoholic fatty liver disease. Hepatology Research, 2022, 52, 433-448.	1.8	2
2259	Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study. Gene, 2022, 820, 146235.	1.0	2
2260	Diet therapy in patients with metabolically associated fatty liver disease: what is the choice for particular patient?. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, , 109-117.	0.1	0
2261	Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis. Alimentary Pharmacology and Therapeutics, 2021, 53, 830-843.	1.9	9
2262	A small supernumerary marker chromosome resulting in mosaic partial tetrasomy 4q26-q31.21 in a foetus with multiple congenital malformations. Journal of Genetics, 2019, 98, .	0.4	1
2263	Computational Pipeline for Next-Generation Sequencing (NGS) Studies in Genetics of NASH. Methods in Molecular Biology, 2022, 2455, 203-222.	0.4	2
2264	Association between rs738409 and rs2896019 single nucleotide polymorphisms of phospholipase domain-containing protein 3 and susceptibility to nonalcoholic fatty liver disease in Greek children and adolescents. Annals of Gastroenterology, 2022, , .	0.4	2
2265	Generation of a Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease. Methods in Molecular Biology, 2022, 2455, 19-30.	0.4	4

#	Article	IF	Citations
2266	Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Nature Reviews Drug Discovery, 2022, 21, 417-439.	21.5	24
2268	Dose-Response Associations of Metabolic Score for Insulin Resistance Index with Nonalcoholic Fatty Liver Disease among a Nonobese Chinese Population: Retrospective Evidence from a Population-Based Cohort Study. Disease Markers, 2022, 2022, 1-10.	0.6	19
2269	Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico. Clinical Liver Disease, 2022, 19, 68-72.	1.0	3
2270	The Molecular Brakes of Adipose Tissue Lipolysis. Frontiers in Physiology, 2022, 13, 826314.	1.3	23
2271	Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis. International Journal of Molecular Sciences, 2022, 23, 2636.	1.8	11
2273	Hepatocyte nuclear factor 4Î± in the pathogenesis of non-alcoholic fatty liver disease. Chinese Medical Journal, 2022, 135, 1172-1181.	0.9	13
2274	Clinical Intervention to Reduce Dietary Sugar Does Not Affect Liver Fat in Latino Youth, Regardless of PNPLA3 Genotype: A Randomized Controlled Trial. Journal of Nutrition, 2022, 152, 1655-1665.	1.3	8
2276	Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?. World Journal of Hepatology, 2022, 14, 354-371.	0.8	4
2277	Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank. Hepatology International, 2022, 16, 325-336.	1.9	9
2278	Metabolic dysfunction-related liver disease as a risk factor for cancer. BMJ Open Gastroenterology, 2022, 9, e000817.	1.1	10
2279	NAFLD in normal weight individuals. Diabetology and Metabolic Syndrome, 2022, 14, 45.	1.2	20
2280	Plasma and aqueous humor levels of adiponutrin and pannexin 1 in patients with and without diabetic retinopathy. International Journal of Ophthalmology, 2022, 15, 453-460.	0.5	1
2281	A cholestatic pattern predicts major liverâ€related outcomes in patients with nonâ€alcoholic fatty liver disease. Liver International, 2022, 42, 1037-1048.	1.9	4
2283	The association between rs1260326 with the risk of NAFLD and the mediation effect of triglyceride on NAFLD in the elderly Chinese Han population. Aging, 2022, 14, 2736-2747.	1.4	5
2284	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). GastroenterologÃa Y HepatologÃa, 2022, 45, 724-734.	0.2	3
2285	Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. Journal of Obesity and Metabolic Syndrome, 2022, 31, 17-27.	1.5	39
2286	PNPLA3 rs 738409 and Other Nongenetic Factors Associated with Hepatic Steatosis Estimated by Magnetic Resonance Imaging Proton Density Fat Fraction in Adult Greek Subjects with Type 2 Diabetes Mellitus. Metabolic Syndrome and Related Disorders, 2022, 20, 124-131.	0.5	2
2287	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology, 2022, 76, 1121-1134.	3.6	31

#	Article	IF	Citations
2288	Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. Frontiers in Medicine, 2022, 9, 864570.	1.2	5
2289	Metabolic and genetic contributions to NAFLD: Really distinct and homogeneous?. Journal of Hepatology, 2022, 76, 498-500.	1.8	7
2290	The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease. Clinics in Liver Disease, 2022, 26, 213-227.	1.0	6
2291	A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population. Hepatology International, 2022, 16, 702-711.	1.9	4
2292	Small-Molecule Inhibitors Targeting Lipolysis in Human Adipocytes. Journal of the American Chemical Society, 2022, 144, 6237-6250.	6.6	16
2293	Serum proteome profiling reveals differentially expressed proteins between subjects with metabolically healthy obesity and nonalcoholic fatty liver disease. Journal of Proteomics, 2022, 260, 104556.	1.2	1
2294	Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2022, 130, 155179.	1.5	2
2295	The impact of singleâ€‘nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with directâ€‘acting antiviral drugs for hepatitis C infection. Biomedical Reports, 2021, 16, 9.	0.9	3
2296	Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis. Biomedicines, 2022, 10, 15.	1.4	21
2297	New progress in research of intestinal microbiota in fatty liver disease. World Chinese Journal of Digestology, 2021, 29, 1355-1361.	0.0	0
2298	Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD). Cureus, 2021, 13, e20776.	0.2	6
2299	PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opinion on Therapeutic Targets, 2021, 25, 1033-1043.	1.5	22
2300	Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study. BMC Gastroenterology, 2021, 21, 458.	0.8	2
2301	Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications. Current Opinion in Lipidology, 2022, 33, 95-102.	1.2	6
2302	De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation. World Journal of Hepatology, 2021, 13, 1991-2004.	0.8	3
2303	Metabolic Associated Fatty Liver Disease in Childrenâ€”From Atomistic to Holistic. Biomedicines, 2021, 9, 1866.	1.4	3
2304	Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities. Frontiers in Endocrinology, 2021, 12, 777075.	1.5	8
2305	Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genomics, 2021, 1, 100066.	3.0	34

#	Article	IF	Citations
2306	Nonâ€Invasive Approaches to Estimate Liver Steatosis and Stiffness in Children With Nonâ€Alcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2022, 74, 495-502.	0.9	1
2307	Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review. Journal of Clinical Medicine, 2021, 10, 5721.	1.0	24
2308	The Association Between Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease Diagnosis Varies by Race. Metabolic Syndrome and Related Disorders, 2022, , .	0.5	2
2309	Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17â€beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms. Hepatology Communications, 2022, 6, 1934-1948.	2.0	18
2310	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 101161ATV0000000000000153.	1.1	167
2311	PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features. Hepatology, 2022, 76, 1482-1494.	3.6	9
2312	Relationship between NAFLD and coronary artery disease: A Mendelian randomization study. Hepatology, 2023, 77, 230-238.	3.6	45
2313	A good step toward low-cost prognostication of liver-related outcome awaits more validation. Journal of Hepatology, 2022, 77, 887-889.	1.8	4
2314	Impact of PNPLA3 p.I148M and Hepatic Steatosis on Long-Term Outcomes for Hepatocellular Carcinoma and HBsAg Seroclearance in Chronic Hepatitis B. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 301-313.	1.8	11
2315	Paediatric non-alcoholic fatty liver disease: an approach to pathological evaluation. Journal of Clinical Pathology, 2022, 75, 443-451.	1.0	4
2316	Potential Therapeutic Targets and Promising Agents for Combating NAFLD. Biomedicines, 2022, 10, 901.	1.4	6
2333	The Kidney in Liver Disease. , 0, , 619-638.		0
2334	Editorial: the polygenic risk of cirrhosis development. Alimentary Pharmacology and Therapeutics, 2021, 53, 849-850.	1.9	0
2335	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. Hypertension, 2022, 79, 1319-1326.	1.3	50
2337	Impact of comorbid hepatic steatosis on treatment of chronic hepatitis C in Japanese patients and the relationship with genetic polymorphism of IL28B, PNPLA3 and LDL receptor. Acta Medica Okayama, 2014, 68, 17-22.	0.1	7
2338	Nonalcoholic Fatty Liver Disease in Children.. Gastroenterology and Hepatology, 2021, 17, 579-587.	0.2	0
2339	NAFLDâ€related hepatocellular carcinoma: The growing challenge. Hepatology, 2023, 77, 323-338.	3.6	62
2340	Liver Steatosis: A Marker of Metabolic Risk in Children. International Journal of Molecular Sciences, 2022, 23, 4822.	1.8	6

#	Article	IF	Citations
2341	Serum Macâ€2 binding protein level predicts the development of liverâ€related events and colorectal cancer in patients with NAFLD. Hepatology Communications, 2022, 6, 1527-1536.	2.0	3
2342	Influence of Type 2 Diabetes in the Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms in NASH Advanced Liver Fibrosis. Biomedicines, 2022, 10, 1015.	1.4	7
2343	A minority of somatically mutated genes in preâ€existing fatty liver disease have prognostic importance in the development of <scp>NAFLD</scp>. Liver International, 2022, 42, 1823-1835.	1.9	3
2344	Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. Fertility and Sterility, 2022, 117, 897-911.	0.5	6
2345	Endoplasmic reticulum stress in nonalcoholic (metabolic associated) fatty liver disease (NAFLD/MAFLD). Journal of Cellular Biochemistry, 2022, 123, 1585-1606.	1.2	23
2346	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. Endocrine Practice, 2022, 28, 528-562.	1.1	323
2347	Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics. World Journal of Clinical Pediatrics, 2022, 11, 221-238.	0.6	7
2348	Prevalence and clinical-epidemiologic characteristics of a Mexican population with metabolic (dysfunction) associated fatty liver disease: An open population study. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2022, , .	0.1	2
2349	Nonalcoholic fatty liver disease risk and histologic severity are associated with genetic polymorphisms in children. Hepatology, 2023, 77, 197-212.	3.6	8
2350	Non-Alcoholic Fatty Liver Disease in Long-Term Type 2 Diabetes: Role of rs738409 PNPLA3 and rs499765 FGF21 Polymorphisms and Serum Biomarkers. Molecules, 2022, 27, 3193.	1.7	5
2351	Dynamic human liver proteome atlas reveals functional insights into disease pathways. Molecular Systems Biology, 2022, 18, e10947.	3.2	22
2352	Impact of non-invasive biomarkers on hepatology practice: Past, present and future. Journal of Hepatology, 2022, 76, 1362-1378.	1.8	78
2353	From fatty liver to nonalcoholic steatohepatitis with fibrosis. , 2022, , 147-173.		1
2354	Impact of Evolutionary Changes in Nonalcoholic Fatty Liver Disease on Lung Function Decline. Gut and Liver, 2023, 17, 139-149.	1.4	1
2355	Nonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study. Metabolism: Clinical and Experimental, 2022, 133, 155220.	1.5	23
2356	GCKIII kinases in lipotoxicity: Roles in NAFLD and beyond. Hepatology Communications, 2022, 6, 2613-2622.	2.0	4
2357	Pregnancy and Metabolic-associated Fatty Liver Disease: A Clinical Update. Journal of Clinical and Translational Hepatology, 2022, 10, 947-954.	0.7	7
2358	Contribution of a genetic risk score to ethnic differences in fatty liver disease. Liver International, 2022, 42, 2227-2236.	1.9	16

#	Article	IF	Citations
2359	Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. Antioxidants, 2022, 11, 1060.	2.2	2
2360	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nature Genetics, 2022, 54, 761-771.	9.4	68
2361	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. Hormones, 2022, 21, 349-368.	0.9	12
2362	Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication. Journal of Medical Virology, 2022, 94, 5007-5014.	2.5	1
2363	Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. Journal of Hepatocellular Carcinoma, 0, Volume 9, 477-496.	1.8	13
2364	Hypothesis Testing in High-Dimensional Instrumental Variables Regression With an Application to Genomics Data. Statistica Sinica, 2023, , .	0.2	0
2365	NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook. Antioxidants, 2022, 11, 1131.	2.2	20
2366	The Role of Chronic Liver Diseases in the Emergence and Recurrence of Hepatocellular Carcinoma: An Omics Perspective. Frontiers in Medicine, 0, 9, .	1.2	2
2367	Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants. PLoS ONE, 2022, 17, e0269641.	1.1	5
2368	Metabolic-associated fatty liver disease from childhood to adulthood: State of art and future directions. World Journal of Hepatology, 2022, 14, 1087-1098.	0.8	1
2369	Mediterranean Diet: The Beneficial Effects of Lycopene in Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2022, 11, 3477.	1.0	11
2370	African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population. Annals of Hepatology, 2022, 27, 100728.	0.6	5
2371	Apolipoprotein F is reduced in humans with steatosis and controls plasma triglycerideâ€rich lipoprotein metabolism. Hepatology, 2023, 77, 1287-1302.	3.6	3
2372	I148M variant of PNPLA3-gene is not associated with metabolic syndrome in patients with NAFLD in the Indian ethnicity. , 2022, 33, 201073.		2
2373	Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheepâ€™s Clothing?. Current Oncology, 2022, 29, 4478-4510.	0.9	6
2374	Statins in Alcoholic and Non-Alcoholic Fatty Liver Disease and Chronically Elevated Liver Enzymes. International Journal of Clinical Medicine, 2022, 13, 229-252.	0.1	1
2375	The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. Journal of Clinical Medicine, 2022, 11, 3649.	1.0	19
2376	Genetic Factors Associated with Response to Vitamin E Treatment in NAFLD. Antioxidants, 2022, 11, 1284.	2.2	3

#	Article	IF	Citations
2378	KHK, PNPLA3 and PPAR as Novel Targets for the Anti-Steatotic Action of Bempedoic Acid. Biomedicines, 2022, 10, 1517.	1.4	6
2379	Epigenetic Aspects and Prospects in Autoimmune Hepatitis. Frontiers in Immunology, 0, 13, .	2.2	6
2380	Relatively Poor Long-term Outcomes Following Liver Transplantation for NASH in the United States. Transplantation, 2022, 106, 2006-2018.	0.5	8
2381	Multiomics technologies: role in disease biomarker discoveries and therapeutics. Briefings in Functional Genomics, 2023, 22, 76-96.	1.3	5
2382	Integrated Bioinformatics Analysis Identifies Robust Biomarkers and Its Correlation With Immune Microenvironment in Nonalcoholic Fatty Liver Disease. Frontiers in Genetics, 0, 13, .	1.1	3
2383	Prevalence, coâ€morbidities, and inâ€hospital mortality of patients hospitalized with alcoholâ€associated hepatitis in the United States from 2015 to 2019. Alcoholism: Clinical and Experimental Research, 2022, 46, 1472-1481.	1.4	9
2384	Mechanism and therapeutic strategy of hepatic TM6SF2-deficient non-alcoholic fatty liver diseases via in vivo and in vitro experiments. World Journal of Gastroenterology, 2022, 28, 2937-2954.	1.4	8
2385	Altered branched-chain Î±-keto acid metabolism is a feature of NAFLD in individuals with severe obesity. JCI Insight, 2022, 7, .	2.3	16
2386	The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products. Frontiers in Pharmacology, 0, 13, .	1.6	11
2387	Non-alcoholic fatty liver disease and the impact of genetic, epigenetic and environmental factors in the offspring. World Journal of Gastroenterology, 2022, 28, 2890-2899.	1.4	7
2388	Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives. World Journal of Gastroenterology, 2022, 28, 3410-3421.	1.4	7
2389	HSPA8 Single-Nucleotide Polymorphism Is Associated with Serum HSC70 Concentration and Carotid Artery Atherosclerosis in Nonalcoholic Fatty Liver Disease. Genes, 2022, 13, 1265.	1.0	1
2390	Genetic variation inTERTmodifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut, 2023, 72, 381-391.	6.1	19
2391	Hepatic patatinâ€like phospholipase domainâ€containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans. Hepatology Communications, 2022, 6, 2689-2701.	2.0	5
2392	Metabolic analysis as a driver for discovery, diagnosis, and therapy. Cell, 2022, 185, 2678-2689.	13.5	51
2393	Metabolic dysfunction-associated fatty liver disease in obese youth with insulin resistance and type 2 diabetes. Current Opinion in Pediatrics, 2022, 34, 414-422.	1.0	1
2394	Recent advances in lean NAFLD. Biomedicine and Pharmacotherapy, 2022, 153, 113331.	2.5	34
2395	Germline Mutations in CIDEB and Protection against Liver Disease. New England Journal of Medicine, 2022, 387, 332-344.	13.9	42

#	Article	IF	Citations
2396	Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review. KreativnaÃ¢ HirurgiÃ¢ I OnkologiÃ¢, 2022, 12, 139-150.	0.1	2
2397	Liver biomarkers, genetic and lifestyle risk factors in relation to risk of cardiovascular disease in Chinese. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
2398	The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. Frontiers in Genetics, 0, 13, .	1.1	16
2399	Health disparities in chronic liver disease. Hepatology, 2023, 77, 1382-1403.	3.6	36
2400	Shared Mechanisms between Cardiovascular Disease and NAFLD. Seminars in Liver Disease, 2022, 42, 455-464.	1.8	11
2401	Interplay between fatty acids, SCD, mTORC1 and YAP/TAZ in promoting hepatocellular carcinoma. , 2022, , .		1
2402	Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification. Atherosclerosis, 2022, 357, 51-59.	0.4	13
2404	PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study. BMC Gastroenterology, 2022, 22, .	0.8	2
2405	Characterization of Nutrient Intake in Biopsy-Confirmed NAFLD Patients. Nutrients, 2022, 14, 3453.	1.7	2
2406	Association of rs738409 Polymorphism in Adiponutrin Gene with Liver Steatosis and Atherosclerosis Risk Factors in Greek Children and Adolescents. Nutrients, 2022, 14, 3452.	1.7	1
2407	Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease. IScience, 2022, 25, 104949.	1.9	12
2408	NAFLD: genetics and its clinical implications. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 102003.	0.7	14
2409	Non-Alcoholic Fatty Liver Disease and Steatohepatitis. , 2023, , 610-621.		2
2410	Gut microbiome in non-alcoholic fatty liver disease. Zdrowie Publiczne, 2022, 132, 11-15.	0.2	0
2411	Pathophysiologie: Genetik. , 2022, , 75-92.		0
2412	Prevalence of non-alcoholic fatty liver disease (NAFLD) in a cohort of patients with type 2 diabetes: the PHIGNA-DM2 study. Nutricion Hospitalaria, 2022, , .	0.2	2
2413	Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction. , 2022, 2, 12.		19
2414	Recent advances in liver organoids and their use in in vitro modeling of non-alcoholic fatty liver disease. Organoid, 0, 2, e6.	0.0	0

#	Article	IF	Citations
2415	Obesity and cancers of the liver, gallbladder, and pancreas. , 2023, , 155-177.		1
2416	Molecular Changes in Relation to Alcohol Consumption and Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2022, 23, 9679.	1.8	9
2417	African genetic ancestry and protection against fatty liver disease. Liver International, 2022, 42, 2122-2123.	1.9	4
2418	IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease. Journal of Hepatology, 2023, 78, 45-56.	1.8	29
2419	Identification of two pathways mediating protein targeting from ER to lipid droplets. Nature Cell Biology, 2022, 24, 1364-1377.	4.6	29
2420	Natural flavonoids: Potential therapeutic strategies for non-alcoholic fatty liver disease. Frontiers in Pharmacology, 0, 13, .	1.6	15
2421	Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology, 2023, 77, 1404-1427.	3.6	43
2422	Knockdown of hepatocyte Perilipin-3 mitigates hepatic steatosis and steatohepatitis caused by hepatocyte CGI-58 deletion in mice. Journal of Molecular Cell Biology, 2022, 14, .	1.5	3
2423	Racial and ethnic differences in diet quality and food insecurity among adults with fatty liver and significant fibrosis: a U.S. populationâ€based study. Alimentary Pharmacology and Therapeutics, 2022, 56, 1383-1393.	1.9	9
2424	Molecular Advances in MAFLDâ€”A Link between Sphingolipids and Extracellular Matrix in Development and Progression to Fibrosis. International Journal of Molecular Sciences, 2022, 23, 11380.	1.8	1
2425	The impact of polymorphism in PNPLA3 and TM6SF2 genes on the susceptibility and survival of hepatitis C-related hepatocellular carcinoma. Egyptian Liver Journal, 2022, 12, .	0.3	0
2426	Modelling metabolic diseases and drug response using stem cells and organoids. Nature Reviews Endocrinology, 2022, 18, 744-759.	4.3	30
2427	Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice. Cell Reports, 2022, 40, 111321.	2.9	7
2428	Effect of common genetic variants on the risk of cirrhosis in nonâ€alcoholic fatty liver disease during 20â€‰years of followâ€up. Liver International, 2022, 42, 2769-2780.	1.9	13
2429	Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality. JAMA Network Open, 2022, 5, e2234221.	2.8	9
2430	The role of oxidized lipid species in insulin resistance and NASH in children. Frontiers in Endocrinology, 0, 13, .	1.5	1
2431	The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition. Expert Review of Clinical Pharmacology, 2022, 15, 1199-1208.	1.3	11
2432	Update on genetics and epigenetics in metabolic associated fatty liver disease. Therapeutic Advances in Endocrinology and Metabolism, 2022, 13, 204201882211321.	1.4	7

#	Article	IF	Citations
2433	Lifestyle and Genetic Modifiers of Liver Disease Progression. , 2022, , 29-41.		0
2434	Genetic variants associated with circulating liver injury markers in Mexican Americans, a population at risk for non-alcoholic fatty liver disease. Frontiers in Genetics, 0, 13, .	1.1	3
2436	Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review. Nutrients, 2022, 14, 4556.	1.7	16
2437	Different Types of Dietary Fat and Fructose Interactions Result in Distinct Metabolic Phenotypes in Male Mice. Journal of Nutritional Biochemistry, 2023, 111, 109189.	1.9	2
2438	Dennd5b-Deficient Mice are Resistant to PCSK9-Induced Hypercholesterolemia and Diet-Induced Hepatic Steatosis. Journal of Lipid Research, 2022, 63, 100296.	2.0	2
2439	The association of nonâ€alcoholic fatty liver disease between parents and adolescent children. Alimentary Pharmacology and Therapeutics, 2023, 57, 245-252.	1.9	8
2440	NAFLD in Polycystic Ovary Syndrome: Association with PNPLA3 and Metabolic Features. Biomedicines, 2022, 10, 2719.	1.4	1
2441	Genetic Aspects of Micronutrients Important for Inflammatory Bowel Disease. Life, 2022, 12, 1623.	1.1	3
2442	Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 37-49.	8.2	94
2443	Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective. Seminars in Liver Disease, 2022, 42, 434-445.	1.8	3
2444	Wnt/betaâ€catenin signaling and its modulators in nonalcoholic fatty liver diseases. Hepatobiliary and Pancreatic Diseases International, 2023, 22, 333-345.	0.6	7
2445	ABHD5â€"A Regulator of Lipid Metabolism Essential for Diverse Cellular Functions. Metabolites, 2022, 12, 1015.	1.3	8
2446	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clinical and Molecular Hepatology, 2023, 29, 77-98.	4.5	27
2447	Lipid droplet turnover at the lysosome inhibits growth of hepatocellular carcinoma in a BNIP3-dependent manner. Science Advances, 2022, 8, .	4.7	15
2448	Multiomics study of nonalcoholic fatty liver disease. Nature Genetics, 2022, 54, 1652-1663.	9.4	53
2449	Mouse models of nonalcoholic steatohepatitis and their application to new drug development. Archives of Pharmacal Research, 2022, 45, 761-794.	2.7	5
2450	Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease. Hepatology Research, 2023, 53, 184-195.	1.8	3
2451	Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice. Molecular Metabolism, 2022, 66, 101639.	3.0	4

#	Article	IF	Citations
2452	Assessing causal relationships between sarcopenia and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study. Frontiers in Nutrition, 0, 9, .	1.6	6
2453	Noninvasive tests for nonalcoholic fatty liver disease in a multiâ€ethnic population: The HELIUS study. Hepatology Communications, 2023, 7, e2109-e2109.	2.0	1
2454	Review article: the role of <scp>HSD17B13</scp> on global epidemiology, natural history, pathogenesis and treatment of <scp>NAFLD</scp>. Alimentary Pharmacology and Therapeutics, 2023, 57, 37-51.	1.9	17
2455	Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis. Journal of Hepatology, 2023, 78, 238-246.	1.8	14
2456	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). GastroenterologÃa Y HepatologÃa (English Edition), 2022, 45, 724-734.	0.0	0
2457	The link between liver fat and cardiometabolic diseases is highlighted by genome-wide association study of MRI-derived measures of body composition. Communications Biology, 2022, 5, .	2.0	4
2458	A nem alkoholos zsÃ₹mÃ¡jbetegsÃ©g Ã©s a 2-es tÃ₱usÃº cukorbetegsÃ©g.. Orvosi Hetilap, 2022, 163, 815-825.	0.1	4
2459	Different effects of low muscle mass on the risk of nonâ€alcoholic fatty liver disease and hepatic fibrosis in a prospective cohort. Journal of Cachexia, Sarcopenia and Muscle, 2023, 14, 260-269.	2.9	4
2461	Regulators of Genetic Risk for the Progression of Non-alcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Reconstruction of Transcriptional Network and Signature-Based Metabolic Profiling. , 2022, , 193-227.		0
2462	Emerging role of aging in the progression of NAFLD to HCC. Ageing Research Reviews, 2023, 84, 101833.	5.0	21
2463	Cancer of the Liver and its Relationship with Diabetes mellitus. Technology in Cancer Research and Treatment, 2022, 21, 153303382211197.	0.8	3
2464	The Role of Senescence in NASH-Related HCC. , 2022, , 167-191.		1
2465	Association Between Liver Steatosis and Single Nucleotide Polymorphisms in the <i>PNPLA3</i> Gene in the Northern Part of Okinawa, Japan. Journal of the Japanese Association of Rural Medicine, 2022, 71, 309-320.	0.0	0
2466	Alcohol or Not: A Review Comparing Initial Mechanisms, Contributing Factors, and Liver Transplantation Outcomes Between Alcoholic and Nonalcoholic Steatohepatitis. European Medical Journal (Chelmsford, England), 0, , 40-48.	3.0	2
2468	Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. Journal of Cardiovascular Development and Disease, 2022, 9, 419.	0.8	5
2469	Lipid droplets as the genetic nexus of fatty liver. Liver International, 2022, 42, 2594-2596.	1.9	3
2470	PPARÎ± in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?. Biomedicines, 2022, 10, 3041.	1.4	5
2471	Non-alcoholic Fatty Liver Disease in Children. Current Vascular Pharmacology, 2023, 21, 4-25.	0.8	7

#	Article	IF	Citations
2472	Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm. International Journal of Molecular Sciences, 2022, 23, 14762.	1.8	5
2473	Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis. Journal of Hepatology, 2023, 78, 584-595.	1.8	16
2474	Hypertension and diabetes mellitus are associated with high FIB-4 index in a health checkup examination cohort without known liver disease. BMC Gastroenterology, 2022, 22, .	0.8	4
2475	An update on the genetics of alcoholic liver disease. , 0, 1, .		4
2476	Non-alcoholic fatty liver disease establishment and progression: genetics and epigenetics as relevant modulators of the pathology. Scandinavian Journal of Gastroenterology, 2023, 58, 521-533.	0.6	0
2477	Genome Editing and Fatty Liver. Advances in Experimental Medicine and Biology, 2023, , 191-206.	0.8	0
2478	Clearing Steatosis Prior to Liver Surgery for Colorectal Metastasis: A Narrative Review and Case Illustration. Nutrients, 2022, 14, 5340.	1.7	0
2479	Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	3
2480	Molecular Screening via Sanger Sequencing of the Genetic Variants in Non-Alcoholic Fatty Liver Disease Subjects in the Saudi Population: A Hospital-Based Study. Metabolites, 2022, 12, 1240.	1.3	4
2481	Comparison between obese and non-obese nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 2023, 29, S58-S67.	4.5	12
2482	MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery. International Journal of Molecular Sciences, 2022, 23, 15825.	1.8	6
2483	Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nature Genetics, 2022, 54, 1803-1815.	9.4	150
2484	State-of-the-art liver disease research using liver-on-a-chip. Inflammation and Regeneration, 2022, 42, .	1.5	9
2485	Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers. Journal of Physiology and Biochemistry, 2023, 79, 851-868.	1.3	4
2486	Understanding the Changing Landscape of Health Disparities in Chronic Liver Diseases and Liver Cancer. , 2023, 2, 505-520.		1
2487	Mapping transcriptional heterogeneity and metabolic networks in fatty livers at single-cell resolution. IScience, 2023, 26, 105802.	1.9	4
2488	Global incidence and prevalence of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 2023, 29, S32-S42.	4.5	67
2489	Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. Cancers, 2023, 15, 23.	1.7	21

#	Article	IF	Citations
2490	Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response. Clinical and Molecular Hepatology, 2023, 29, S184-S195.	4.5	8
2492	Antisense oligonucleotide is a promising intervention for liver diseases. Frontiers in Pharmacology, 0, 13, .	1.6	2
2493	A case of NASH with genetic predisposition successfully treated with an SGLT2 inhibitor: a possible involvement of mitochondrial dysfunction. Endocrinology, Diabetes and Metabolism Case Reports, 2022, 2022, .	0.2	0
2494	Exome-wide association analysis of CT imaging-derived hepatic fat in a medical biobank. Cell Reports Medicine, 2022, 3, 100855.	3.3	3
2495	PNPLA3 allele frequency has no impact on biliary bile acid composition or disease course in patients with primary sclerosing cholangitis. PLoS ONE, 2022, 17, e0277084.	1.1	0
2496	Association of HSD17B13 and PNPLA3 With Liver Enzymes and Fibrosis in Hispanic/Latino Individuals of Diverse Genetic Ancestries. Clinical Gastroenterology and Hepatology, 2023, 21, 2578-2587.e11.	2.4	3
2497	Clinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity. Frontiers in Endocrinology, 0, 14, .	1.5	2
2498	Association between Serum Uric Acid and Liver Enzymes in Adults Aged 20 Years and Older in the United States: NHANES 2005â€“2012. Journal of Clinical Medicine, 2023, 12, 648.	1.0	1
2499	Normalization of circulating plasma levels of miRNAs in HIV-1/HCV co-infected patients following direct-acting antiviralâ€“induced sustained virologic response. Heliyon, 2023, 9, e12686.	1.4	2
2500	MAFLD and Celiac Disease in Children. International Journal of Molecular Sciences, 2023, 24, 1764.	1.8	3
2501	Prevalence and factors associated with liver fibrosis among firstâ€degree relatives of Mexican Americans with hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2023, 57, 378-386.	1.9	7
2502	Communicating PNPLA3 genetic risk status for NAFLD among Mexican-origin men. Frontiers in Public Health, 0, 10, .	1.3	1
2504	HÃgado graso (parte 1): aspectos generales, epidemiologÃa, fisiopatologÃa e historia natural. Revista Colombiana De Gastroenterologia, 2022, 37, 420-433.	0.1	1
2505	Genetic Polymorphisms and Diversity in Nonalcoholic Fatty Liver Disease (NAFLD): A Mini Review. Biomedicines, 2023, 11, 106.	1.4	11
2506	The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD. Nutrients, 2023, 15, 66.	1.7	5
2507	PNPLA3(I148M) Inhibits Lipolysis by Perilipin-5-Dependent Competition with ATGL. Cells, 2023, 12, 73.	1.8	2
2508	Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia. JAMA Network Open, 2022, 5, e2248803.	2.8	7
2509	Screening for MAFLD: who, when and how?. Therapeutic Advances in Endocrinology and Metabolism, 2023, 14, 204201882211456.	1.4	5

#	Article	IF	Citations
2510	MAFLD: a multisystem disease. Therapeutic Advances in Endocrinology and Metabolism, 2023, 14, 204201882211455.	1.4	28
2511	Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients, 2023, 15, 687.	1.7	12
2512	<scp>PNPLA3 I148M</scp> and response to treatment for hepatic steatosis: A systematic review. Liver International, 2023, 43, 975-988.	1.9	6
2513	INASLâ€“SAASL Consensus Statements on NAFLD Name Change to MAFLD. Journal of Clinical and Experimental Hepatology, 2023, 13, 518-522.	0.4	1
2514	Using epigenomics to understand cellular responses to environmental influences in diseases. PLoS Genetics, 2023, 19, e1010567.	1.5	3
2515	Epigenetics of NAFLD and NASH. , 2023, , 423-445.		0
2516	A natural history study of paediatric non-alcoholic fatty liver disease over 10 years. JHEP Reports, 2023, 5, 100685.	2.6	4
2517	Nonalcoholic fatty liver disease and cardiovascular disease. , 2023, , 11-16.		0
2518	Impaired Function of Solute Carrier Family 19 Leads to Low Folate Levels and Lipid Droplet Accumulation in Hepatocytes. Biomedicines, 2023, 11, 337.	1.4	0
2519	Association of PNPLA3 SNP With the Development of HBV-related Hepatocellular Carcinoma. In Vivo, 2023, 37, 763-770.	0.6	0
2520	Nafion by-product 2 disturbs lipid homeostasis in zebrafish embryo. Environmental Pollution, 2023, 322, 121178.	3.7	0
2521	Actionable Solutions to Achieve Health Equity in Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 2023, 21, 1992-2000.	2.4	4
2522	Editorial: firstâ€degree relatives of Mexican Americans with <scp>HCC</scp> are at increased risk of significant fibrosisâ€”authors' reply. Alimentary Pharmacology and Therapeutics, 2023, 57, 1038-1039.	1.9	0
2523	The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond. , 2023, 244, 108382.		4
2524	Concise review of lipidomics in nonalcoholic fatty liver disease. Diabetes and Metabolism, 2023, 49, 101432.	1.4	5
2525	Genetic Markers Predisposing to Nonalcoholic Steatohepatitis. Clinics in Liver Disease, 2023, 27, 333-352.	1.0	1
2526	Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2023, 27, 373-395.	1.0	3
2527	Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2023, 27, 239-250.	1.0	2

#	Article	IF	Citations
2528	Special Population. Clinics in Liver Disease, 2023, 27, 471-482.	1.0	0
2529	Hepatic phosphatidylcholine catabolism driven by PNPLA7 and PNPLA8 supplies endogenous choline to replenish the methionine cycle with methyl groups. Cell Reports, 2023, 42, 111940.	2.9	9
2530	Adipose Tissue, Metabolic Syndrome, and Non-Alcoholic Fatty Liver Disease â€“ A Short Review. European Medical Journal Hepatology, 0, , 62-70.	1.0	2
2531	Longâ€term risk of a fatty liver in liver donors. Annals of Gastroenterological Surgery, 0, , .	1.2	0
2532	iPSC-derived organ-on-a-chip models for personalized human genetics and pharmacogenomics studies. Trends in Genetics, 2023, 39, 268-284.	2.9	12
2533	The role of hepatokines in NAFLD. Cell Metabolism, 2023, 35, 236-252.	7.2	55
2534	Association between Dietary Fatty Acid Intake and Liver Steatosis and Fibrosis in a Sample of Mexican-Origin Hispanic Adults with Overweight or Obesity. International Journal of Environmental Research and Public Health, 2023, 20, 3103.	1.2	1
2535	Plasma Metabolite Signatures in Male Carriers of Genetic Variants Associated with Non-Alcoholic Fatty Liver Disease. Metabolites, 2023, 13, 267.	1.3	2
2536	Non-Alcoholic Fatty Liver Disease â€“ Changing the Prevalence of Liver Cancer?. European Medical Journal Hepatology, 0, , 12-18.	1.0	1
2537	PNPLA3 148M/M Is More Susceptible to Palmitic Acid-Induced Endoplasmic Reticulum Stress-Associated Apoptosis in HepG2 Cells. International Journal of Endocrinology, 2023, 2023, 1-10.	0.6	0
2538	The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression. Journal of Experimental Medicine, 2023, 220, .	4.2	13
2539	Correlation between PNPLA3 rs3747207 Polymorphism and Non-Alcoholic Fatty Liver Disease. Advances in Clinical Medicine, 2023, 13, 1974-1981.	0.0	0
2540	A metagenomic study identifies a Prevotella copri enriched microbial profile associated with nonâ€alcoholic steatohepatitis in subjects with obesity. Journal of Gastroenterology and Hepatology (Australia), 2023, 38, 791-799.	1.4	5
2541	Multivariate GWAS analysis reveals loci associated with liver functions in continental African populations. PLoS ONE, 2023, 18, e0280344.	1.1	0
2542	Transforming Genes to Protect Against Liver Disease: Will siRNA-based Therapeutics Reduce the Need for Liver Transplantation?. Transplantation, 2023, 107, 556-557.	0.5	0
2543	Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants. Hepatology International, 2023, 17, 595-605.	1.9	8
2544	An association study of the PNPLA3 I148M polymorphism (rs738409) with serum lipids in patients with dyslipidemia. Exploration of Medicine, 0, , 16-22.	1.5	0
2545	Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis. Nature Biotechnology, 2023, 41, 1567-1581.	9.4	32

#	Article	IF	Citations
2546	TM6SF2-rs58542926 Genetic Variant Modifies the Protective Effect of a â€œPrudentâ€•Dietary Pattern on Serum Triglyceride Levels. Nutrients, 2023, 15, 1112.	1.7	0
2547	Abdominal obesity and alcohol use modify the impact of genetic risk for incident advanced liver disease in the general population. Liver International, 2023, 43, 1035-1045.	1.9	4
2548	Identification of key target genes and pathway analysis in nonalcoholic fatty liver disease via integrated bioinformatics analysis. Balkan Journal of Medical Genetics, 2023, 25, 25-34.	0.5	1
2549	Nutrigenetic Interaction Between Apolipoprotein C3 Polymorphism and Fat Intake in People with Nonalcoholic Fatty Liver Disease. Current Developments in Nutrition, 2023, 7, 100051.	0.1	0
2550	Fecal Metagenomics and Metabolomics Identifying Microbial Signatures in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2023, 24, 4855.	1.8	4
2551	PNPLA3 genotypes modify the adverse effect of the total energy intake on high-risk nonalcoholic steatohepatitis development. American Journal of Clinical Nutrition, 2023, 117, 910-917.	2.2	2
2552	Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation. Journal of Hepatology, 2023, 79, 538-551.	1.8	27
2553	Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease. Endocrinology and Metabolism Clinics of North America, 2023, 52, 459-468.	1.2	4
2554	Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes. Journal of Hepatocellular Carcinoma, 0, Volume 10, 413-428.	1.8	10
2555	Patatin-like phospholipase domain-containing 3 gene (PNPLA3) polymorphic (rs738409) single nucleotide polymorphisms and susceptibility to nonalcoholic fatty liver disease: A meta-analysis of twenty studies. Medicine (United States), 2023, 102, e33110.	0.4	1
2556	Hepatic COX1 loss leads to impaired autophagic flux and exacerbates nonalcoholic steatohepatitis. Acta Pharmaceutica Sinica B, 2023, , .	5.7	0
2557	Association between PNPLA3 rs738409 variant and 5-year estimated glomerular filtration rate decline in post-menopausal women with type 2 diabetes: A panel-data analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2023, 33, 1093-1097.	1.1	2
2558	Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making. Expert Review of Gastroenterology and Hepatology, 2023, 17, 317-324.	1.4	3
2559	Azonal steatosis correlates with disease severity and poor outcome of nonalcoholic fatty liver disease. Journal of Digestive Diseases, 0, , .	0.7	0
2560	Integrative network-based analysis on multiple Gene Expression Omnibus datasets identifies novel immune molecular markers implicated in non-alcoholic steatohepatitis. Frontiers in Endocrinology, 0, 14, .	1.5	6
2561	Longitudinal association between overweight years, polygenic risk and NAFLD, significant fibrosis and cirrhosis. Alimentary Pharmacology and Therapeutics, 2023, 57, 1143-1150.	1.9	4
2562	Silencing of STE20-type kinase TAOK1 confers protection against hepatocellular lipotoxicity through metabolic rewiring. Hepatology Communications, 2023, 7, .	2.0	4
2565	Genomic analyses of hair from Ludwig van Beethoven. Current Biology, 2023, 33, 1431-1447.e22.	1.8	20

#	Article	IF	Citations
2566	Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges. Therapeutic Advances in Endocrinology and Metabolism, 2023, 14, 204201882311603.	1.4	3
2567	Glutathione: Pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease. Frontiers in Medicine, 0, 10, .	1.2	4
2568	PNPLA3 rs738409 risk genotype decouples TyG index from HOMA2-IR and intrahepatic lipid content. Cardiovascular Diabetology, 2023, 22, .	2.7	2
2570	Hepatic stellate cell activation markers are regulated by the vagus nerve in systemic inflammation. Bioelectronic Medicine, 2023, 9, .	1.0	1
2571	Developmental and Inherited Liver Disease. , 2024, , 122-294.		0
2572	Combined Methylation and Transcriptome Analysis of Liver Injury of Nonalcoholic Fatty Liver Disease Induced by High Alcohol-Producing Klebsiella pneumoniae. Microbiology Spectrum, 2023, 11, .	1.2	1
2573	Fatty Liver Disease. , 2024, , 330-401.		1
2574	Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. Journal of Hepatology, 2023, 79, 287-295.	1.8	43
2575	Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease. Cell, 2023, 186, 1968-1984.e20.	13.5	11
2576	Towards omics-based risk assessment in NAFLD. Nature Metabolism, 0, , .	5.1	0
2577	Increased letâ€7dâ€5p in nonâ€alcoholic fatty liver promotes insulin resistance and is a potential blood biomarker for diagnosis. Liver International, 2023, 43, 1714-1728.	1.9	4
2578	Low vitamin A levels are associated with liver-related mortality: a nationally representative cohort study. Hepatology Communications, 2023, 7, .	2.0	4
2579	Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH. Cell Reports Medicine, 2023, 4, 101016.	3.3	2
2580	Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome. International Journal of Molecular Sciences, 2023, 24, 7454.	1.8	1
2581	Longâ€term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals. Liver International, 2023, 43, 1699-1713.	1.9	3
2582	Peptic ulcer disease in non-alcoholic fatty liver disease hospitalizations: A new challenge on the horizon in the United States. World Journal of Hepatology, 0, 15, 564-576.	0.8	0
2583	Postprandial dysfunction in fatty liver disease. Physiological Reports, 2023, 11, .	0.7	4
2584	Metabolic disorders across the body mass index spectrum in a Colombian population with nonalcoholic fatty liver disease. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2023, , .	0.1	0

#	Article	IF	Citations
2585	Peroxisome Proliferator-Activated Receptor-Î³ as a Target and Regulator of Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease. Cells, 2023, 12, 1205.	1.8	5
2594	Editorial: <scp>NAFLD</scp>, chronic kidney disease, and pleiotropyâ€"Why is <scp>PNPLA3</scp> omnipresent?. Alimentary Pharmacology and Therapeutics, 2023, 57, 1180-1182.	1.9	1
2598	Human Hepatic Stellate Cells: Isolation and Characterization. Methods in Molecular Biology, 2023, , 221-232.	0.4	0
2607	Predictive risk markers in alcoholism. Advances in Clinical Chemistry, 2023, , 113-181.	1.8	1
2618	Lipid droplet biogenesis and functions in health and disease. Nature Reviews Endocrinology, 2023, 19, 443-459.	4.3	49
2633	Natural History of Nonalcoholic Fatty Liver Disease. , 2023, , 19-43.		0
2637	Signal transduction mechanisms of phospholipases and their roles in cancer signaling and progression. , 2023, , 87-124.		0
2649	From target discovery to clinical drug development with human genetics. Nature, 2023, 620, 737-745.	13.7	14
2652	Mitochondrial dynamics in health and disease: mechanisms and potential targets. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	25
2656	Mechanisms Behind NAFLD: a System Genetics Perspective. Current Atherosclerosis Reports, 2023, 25, 869-878.	2.0	1
2657	Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitors response. Molecular Biology Reports, 2023, 50, 9637-9647.	1.0	1
2659	Genetics and Epigenetics in Nonalcoholic Fatty Liver Disease. , 2023, , 59-71.		0
2683	Molecular pathology of hepatocellular carcinoma. , 2024, , 561-568.		0
2707	22.ÂChronic Liver Disease. , 2023, , .		0